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Role of the glucocorticoid receptor and HIV-1 Vpr in inflammatory gene 
expression and HIV-1 LTR transcription in response to dexamethasone 
and progestogens 
 
Y. Govender (November 2014) 
Abstract 
The relationship between progestin-only injectable contraception and risk of HIV-1 
acquisition is controversial. Most clinical data suggests that the injectable contraceptive 
medroxyprogesterone acetate (MPA), unlike norethisterone enanthate (NET-EN), increases 
susceptibility to infections such as HIV-1. The first part of this thesis investigated the 
differential effects, molecular mechanisms of action and steroid receptor involvement in gene 
expression by MPA as compared to NET and progesterone (P4) in the End1/E6E7 and HeLa 
cell line models for the endocervical epithelium, a key point of entry for pathogens in the 
lower female genital tract (FGT). Quantitative real-time PCR analysis showed that MPA, 
unlike NET-acetate (NET-A) and P4, increases mRNA expression of the anti-inflammatory 
GILZ and IκBα genes. Similarly, MPA unlike NET-A, decreases mRNA expression of the 
pro-inflammatory IL-6, IL-8 and RANTES genes, and IL-6 and IL-8 protein levels. The 
predominant steroid receptor expressed in the cervical cell lines and primary endocervical 
epithelial cells is the glucocorticoid receptor (GR), and GR siRNA experiments show that the 
anti-inflammatory effects of MPA are mediated by the GR. Chromatin-immunoprecipitation 
results suggest that MPA, unlike NET-A and P4, represses pro-inflammatory cytokine gene 
expression in cervical epithelial cells via a mechanism involving recruitment of the GR to 
cytokine gene promoters, like the GR agonist dexamethasone (DEX). This is at least in part 
consistent with direct effects on transcription, without a requirement for new protein 
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synthesis. This is the first study to show direct proof for a GR-mediated mechanism of action 
in anti-inflammatory effects of MPA.  Dose response analysis shows that MPA has a potency 
of ~24 nM for transactivation of the anti-inflammatory GILZ gene and ~4 – 20 nM for 
repression of the pro-inflammatory genes, suggesting that these effects are likely to be 
relevant at injectable contraceptive doses of MPA. These findings suggest that MPA effects 
on genital mucosal immune function and susceptibility to infections are likely to be very 
different to those of NET and P4, when mediated by the GR 
The second part of this thesis investigated the effects of the virion associated HIV-1 protein, 
Vpr, on GR-regulated inflammatory genes in the presence of the ligands. Based on evidence 
in the literature it was hypothesized that Vpr may act as a co-activator of the GR in the 
regulation of inflammatory genes in the presence of DEX. Additionally, since the GR has 
been shown to be activated by MPA and P4, it was hypothesized that Vpr may also modulate 
progestogen-mediated inflammatory gene regulation. Promoter-reporter gene assays in HeLa 
cells suggested that Vpr acts as a co-activator of the GR in the presence of both DEX and 
MPA but not P4 or NET-A.  However, Vpr did not enhance ligand-mediated transactivation 
of the endogenous GRE-containing genes, GILZ and IκBα. Furthermore, Vpr did not affect 
ligand-mediated transrepression of the endogenous NF-κB/AP-1 containing genes, IL-6 and 
IL-8. Results suggest that the effect of Vpr on the GR in the presence of ligands may be 
promoter-specific, depend on presence of native chromatin and/or be sensitive to the relative 
concentrations of Vpr. Interestingly Vpr appeared to only regulate basal expression of  the 
pro-inflammatory genes, suggesting an effect of Vpr on the unliganded GR. Taken together, 
results suggest that depending on the HIV-1 life cycle and Vpr concentration that Vpr may 




In addition to its role in host inflammatory gene regulation, the GR has been reported to be 
involved in the regulation of HIV-1 LTR transcription in the presence of DEX. However, a 
direct role for the GR in this DEX-mediated modulation has not been previously shown. 
Literature reports suggest that Vpr plays an important role in HIV-1 LTR transcription. 
However, there are limited data on role of Vpr in the regulation of HIV-1 LTR transcription 
in the presence of DEX and no data for the synthetic progestins. The role of GR and Vpr in 
the regulation of HIV-1 LTR transcription in the presence of ligands was investigated. It was 
found that DEX and the progestogens all repressed Tat-activated LTR transcription in HeLa 
cells. Similar results were found with HIV-1 pseudovirus-activated LTR in TZM-bl cells. GR 
reduction by siRNA revealed that the LTR gene may be hypersensitive to GR and require 
small amounts of GR protein to mediate an effect. The rank-order of the effects of the ligands 
suggests that the GR is involved in the ligand-mediated repression of the LTR and Vpr plays 
no role in this regulation. These results suggest consequences for HIV-1 replication and 
disease progression. Depending on the stage of HIV-1 disease, the progestogens and DEX 
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Chapter 1: Literature Review 
1.1 Inflammation 
Inflammation is a physiological response as a consequence of tissue injury associated with 
various causes such as trauma, autoimmune reactions, and the detection of antigens or 
pathogens (Harada et al. 1994; Feghali & Wright 1997). This response consists of two 
phases; acute and chronic (Feghali & Wright 1997). Acute phase is characterized by 
increased blood flow and vascular permeability along with the accumulation of fluid, 
leukocytes, and inflammatory mediators such as cytokines (Feghali & Wright 1997). In the 
chronic phase, inflammation is characterized by the development of a specific humoral 
immune response, which is mediated by B-cells and involves the production of antibodies, 
and a cellular immune response, which involves the activation of macrophages, natural killer 
cells and T-cells, to the pathogen present at the site of injury (Rhoades & Bell 2012). During 
both acute and chronic inflammatory processes, a variety of soluble factors are involved in 
leukocyte recruitment through increased expression of cellular adhesion molecules and 
chemoattraction (Newton 2000; Busillo & Cidlowski 2013). Several cytokines play key roles 
in mediating acute inflammatory reactions, namely interleukin (IL)-1, TNF-α, IL-6, IL-11 
and chemokines, IL-8, regulated-upon-activation-normal-T-cell-expressed-and-secreted 
(RANTES), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Feghali & Wright 1997). Chronic inflammation may 
develop following acute inflammation and may last for weeks or months, and in some 
instances for years. The cytokines known to mediate chronic inflammatory processes can be 
divided into those contributing to cellular inflammation such as IL-2, IL-12, interferons 
(IFNs), IFN-γ inducing factor (IGIF), and TNF-α and –β, and those participating in humoral 
inflammation such as IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β) (Feghali 
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& Wright 1997; Elenkov 2004; Akdis et al. 2004). T helper 1 (Th1) immunity provides 
protection against intracellular bacteria, protozoa, fungi, and several viruses, whereas T 
helper 2 (Th2) immunity provides protection against multicellular parasites, extracellular 
bacteria, some viruses, soluble toxins, and allergens (Elenkov & Chrousos 2002; Belardelli & 
Ferrantini 2002). The Th1 response supports the activities of macrophages and cytotoxic T-
cells of the cellular immune system while the Th2 response promotes the actions B-cells of 
the humoral immune system (Rhoades & Bell 2012).  It has been found that the Th1 and Th2 
responses are mutually inhibitory, whereby IL-12 and IFN-γ inhibit Th2 cells’ activities, 
while IL- 4 and IL-10 inhibit Th1 responses (Mosmann & Sad 1996; Elenkov 2004).  
Cytokines can be further classified into two groups’ pro-inflammatory and anti-inflammatory. 
The regulation of pro-inflammatory cytokines, such as IL-6, TNF-α and interferon (IFN)-γ, 
and anti-inflammatory cytokines, such as IL-4 and IL-10, may provide critical insights into 
mechanisms underlying a variety of common human diseases (Wong et al. 2001; Elenkov & 
Chrousos 2002). Although the list of hormones and neurotransmitters that are able to 
modulate the production of pro/anti-inflammatory cytokine production is constantly 
enlarging, the best-characterized neuroendocrine factors that regulate the production of these 
cytokines include glucocorticoids (GCs), key stress hormones (Elenkov & Chrousos 2002). 
1.2 Glucocorticoids in inflammation 
Glucocorticoids (GCs) are the most potent and currently used treatment to combat allergic 
and chronic inflammatory diseases such as asthma, pulmonary diseases, dermatitis, 
rheumatoid arthritis and even some cancers (Baschant & Tuckermann 2010; Newton et al. 
2010).  The hypothalamic-pituitary-adrenal (HPA) axis controls the synthesis of GCs in the 
adrenal cortex (Yudt & Cidlowski 2002). Endogenous GCs, e.g. cortisol circulate in the body 
bound to corticosteroid-binding globulin and serum albumin (McKay & Cidlowski 1999). 
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Synthetic GCs such as prednisone and dexamethasone (DEX) are drugs that have been 
designed to resemble natural GCs (Newton 2000). However, they differ from natural GCs by 
their potency and metabolic clearance. Furthermore, unlike natural GCs, synthetic GCs do 
not bind corticosteroid-binding globulin and are thereby not susceptible to their regulation of 
available levels (Kadmiel & Cidlowski 2013). GCs can suppress inflammation by down-
regulating the expression of pro-inflammatory cytokines such as IL-6 and TNF-α or by up-
regulating cytokines such as IL-10, which in turn suppress the production of pro-
inflammatory mediators (Barnes 1998; Verhoog et al. 2011). Evidence also indicates that 
GCs shift the cytokine response from Th1 to Th2 to suppress inflammation (Clerici et al. 
1997). GCs mediate their action through binding of the glucocorticoid receptor (GR), which 
in turn regulates transcription of inflammatory genes to obtain the desired anti-inflammatory 
effects (Newton 2013). 
1.3 Molecular mechanisms of action of the glucocorticoid receptor 
1.3.1 Ligand-binding, GR activation and nuclear translocation 
The glucocorticoid receptor (NR3C1, GR) belongs to the nuclear receptor superfamily and is 
a ligand-dependent transcription factor (Ratman et al. 2013; De Bosscher et al. 2013). The 
GR gene is comprised of ten exons spanning 110 kb, encoded on the fifth chromosome at 
region 5q31p (Encio & Detera-Wadleighs 1991). GRα is the classic receptor subtype which 
binds to GCs. It is mainly cytoplasmic and is most extensively studied. However, it is worth 
noting that an additional four isoforms exist that are generated via alternative splicing: GRβ, 
GRγ, GR-A and GR-P (Oakley & Cidlowski 2011). The GRβ isoform resides constitutively 
in the nucleus and acts as a natural dominant negative inhibitor of the GRα isoform (Kadmiel 
& Cidlowski 2013). GRβ can also directly regulate genes that are not regulated by GRα 
(Kino et al. 2009). The other isoforms are less well-characterized and have been associated 
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with glucocorticoid insensitivity (Kadmiel & Cidlowski 2013). The GRα consists of three 
modular domains: an N-terminal transactivation domain (NTD), a central DNA-binding 
domain (DBD), and a C-terminal ligand-binding domain (LBD) (Busillo & Cidlowski 2013). 
In the absence of hormone, inactive GR is in a chaperone complex associated with heat shock 
protein 90 and 70 and several immunophilins such as FKBP51 in the cytoplasm (Zhou & 
Cidlowski 2005; Flammer & Rogatsky 2011). GCs are lipophilic and passively diffuse across 
the cell membrane (Zhou & Cidlowski 2005). Upon ligand binding the GR undergoes a 
conformational change and the GR translocates to the nucleus (Flammer & Rogatsky 2011). 
1.3.2 Direct DNA binding or protein-protein interactions 
Once in the nucleus, the active GR can either bind directly to the DNA through binding to 
glucocorticoid response elements (GREs) or bind to other transcription factors (De Bosscher 
2010). The activated GR-ligand complexes can either dimerise to form homodimers or 
remain as monomers (Robertson et al. 2010). Dimerisation has been found to be ligand-
specific and is required for transcriptional activation (transactivation), but not for 
transcriptional repression (transrepression) via tethering (Reichardt et al. 1998; Robertson et 
al. 2010). The activated GR dimers or monomers then translocates to the nucleus where the 
DBD of the active GR binds to GRE sequences in targeted genes and thereby activate 
transcription. The consensus sequence for GRE binding is the palindromic 15-bp sequence 
GGTACAnnnTGTTCT (where n is any nucleotide) (Barnes 1998). GC-responsive genes 
containing such simple-acting GREs include serine/threonine protein kinase (sgk1) 
(Schoneveld et al. 2004). In contrast, many genes contain glucocorticoid response units 
(GRU’s), in which transcription not only depends on GR binding to the GRE, but also 
requires the binding of other transcription factors to adjacent sites e.g. phenylalanine 
hydroxylase gene (Schoneveld et al. 2004). The GR can also bind as a monomer to composite 
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GRE half sites. The GR has also been shown to bind to specific, widely prevalent inverted 
palindromic sequences called ‘simple’ negative GREs (nGREs) on target genes (Kadmiel & 
Cidlowski 2013). GR binds to nGREs which overlap response elements and subsequently 
prevents binding of the positively acting transcription factors to its recognition sequence and 
results in transrepression (Zhou & Cidlowski 2005). An example is the osteocalcin gene 
promoter, in which the nGRE overlaps with the TATA box and thereby prevents binding of 
the TFIID (Stromstedt et al. 1991). Another example is the prolactin gene promoter, in which 
the nGRE site overlaps with two other transcription factor binding sites, Oct-1 and Pbx 
(Subramaniam et al. 1998).  
 
As mentioned earlier, in certain genes transcriptional regulation by the GR does not involve 
direct binding of the GR to DNA, but rather regulation via protein-protein interactions 
(Ratman et al. 2013). Although tethering is predominantly a transrepressive mechanism there 
have been reports of transactivation as a result of tethering (Kassel & Herrlich 2007). An 
example of tethering that results in transactivation is GR binding to Stat5 on the β-casein 
gene while an example of transrepression is GR binding to activator protein-1 (AP-1) or 
nuclear factor kappa B (NF-κB) on the collagenase, IL6 and IL8 genes (Kassel & Herrlich 
2007). Another example of protein-protein interaction is mutual antagonism of GR and NF-
κB/AP-1 whereby NF-κB and AP-1 proteins and GR reciprocally modulate each other’s 
activity (De Bosscher et al. 2003). Other models include GR-mediated co-factor competition, 
chromatin remodelling co-factors and modification of the basal transcriptional machinery (De 




After DNA binding; the GR recruits the basal transcription machinery, chromatin 
remodelling complexes, co-activators, as well as a variety of other transcription factors which 
facilitate GR mediated transactivation (Chinenov et al. 2013). Many GC-responsive genes are 
upregulated by the direct binding of activated GR-ligand complexes to GREs (as illustrated in 
Figure 1.1). GCs generally transactivate genes that are involved in producing an anti-
inflammatory response such as the glucocorticoid-induced leucine zipper (GILZ) and 
inhibitor of kappa B alpha (IκBα) genes (Newton & Holden 2007; Reddy et al. 2009). GILZ 
codes for a leucine zipper protein and was first isolated as a DEX-responsive gene from 
thymocytes (D’Adamio et al. 1997). DEX-induced GILZ overexpression has been shown to 
inhibit both T-cell receptor (TCR)–induced IL-2/IL-2 receptor expression and apoptosis 
(Ayroldi et al. 2001; Berrebi et al. 2003). Furthermore, GILZ reduces NF-κB activity; in 
particular, inhibits NF-κB nuclear translocation and DNA binding due to a direct protein-
protein interaction of GILZ with the NF-κB subunits (Ayroldi et al. 2001). Transcriptional 
regulation of GILZ by GCs involves GR interaction with multiple GRE sequences (~6 sites) 
contained on the GILZ promoter (Ayroldi & Riccardi 2009). IκBα codes for an inhibitory 
protein of NF-κB that hold NF-κB (p50/p65) inactive in the cytoplasm (Rupec et al. 1999). 
DEX-induced IκBα upregulation has been shown to inhibit NF-κB activation (Auphan et al. 
1995). This inhibition is a result of the sequestration of NF-κB dimers by IκBα in the 
cytoplasm and thereby reduction in NF-κB nuclear translocation (Auphan et al. 1995; 
Scheinman et al. 1995). 
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Figure 1.1: GR mechanism of action. Taken and modified from (Bogaert et al. 2010). Upon 
ligand binding, the GR undergoes a conformational change and translocates to the nucleus 
where it occupies GRE sites on anti-inflammatory genes to activate transcription or interacts 
with TFs bound to TFRE sites of pro-inflammatory genes to suppress transcription. 
Abbreviations: GC = glucocorticoid, GR = glucocorticoid receptor, GRE = glucocorticoid 
response element, TF = transcription factor; TFRE = transcription factor response element. 
1.3.4 Transrepression 
GR binds to nGREs or tethers to transcription factors and results in recruitment of co-
repressors and chromatin remodelling complexes which facilitate chromatin condensation 
and transrepression (Chinenov et al. 2013). The transrepression of pro-inflammatory genes 
(such as IL-6 and IL-8) which contain AP-1 or NF-κB binding sites occurs via the GR 
tethering to AP-1 or NF-κB proteins, respectively (as illustrated in Figure 1.1). 
1.4 Rapid non-genomic actions of GCs 
In addition to genomic actions which are mediated by transactivation and transrepression, 
GCs can act via rapid non-genomic effects. Literature shows that rapid non-genomic GC 
actions include modulation of general cellular functions, brain and neurophysiological 
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functions as well as behavioural responses (Groeneweg et al. 2011). Evidence suggests that 
rapid non-genomic GCs effects are mediated by three different mechanisms. The first is 
direct interactions with biological membranes and this is a non-specific non-genomic effect 
(Buttgereit et al. 1999). Some non-specific non-genomic effects of GCs have been shown to 
be mediated by alteration of the physicochemical property of cell membranes (Song & 
Buttgereit 2006). It has been hypothesized that GCs intercalate at high concentrations in 
cellular membranes e.g. plasma and mitochondrial membranes which alter cell functions by 
influencing cation transport through the plasma membrane and by increasing the proton leak 
of the mitochondria (Song & Buttgereit 2006). The second is membrane-bound GR-mediated 
non-genomic effects. The presence of the membrane-bound GR in immune cells such as 
PBMCs provides evidence for the hypothesis that non-genomic GC signalling is involved in 
modulating immune function (Bartholome et al. 2004). Membrane-bound GR has also been 
shown to mediate rapid actions of GCs in mouse skeletal muscle fibres and LβT2 cells (Pérez 
et al. 2013; Wehmeyer et al. 2014). The third proposed mechanism is via cytosolic GR-
mediated non-genomic effects. In addition to genomic effects, cytosolic GR has been shown 
to be involved in non-genomic actions via interactions with intracellular signalling proteins 
(Simoncini & Genazzani 2003). This is supported by studies that show crosstalk mechanisms 
between the classical GR and other signalling pathways (Qi et al. 2005; Kotitschke et al. 
2009). For example, GCs have been reported to rapidly activate p38 and JNK in hippocampal 
cells (Qi et al. 2005). In addition, the GR has been shown to crosstalk with the protein kinase 




1.5 The role of GR in HIV-1 pathogenesis 
1.4.1 GR-mediated immune function in HIV-1 infection 
Evidence shows that human immunodeficiency virus (HIV-1) disease progression is 
accompanied by a defective production of Th1 cytokines such as IL-2, IL-12 and IFN-γ, and 
an increased production of Th2 cytokines such as IL-4 and IL-10 (Clerici et al. 1994; 
Meyaard et al. 1996; Klein et al. 1997; Norbiato et al. 1997). As mentioned earlier, GCs 
acting via the GR suppress inflammation by shifting the immune response from Th1 to Th2, 
supporting a role for the GR in HIV-1 induced modulation of cytokine networks (Clerici et 
al. 1997; Hapgood & Tomasicchio 2010). The important role for the GR in HIV-1 
pathogenesis is further supported by studies that show HIV-1 infection is accompanied by a 
chronic activation of the HPA system which either leads to GC hypersensitivity or results in 
elevated cortisol levels (Norbiato et al. 1997; Kino & Chrousos 2001; Kino et al. 2003). In 
HIV-1 infected patients, elevated levels of cortisol results in a compromised immune 
response which may promote disease progression (Norbiato et al. 1997). 
There have also been reports of GC resistance in HIV-1 infected individuals (Norbiato et al. 
1997). Although the mechanism of HIV-1 induced GC resistance is unclear, possible 
explanations have been proposed in literature. It has been suggested that GC resistance is due 
to lowered GR affinity for ligand as a result of the imbalance in cytokine production found in 
HIV-infected patients (Norbiato et al. 1997). This is supported by findings that show that the 
combination of IL-2 and IL-4 reduces the ligand binding affinity of the GR (Kam et al. 
1993). Another possible explanation for the GC resistance is the relative increased expression 
of the GRβ isoform to the GRα isoform (Zapanti et al. 2008). The GRα isoform is the main 
mediator of GC activity while the GRβ isoform is known to inhibit GRα action (Bamberger 
et al. 1995). Thus, the increased proportion of GRβ isoform leads to a decreased GC effect. It 
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has also been proposed that viral protein R (Vpr) may play a role in lowering GR affinity for 
GCs (Norbiato et al. 1997; Kogan & Rappaport 2011). 
1.4.2 The role of GR in HIV-1 replication 
In addition to a role for the GR in modulating host immune function in response to HIV 
infection, GCs have been shown to affect HIV replication by regulation of the HIV-1 LTR 
(Laurence et al. 1989; Kolesnitchenko & Snart 1992; Mitra et al. 1995; Russo et al. 1999; 
Kino et al. 2000). The identical copies of the HIV-1 LTR is located at the 5’ and 3’ end of the 
integrated provirus and contains the promoter and enhancer elements that regulate HIV-1 
expression (Geeraert et al. 2008). In the presence of the HIV-1 transactivator (Tat) protein, 
the transcription of the HIV-1 LTR is activated, through its interaction with the 
transactivation response region (TAR) (Ammosova et al. 2006; Hapgood & Tomasicchio 
2010). The HIV-1 LTR contains a variety of cis elements. Mutational analysis revealed that 
the SP-1, NF-κB and AP-1 sites are required for viral replication (Ross et al. 1991; Ghosh 
1992; Mitra et al. 1995; Van Lint et al. 1997). The HIV-1 LTR also contains three non-
classical GRE elements: GRE I, GRE II and GRE III (Mitra et al. 1995). GRE I 
(AGAACAnnnnGCTTGT) is an imperfect palindrome, while GRE II (TGTACT) and III 
(AGACCA) are half sites (Mitra et al. 1995). GR has been shown to bind to all three GRE 
sites (Ghosh 1992; Mitra et al. 1995), however, mutational analysis shows that GRE I and 
GRE II do not have a functional role in HIV-1 transcription but it appears that GRE III may 
play a role in the GC-regulated HIV-1 transcription (Mitra et al. 1995). Figure 1.2 illustrates 









Figure 1.2: Structure of HIV-1 long terminal repeat. Taken and modified from (Mitra et 
al. 1995; Kilareski et al. 2009). The U3 region is divided into the modulatory (M), enhancer 
(E) and promoter regions (P). The promoter region contains the TATA box and SP factor 
binding sites while the enhancer contains the NF-κB binding sites. The repeat (R) region 
contains a trans-acting responsive element (TAR) that forms an RNA stem loop structure 
upon transcription that binds to the viral protein Tat. A negative regulatory element (NRE) 
was identified that was subsequently shown to serve as both activator and repressor by 
binding NFAT proteins, AP-1 proteins and C/EBP factors. The sequences responsible for 
glucocorticoid receptor binding are highlighted and written in the order 5’ to 3’, GRE-I, -II 
and -III, respectively.  
 
There are conflicting reports about regulation of the HIV-1 LTR by GCs. Some studies have 
shown in vitro that DEX upregulates HIV-1 LTR transcription in CEM-T4 (Human T 
lymphoblastoid) and 3T3 (mouse fibroblast) cell lines (Furth et al. 1990; Russo et al. 1999). 
However, the majority of studies show that DEX represses both overexpressed plasmid Tat-
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activated and viral-activated HIV-1 LTR transcription in multiple human cell lines such as 
U937 (monocyte), H9 (embryonic stem cell), CD4+ Raji (B lymphocyte), H9V3 (chronic 
HIV-infection) and U1.1 (chronic HIV-infection) (Laurence et al. 1989; Kolesnitchenko & 
Snart 1992; Mitra et al. 1995; Kurata & Yamamoto 1999; Russo et al. 1999; Kino et al. 
2000). Similarly, there are conflicting reports on the effect of GCs on viral replication as 
measured by HIV-1 p24 levels. Evidence shows that in peripheral blood mononuclear cells 
(PBMCs), GCs upregulate HIV-1 p24 levels while another report shows in CD4+ T cells that 
GCs reduce HIV-1 p24 levels (Ayyavoo, Mahalingam, et al. 1997; Chun et al. 1998; Wang et 
al. 1998). Although these studies suggest a role for the GR in viral replication, this has not 
been shown. Consequently, it remains to be determined whether GCs, acting via the GR, 
increase or decrease HIV-1 transcription in HIV-infected cells in a manner dependent on 
chromatin structure and cell-type. 
1.6  The role of Vpr in HIV-1 pathogenesis 
HIV-1 encodes retroviral Gag, Pol, and Env proteins along with six additional accessory 
proteins, Tat, Rev, Vpu, Vif, Nef, and Vpr (Kogan et al. 2012). Vpr is a 96 amino acid, 14 
kDa protein and is highly conserved in both HIV-1 and simian immunodeficiency virus (SIV) 
(Forget et al. 1998; Morellet et al. 2003; Ayinde et al. 2010). Vpr protein is present in 
significant quantities in the serum of HIV-1 positive individuals (Levy et al. 1994) thereby 
indicating its importance in the virus life cycle. Interestingly, Vpr is found to occur 
unassociated with other proteins in serum and has the ability to passively diffuse across cell 
membranes (Tungaturthi et al. 2003). Vpr has multiple functions in viral pathogenesis, 
including host cell arrest in G2/M phase of the cell cycle, increasing the translocation of the 
HIV-1 pre-integration complex which is needed for reverse transcription and integration to 
the host cell nucleus and enables T cell and macrophage infection (Ayyavoo, Rafaeli, et al. 
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1997; Kino et al. 1999; Iijima et al. 2004; Muthumani et al. 2004). It is also suggested that 
Vpr’s role in G2 cell cycle arrest creates a cellular environment in which the LTR is 
transcriptionally more active (Forget et al. 1998). Multiple studies have shown in vitro, in 
human cell lines and PBMCs using overexpressed Tat or HIV-1 pseudovirus or infectious 
molecular clones, that Vpr enhances Tat-/viral-activated LTR transcription (Felzien et al. 
1998; Forget et al. 1998; Sawaya et al. 2000; Vanitharani et al. 2001; Kino et al. 2002; Cui et 
al. 2006). It has been suggested that this enhancement in viral transcription is due to co-
operativity between Vpr, Tat, cyclin T1 and cyclin dependent kinase (CDK)-9 (Sawaya et al. 
2000). In addition, Vpr has shown to bind directly to co-activators p300/CREB-binding 
protein (CBP) in enhancing Tat-mediated HIV-1 LTR transcription (Kino et al. 2002). 
Evidence also suggests that Vpr could play a role in viral reactivation whereby Vpr can 
activate LTR transcription in the absence of Tat (Kino et al. 1999; Sawaya et al. 2000; Zhu et 
al. 2001; Varin et al. 2005). The study by Varin et al. 2005 has shown by mutational analysis 
in U937 and primary macrophages that Vpr activates transcription factors AP-1, c-Jun N-
terminal kinase (JNK) and NF-κB and thereby stimulates LTR transcription. Furthermore, it 
has been shown that purified serum Vpr activated virus expression from five latently infected 
cell lines (Levy et al. 1994). Serum Vpr also activated virus expression from resting PBMCs 
of HIV-infected individuals (Levy et al. 1994).  
In addition to its role in viral transcription, it is suggested that Vpr has anti-inflammatory 
activity (Muthumani et al. 2004). Vpr has been shown in PBMCs to suppress pro-
inflammatory cytokines such as IL-2, IL-12 and TNF-α similar to the synthetic GC, DEX 
(Ayyavoo, Mahboubi, et al. 1997; Mirani et al. 2002). It has been proposed that the Vpr-
mediated anti-inflammatory effects are via the ability of the viral protein to suppress NF-κB 
activity through effects on IκBα expression (Ayyavoo, Mahboubi, et al. 1997; Kogan & 
Rappaport 2011). This is a similar mechanism used by the GR to inhibit NF-κB (Auphan et 
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al. 1995). Another proposed mechanism is that Vpr acts as a co-activator of the GR and 
thereby promotes an anti-inflammatory response (Kino et al. 1999). 
1.7  Evidence for crosstalk between the GR and Vpr in transcriptional regulation 
Like host GR co-activator GR-interacting protein (GRIP)-1, Vpr contains a co-activator 
signature motif sequence LXXLL (at amino acids 64 to 68), which is necessary for 
interaction with the hormone receptor (Kino et al. 2002). It has been reported that Vpr co-
activates DEX-dependent GR-mediated transactivation on GR responsive promoters’ mouse 
mammary tumour virus (MMTV) and TAT-GRE (Kino et al. 1999; Sherman et al. 2000). In 
addition, GR/progesterone receptor (PR) antagonist (RU-486) repressed this Vpr-GR 
mediated transactivation. Furthermore, it has been shown in PBMCs that Vpr co-activates 
DEX-mediated upregulation of the endogenous gene, receptor of activated NF-κB ligand 
(RANKL) (Fakruddin & Laurence 2005). As mentioned earlier, Vpr downregulates NF-κB 
inducible cytokines, including IL-2, IL-12, TNF-α, and IL-4, and chemokines, MIP-1α, MIP-
1β, and RANTES (Ayyavoo, Mahboubi, et al. 1997; Muthumani et al. 2000; Mirani et al. 
2002) in a manner that suggests a role for the GR. This is supported by the Muthumani et al. 
study which shows that Vpr uses the GR pathway to recruit the NF-κB co-activating protein, 
poly(ADP-ribose) polymerase- 1 (PARP-1) (Muthumani et al. 2006). The GR interaction 
with Vpr was found to be both necessary and sufficient to facilitate formation of a Vpr–GR–
PARP-1 complex. Evidence also suggests that the recruitment of PARP-1 by the Vpr–GR 
complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-κB. An 
interaction between the GR and Vpr has been further demonstrated in vitro by co-
immunoprecipitation experiments (Kino et al. 1999). Consistent with a role for GR in Vpr-
mediated gene regulation it has been shown that GR antagonist, RU-486, reversed the Vpr-
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mediated repression of several cytokine genes in PBMCs (Ayyavoo, Mahboubi, et al. 1997; 
Mirani et al. 2002).   
Although RU-486 has shown to inhibit Vpr-activated LTR transcription (Soudenys & 
Wainberg 1997; Schafer et al. 2006) there is currently no direct evidence that a GR–Vpr 
interaction plays a role in HIV-LTR transcription via the non-classical GREs in the LTR 
(Hapgood & Tomasicchio 2010). 
1.8  Progesterone and the progestins medroxyprogesterone acetate & 
norethisterone acetate 
In addition to GCs, the GR can be activated by other steroid hormones such as the 
progestogens; progesterone (P4), medroxyprogesterone acetate (MPA) and norethisterone 
(NET) and its derivatives NET-acetate (NET-A) or NET-enanthate (NET-EN) (Hapgood et 
al. 2004; Koubovec et al. 2005). Progestogens can be divided into two types, natural and 
synthetic (Stanczyk et al. 2013). There is only one natural progestogen which is P4 (Figure 
1.3 A) (Schindler et al. 2003).  P4 is secreted primarily by the corpus luteum in the ovaries of 
females and plays a key role in the mammalian reproductive system (Graham & Clarke 1997; 
Africander, Verhoog, et al. 2011). For example it is important for the development and 
regular functioning of the mammary gland and uterus, for the control of ovulation, and it 
prepares the endometrium for implantation through cell proliferation (Madauss et al. 2007; 
Winneker et al. 2008). Furthermore, high levels of P4 are responsible for the lack of 
ovulation during pregnancy and this inhibitory effect of P4 is the basis for oral contraceptives 
(OCs) (Madauss et al. 2007). However, due to poor bioavailability (< 5%) and short half-life 
of P4, its use as a contraceptive is limited (Stanczyk et al. 2013). Consequently, synthetic 
progestogens (progestins) were designed to mimic the actions of P4, while having a better 
half-life and a more favourable bioavailability than the natural ligand.  The progestin, MPA 
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(Figure 1.3 B), is structurally related to P4 and is a pregnane derivative while NET-A (NET is 
the active metabolite) (Figure 1.3 C) is an estrane derivative and structurally similar to 
testosterone (Stanczyk et al. 2013). Both MPA and NET-A are 1st generation progestins and 
are widely used in contraception and hormone replacement therapy (HRT) (Sitruk-Ware 
2003). 
 
Figure 1.3: The chemical structures of (A) progesterone (P4), (B) medroxyprogesterone 
acetate (MPA) and (C) norethisterone acetate (NET-A) adapted from (Hapgood et al. 2004).  
 
1.7.1. MPA and NET-A in contraception 
MPA and NET-A are used as progestin-only contraceptives and are administered by injection 
(Hapgood et al. 2004). MPA, commercially available as Depo-Provera® or DMPA, is 
administered at a dose of 150 mg every 3 months (Hapgood 2013). The contraceptive effect 
of MPA stems primarily from its action at the pituitary and hypothalamic levels. Specifically, 
MPA prevents the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating 
17 
 
hormone (FSH), which is necessary for ovulation (Rivera et al. 1999; Erkkola & Landgren 
2005). Thus suppression of ovulation is considered the main mechanism of action (Jain et al. 
2004). In addition, MPA has an effect on cervical mucus whereby the mucus becomes thick 
and consequently makes sperm penetration unlikely (Rivera et al. 1999). Changes in the 
cervical mucus usually develop within 24 hours of injection but in some cases may take as 
long as 3 to 7 days (Rivera et al. 1999).  MPA also transforms the endometrium making it 
thin and atrophic (Rivera et al. 1999). These changes stem from inhibition of ovarian function 
(Erkkola & Landgren 2005). NET-A is administered at a dose of 200 mg every 2 months. The 
mechanism of action of NET-A is the same as that of MPA but it is effective for a shorter 
period of time (Rivera et al. 1999). The contraceptive actions of MPA and NET-A are 
mediated by the PR and these actions are generally referred to as progestogenic effects 
(Hapgood et al. 2013). Although the progestins are effective in preventing pregnancy there 
are a range of side-effects (i.e. off-target effects) associated with their use such as irregular 
bleeding, amenorrhea, breast tenderness and migraines (Paul et al. 1997; Schrager 2002; 
Westhoff 2003). In addition, the use of progestins has been associated with more life-
threatening diseases such as increased risk of breast cancer, cardiovascular disease and 
pulmonary emboli (Sitruk-Ware 2004; Ghatge et al. 2005). 
1.7.2. MPA and NET-A off-targets effects are mediated via other steroid receptors 
The off-target/non-progestogenic effects of MPA and NET-A are mediated by other steroid 
receptors (SRs) such as the androgen receptor (AR), mineralocorticoid receptor (MR), 
estrogen receptor (ER) and GR (Schindler et al. 2003; Hapgood et al. 2013). Both MPA and 
NET-A have been reported in cell lines to act like agonists for transactivation via the AR 
(Ghatge et al. 2005; Sonneveld et al. 2006; Sasagawa et al. 2008; Africander et al. 2014). 
This is in agreement with reports that indicate that the disruption of AR action by progestins 
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may increase the risk of developing breast cancer since the balance between estrogen 
signalling and androgen signalling plays a critical role in breast homeostasis (Birrell et al. 
2007). Table 1.1 summarizes the progestogens biological activity via the SRs. 
Table 1.1 Biological activity of the progestogens via the SRs 

















+ + - - + + 
Taken and modified from Schindler et al. 2003 and Hapgood et al. 2013. Key to hormonal activities: 
−, not effective; +, effective; + +, strongly effective. 
Recent reports have confirmed that both MPA and NET-A display similar binding affinities 
for the MR (Africander et al. 2013), however, they display no MR agonist activity and weak 
MR antagonist activity (Sasagawa et al. 2008; Africander et al. 2013). It is suggested that 
they are unlikely to exert significant effects via the MR at doses used in hormonal therapy 
(Africander et al. 2013). This lack of anti-mineralocorticoid activity is associated with 
increased risk of cardiovascular disease and blood pressure in progestin usage (Young et al. 
1994; Delyani 2000). Table 1.2 illustrates the relative binding affinities (RBAs) of the 
progestogens for the SRs. 
It has been reported that MPA has a higher RBA (DEX reference agonist = 100%) compared 
to NET-A and P4 for the human GR as illustrated in Table 1.2  (Koubovec et al. 2005; 
Hapgood et al. 2013). Although RBA does not necessarily reflect biological activity, it has 
been shown in cell lines that MPA acts as a partial to full agonist for both transactivation and 
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transrepression via the GR while P4 acts a partial agonist and NET-A as an antagonist 
(Koubovec et al. 2004; Koubovec et al. 2005; Ronacher et al. 2009; Hapgood et al. 2013). 
This is consistent with MPA having a greater GC potency than P4 and NET-A for 
transactivation and transrepression (Koubovec et al. 2005). Furthermore, it has been reported 
that GR levels dictate the behaviour of MPA in transrepression (Zhao et al. 2003). When GR 
density is high MPA behaves as a full agonist whereas when GR density is low, MPA acts as 
an antagonist (Zhao et al. 2003). The GR agonist activity of MPA has major implications for 
regulation of immune function and inflammation (Hapgood et al. 2004). 
Table 1.2 Relative binding affinities (RBAs) % of the progestogens for the SRs 
Progestogen PR GR MR AR ER 
P4 100 5.6  9 - 1000 3 -80 0.5 
MPA 65 - 298 79 0.1 - 160 36 < 0.02 
NET/NET-
A/NET-EN 
134 0.88 - 1.6 0 – 2.7 55 0.15 
Taken and modified from Koubovec et al. 2005, Africander et al. 2011 and Hapgood et al. 2013. The 
reference radiolabelled ligands and ligands used for 100% RBA were as follows: PR, P4; GR, DEX; 
MR, aldosterone (ALD); AR, testosterone; ER, estradiol (E2).  
1.9  The female genital tract 
The mucosal barrier formed by the epithelial cells of the female genital tract (FGT) forms the 
first line of defence against the entry of pathogens (Shey et al. 2013). STIs, including HIV-1, 
have to breach this barrier to establish infection (Ferreira et al. 2014).  The FGT can be 
divided into two major areas the upper and lower FGT. The upper FGT can be subdivided 
into the sterile uterus and uterine/fallopian tube, while the lower FGT consists of the sterile 
endocervix and non-sterile vagina and ectocervix (Fichorova et al. 1997; Quayle 2002; 
Trifonova et al. 2014) as illustrated in Figure 1.4. The mainly sterile endocervix is separated 
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from the ectocervix by the transformation zone. The endocervix is comprised of columnar 
epithelial cells with numerous glands which produce mucus, which can trap microbial 
pathogens and prevent the ascent of bacteria (Fichorova et al. 1997; Wira et al. 2014). In 
addition, the columnar epithelial cells have tight junctions in between them which provide 
barrier protection (Hickey et al. 2011). In contrast, the ectocervix and vagina consist of 
stratified squamous epithelial cells which produce a hydrophilic layer of glycoprotein called 
the glycocalyx, which provides moisture (Quayle 2002). The commensals such as 
Lactobacillus spp. which colonize the mucosa play a significant role in vaginal defence by 
maintaining an acidic micro-environment (Quayle 2002; Borges et al. 2014).  
 
 
Figure 1.4: Schematic representation of the female genital tract. Taken and modified 




The FGT is capable of both innate and acquired immune responses which are highly 
regulated by cyclic changes in the sex hormones estradiol (E2) and P4 (Beagley & Gockel 
2003). Innate FGT immunity involves mostly macrophages, neutrophils and dendritic cells 
which are important cells that phagocytose and subsequently kill pathogens through acidic 
and enzymatic digestion (Hickey et al. 2011; Shey et al. 2013; Wira et al. 2014). Innate 
immunity is also assisted by the epithelial cells which produce anti-microbial peptides such 
as the defensins (α and β) (Hickey et al. 2011). Acquired immunity entails pathogen-specific 
defence responses and involves the recruitment of CD4+ T-cells, CD8+ T-cells and B-cells 
by antigen-presenting dendritic cells (Hickey et al. 2011; Shanmugasundaram et al. 2014). 
Constitutive expression of cytokines and chemokines ensure the presence and activity of 
immune cells immediately on antigen presentation (Wira et al. 2005). 
1.10  The role of MPA in inflammation, cervical mucosal immunity and HIV-1 
pathogenesis 
Lines of evidence have shown that MPA plays a role in inflammation and it has been 
suggested that the GR may be involved in mediating these actions (Hapgood et al. 2004; 
Hapgood 2013; Huijbregts et al. 2013). It has been shown in numerous in vitro (Bamberger et 
al. 1999; Mantovani et al. 2000; Kurebayashi et al. 2003; Elovitz & Wang 2004; Koubovec 
et al. 2004; Huijbregts et al. 2013) and animal in vivo (Trunova et al. 2006; Kleynhans et al. 
2013) studies over the years that MPA has anti-inflammatory activity. For example, it has 
been reported in cell lines that MPA, unlike P4, represses IL-2, IL-6 and IL-8 synthetic 
promoter reporter genes and endogenous IL-2 and IL-6 protein expression (Bamberger et al. 
1999; Koubovec et al. 2004). Furthermore, it was determined in the KTC-2 (thyroid cancer) 
cell line and PBMCs that MPA represses IL-6 mRNA and IL-6 protein, respectively 
(Bamberger et al. 1999; Kurebayashi et al. 2003). Reports also show that in PBMCs that 
22 
 
MPA suppressed phytohemaglutinin-induced IL-6, IL-1β and TNF-α. It has also been 
reported that MPA suppresses cytokines IL-1α, IL-12 p40, IL-10, IL-13, TNF-α and IFN-γ in 
human PBMCs and mouse models infected with Mycobacterium tuberculosis (Kleynhans et 
al. 2011; Kleynhans et al. 2013). Similarly, Hapgood et al. found in PBMCs that MPA 
suppresses pro-inflammatory mediators IL-6 and IL-8 (Hapgood et al. 2014). In addition, 
MPA suppresses cellular immune responses in simian-human immunodeficiency virus 
(SHIV)-infected rhesus macaques (Trunova et al. 2006). Consistent with this, a recent study 
has found that in both PBMC from non-infected and HIV-1 infected individuals, MPA 
significantly represses the levels of most cytokine and chemokine proteins, such as TNF-α, 
IFN-γ and IL-12 (Huijbregts et al. 2013). Furthermore, MPA has been shown to increase 
apoptosis of T-cells, which is enhanced after HIV-1 infection, potentially decreasing the 
ability of T-cells to mount an anti-viral defence (Tomasicchio et al. 2013). 
In addition to cellular immunity, evidence also shows that MPA plays a role in regulating 
cervical mucosal immunity and thereby influences susceptibility and disease predisposition to 
many genital tract infections (Mestecky et al. 2009; Kaushic, Roth, et al. 2011). As 
mentioned earlier, the mucosal environment of the FGT is comprised of the vaginal, 
ectocervical and endocervical regions and serves as the entry point for STI’s (Fichorova et al. 
1997; Rodriguez-Garcia et al. 2013). These regions display different immunological profiles 
as they constitutively express a distinct array of cytokines (IL-1, IL-6 and TNF-α) and 
chemokines (IL-8 and RANTES) with the endocervical cells being more active in cytokine 
secretion than the vaginal and ectocervical cells (Fichorova & Anderson 1999; Fichorova et 
al. 2001; Rodriguez-Garcia et al. 2013). Reports show that MPA treatment of mice was 
found to increase their susceptibility to genital herpes simplex virus type 2 (HSV-2) infection 
(Kaushic et al. 2003). Consistent with this, MPA-usage has been found to be associated with 
increased acquisition of cervical chlamydial and gonococcal infections (Baeten et al. 2001; 
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Morrison et al. 2004). Clinical reports also show that the use of MPA in HIV-1 seropositive 
patients is associated with an increased risk of genital ulcer disease (Lavreys, Baeten, Kreiss, 
et al. 2004). Evidence also suggests that increased shedding of HIV-1 infected cells from the 
cervix and vagina is associated with MPA usage (Mostad et al. 1997). This is consistent with 
findings that show a modest but significant increase in cervical shedding of HIV-1 DNA 
detected with MPA usage (Wang et al. 2004).  
The risk associated with HIV-1 acquisition and MPA usage is controversial. However, it has 
been reported that there is an increase in risk of both HIV-1 acquisition and transmission with 
the injectable hormonal contraceptive (Martin et al. 1998; Lavreys, Baeten, Martin, et al. 
2004; Baeten et al. 2007; Heffron et al. 2012). In contrast, some findings show no association 
between MPA-usage and HIV-1 acquisition (Morrison et al. 2007; Myer et al. 2007; 
Morrison et al. 2012). Notably, although the Morrison et al. study found no significant 
increase in the risk of HIV-1 acquisition they do mention that the effect estimate of their 
study does not rule out a moderate increase in HIV risk associated with DMPA use found in 
other studies (Morrison et al. 2012). There are several proposed mechanisms for increased 
HIV-1 susceptibility with MPA (Murphy et al. 2014). As reviewed in Murphy et al. possible 
mechanisms include thinning or disruption of the cervicovaginal epithelial barrier and/or 
alterations in the vaginal microbiome (Murphy et al. 2014). Some reports also suggest that 
MPA increases susceptibility by suppressing pro-inflammatory mediators and thereby 
lowering host resistance to HIV-1 and invading pathogens (Hapgood 2013; Huijbregts et al. 
2013) while others associate MPA-usage with an increase in pro-inflammatory markers and 
thereby an increase in the recruitment of HIV-1 target cells (Morrison, Fichorova, et al. 
2014). For example, the Gillgrass et al. study found longer treatment (15 days) with MPA 
failed to protect mice from subsequent HSV-2 challenge due to a decrease in both innate and 
adaptive immune responses (Gillgrass et al. 2003). This is consistent with the Huijbregts et 
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al. study that investigated the effects of MPA on vaginal mucosal mononuclear cells 
(VMMCs) isolated from human vaginal tissue and showed immunosuppressive effects for 
MPA on IFN-γ (Huijbregts et al. 2013). This group also showed that there are lower IFN-γ 
levels in cervico-vaginal lavage (CVL) samples from individuals on MPA (Huijbregts et al. 
2013). In contrast to this, a more recent study by the Morrison group has shown that MPA-
usage is associated with higher pro-inflammatory cytokines and chemokines such as 
RANTES in CVL samples (Morrison, Fichorova, et al. 2014). 
In summary, although there have been conflicting reports on whether MPA increases HIV-1 
acquisition or not, the general consensus is that MPA does play a role in regulating cervical 
mucosal immunity and this increases susceptibility to genital tract infections such as HSV-2 
and possibly HIV-1. In addition, the mechanism of the MPA-mediated regulation of cervical 











Chapter 2: Thesis rationale, Hypotheses & Aims 
2.1 Thesis rationale 
The usage of injectable contraceptives is very high in some areas of South Africa, such as at 
the Kwazulu-Natal site for the CAPRISA microbicide trial, where about 82% of the women 
investigated were on injectable progestin-only contraceptives (DMPA and NET-EN), as 
compared to 15% on oral contraceptives (Abdool Karim et al. 2010). Most, but not all, high 
quality observational clinical studies report that injectable DMPA usage, increases risk of 
HIV-1 acquisition (Heffron et al. 2012; Wand & Ramjee 2012; Crook et al. 2014; Morrison, 
Chen, et al. 2014; Polis et al. 2014). However, whether or not injectable contraceptives 
increase susceptibility to heterosexual transmission of HIV in developing countries is still 
controversial (Morrison et al. 2012; McCoy et al. 2013; Jones 2014; Polis et al. 2014; Rees 
2014; Westhoff & Winikoff 2014). A recent systematic review of epidemiological evidence 
showed most studies suggested no significantly increased HIV risk with NET-EN. However, 
increased HIV risk with NET-EN in some studies tended to be larger than for DMPA, though 
95% confidence intervals overlapped substantially (Polis et al. 2014).  However, the World 
Health Organisation (WHO) 2014 guidance statement does not recommend discontinuation 
of DMPA usage  but they do recommend that women on DMPA should use condoms (WHO 
2014). Following this report there has been raging debate on whether randomized clinical 
trials are needed to conclusively determine whether DMPA increases the risk of HIV-1 
acquisition or whether sufficient evidence already exists on the increased HIV risk with 
DMPA (Jones 2014; Rees 2014; Westhoff & Winikoff 2014).  
The mucosa of the lower FGT which consists of the vaginal, ectocervical and endocervical 
compartments is the first line of defence against pathogens (Fichorova et al. 1997). Although 
the epithelial cells of the FGT do not get productively infected by HIV-1, they express a wide 
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variety of immune mediators aiding in both innate and adaptive immunity (Kaushic et al. 
2010; Kaushic et al. 2011 b; Rodriguez-Garcia et al. 2013). There have been conflicting 
reports on whether MPA increases or decreases inflammation in the FGT (Huijbregts et al. 
2013; Morrison, Fichorova, et al. 2014). A question which remains unanswered is whether 
doses of MPA used in injectable contraception regulate inflammation of cervical mucosal 
immunity and whether this increases host susceptibility to HIV-1 and STIs. In addition, the 
mechanism of MPA-mediated inflammatory regulation in the lower FGT is unclear. It is 
crucial to understand the molecular mechanisms of hormonal contraceptives such as MPA 
since it is a factor that influences inflammation and disease susceptibility of the lower FGT.  
The off-target anti-inflammatory effects of MPA have been proposed to be mediated via the 
GR (Hapgood et al. 2004; Koubovec et al. 2004; Koubovec et al. 2005). The study by 
Koubevec et al. was the first to show by dose-response analysis of GRE- and NF-κB/AP-1 
regulated reporter genes that MPA, unlike NET-A, acts as a partial agonist for the GR in the 
human  lung cancer (A549) cell line (Koubovec et al. 2005). However, it is uncertain whether 
the effects of MPA are mediated by the GR in any of the three compartments of the lower 
FGT. Although a recent study suggested that MPA-mediated anti-inflammatory effects in 
VMMCs are via the GR by antagonist experiments using RU-486, a GR and PR antagonist 
(Huijbregts et al. 2013), there have been no studies showing proof of direct GR mechanism 
of action by MPA in the FGT. In addition, there have been no studies showing the precise 
mechanism of GR-mediated gene regulation in response to MPA in the FGT. 
The role of MPA in modulation of HIV-1 pathogenesis has been proposed to involve not only 
the GR but also HIV-1 Vpr (Hapgood & Tomasicchio 2010). It has been previously reported 
that the virion associated HIV-1 protein, Vpr, is immunosuppressive and possibly interacts 
with the GR (Ayyavoo, Mahboubi, et al. 1997; Mirani et al. 2002). Evidence suggests that 
Vpr may act as a co-activator of the GR in the regulation of reporter genes in the presence of 
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DEX (Kino et al. 1999; Sherman et al. 2000). There are limited data on whether Vpr and GR 
interact to regulate endogenous inflammatory genes in the presence of DEX (Fakruddin & 
Laurence 2005). Additionally, since the GR has been shown to be activated by MPA and P4, 
it is possible that Vpr may also modulate progestin-mediated inflammatory gene regulation. 
The off-target effects of MPA mediated by the GR may not only be important in immune 
function regulation but also for viral gene expression in the FGT in response to HIV-1. In 
addition to its role in inflammatory gene regulation, the GR has been reported to be involved 
in the regulation of HIV-1 LTR transcription in the presence of DEX (Kino et al. 2000; 
Sawaya et al. 2000). However, the direct role of the GR in this DEX-mediated modulation 
has not been shown. In addition, it has been shown that P4 represses Tat-activated HIV-1 
LTR transcription (Lee et al. 1997). However, there are no data showing the effect of 
synthetic progestins on HIV-1 LTR regulation. Vpr has previously been shown to enhance 
Tat-activated HIV-1 LTR transcription (Kino et al. 2002). Considering Vpr may act as co-
activator of the GR in the regulation of inflammatory genes, it is proposed that Vpr may play 
a role in GR-mediated LTR transcription in the presence of DEX and the progestogens. 
2.2 Hypotheses, Aims and Strategies 
From the literature it is clear that the progestins MPA and NET-A differ from each other and 
to that of the natural hormone P4 in their off-target biological activity via SRs other than the 
PR. In particular MPA appears to be immunosuppressive, unlike NET-A and P4.  However, 
little is known about the molecular mechanism of action of MPA and NET-A in the cervical 
mucosa. To this end it was hypothesized that MPA and NET-A would differentially 
regulate inflammatory gene expression in the cervical mucosa. In addition, it was 
hypothesized that the MPA-mediated gene regulation occurs via the GR. Thus in the 
present study, the regulation of inflammatory genes GILZ, IκBα, IL-6, IL-8 and RANTES by 
28 
 
MPA, NET-A and P4 was investigated in cell models for cervical mucosa. Dose response 
analysis, time course experiments, SR screening, GR knockdown, de novo protein synthesis 
inhibition and chromatin immunoprecipitation (ChIP) assays were performed to assess 
mechanism of action. The host genes (GILZ, IκBα, IL-6, IL-8 and RANTES) investigated in 
this thesis were chosen based on the key roles they play in mediating inflammatory actions 
and because they have been previously shown to be regulated in a GR-dependent manner 
(Auphan et al. 1995; Newton & Holden 2007; Hadley et al. 2011; Verhoog et al. 2011) 
whereby GILZ and IκBα are examples of GR transactivation model genes and IL-6, IL-8 and 
RANTES are examples of transrepression model genes.  
The epithelial cells of the endocervix constitutively express IL-6, IL-8, and RANTES genes 
(Fichorova & Anderson 1999), with the endocervical cells being more active in cytokine 
secretion than the ectocervical cells (Fichorova et al. 2001). Thus, the End1/E6E7 
endocervical cell line was chosen as the model to investigate inflammatory gene regulation. 
In addition, this cell line displays similar morphological and immunocytochemical properties 
to those of primary endocervical epithelial cells (Fichorova et al. 1997). The experiments in 
this thesis were performed in the absence of induction of the cytokine/chemokine genes with 
a pro-inflammatory ligand since these genes are constitutively expressed in cervical epithelial 
cells (Fichorova & Anderson 1999). Ligand concentrations for DEX (100 nM), P4 (10 μM), 
MPA (1 μM)  and NET-A (10 μM) were calculated to result in GR saturation based on the 
KD’s and were used for some experiments, unless otherwise indicated (Kontula et al. 1983; 
Ronacher et al. 2009). 
Literature also suggests that the GR may play a key role in regulating immune function and 
HIV-1 pathogenesis via interaction with Vpr. It was therefore hypothesized that Vpr acts a 
co-activator of the GR and results in the modulation of GR-regulated inflammatory 
genes in the presence of DEX, P4 and the synthetic progestins. Thus in the present study, 
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the effect of Vpr on the regulation of GR-regulated reporter gene and endogenous 
inflammatory gene expression in the presence of the ligands was investigated. The Vpr study 
was done in the HeLa cervical epithelial and TZM-bl (modified HeLa cell line that expresses 
CD4, CXCR4 and CCR5 and contains a stably integrated HIV-1 LTR promoter) cell lines. 
Two different strategies were used to deliver Vpr into the cervical epithelial cells. The first 
was the use of a HA-tagged Vpr expression vector and the second was the use of HIV-1 
pseudovirus to deliver physiological amounts of Vpr protein and is thus a more physiological 
delivery method.  
It was also hypothesized that the GR and/or Vpr regulate HIV-LTR transcription in the 
presence of DEX, P4 and the synthetic progestins. This hypothesis was investigated by 
examining the role of Vpr in the regulation of the LTR in the presence of the ligands. In 
addition, the role of GR in LTR transcription in the presence of the ligands was investigated 
by GR knockdown. LTR luciferase reporter gene assays were done in the HeLa and TZM-bl 
cell lines to assess regulation of LTR transcription. The TZM-bl cells contain a stably 
integrated HIV-1 LTR-luc gene while for the HeLa cells; an HIV-1 LTR-luc expression 
vector was used.  
The current study chose cell line models to represent cervical epithelial cells. The author is 
well aware of the limitations of cell line models; however, choice of model is very question 
dependent and cell lines can be a useful tool to perform biochemical experiments to answer 
questions about direct effects and mechanism of action. This was the case in this study, where 
questions regarding the role of the GR, Vpr and progestogens on host inflammatory and viral 





Chapter 3: Material and Methods 
3.1 Compounds and antibodies 
The following primary antibodies were obtained from Santa Cruz Biotechnology, USA; GR 
(H-300; sc-8992), PR (C-20; sc-539), AR (441; sc-7305), ERα (MC-20; sc-542) and MR 
(MCR, H-300; sc-11412) and GAPDH (0411; sc-47724). The HA (12CA5) antibody was 
obtained from Roche Applied Science, South Africa. The flotillin-1 (610820) antibody was a 
purchased from BD Transduction Laboratories (USA).  The following secondary antibodies 
were obtained from Santa Cruz Biotechnology inc., USA; anti-mouse: sc-2005 and anti-
rabbit: sc-2313. Ampicillin was obtained from Sigma-Aldrich, South Africa. The ligands 
dexamethasone (DEX), 6α-Methyl-17α-hydroxyprogesterone acetate (MPA), progesterone 
(P4), norethisterone acetate (NET-A), norethisterone (NET), promegestone (R5020), 
aldosterone (ALD), mibolerone (MIB) and estradiol (E2) were obtained from Sigma-Aldrich, 
South Africa. The hormone ligands were reconstituted in 100% EtOH as recommended in the 
specification sheets provided by Sigma-Aldrich, South Africa. It is also worth noting that 
hormone incubations were performed by using 0.1 % v/v reconstituted hormone or vehicle 
control. Tumor Necrosis Factor-α (TNF-α) was purchased from Merck chemicals, South 
Africa. Cycloheximide (CHX) was purchased from Sigma-Aldrich, South Africa. 
3.2 Plasmids 
The pTAT.GRE-E1b-luc (TAT-GRE) luciferase reporter gene plasmid is controlled by the 
inducible E1b promoter and contains two glucocorticoid response elements (GRE) from the rat 
tyrosine aminotransferase (TAT) gene, and was a gift from Dr. G. Jenster (Erasmus University 
of Rotterdam, Rotterdam, Netherlands) and has been described before (Sui et al. 1999). The 
pcDNA3 (empty vector) plasmid contains a CMV promoter in the pcDNA vector with no 
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inserted downstream DNA sequence and was obtained from Invitrogen, UK. The SR plasmid 
pcDNA3-hGR (GR) constitutively expresses the full length and untagged human GRα isoform 
cloned into the pcDNA3 vector and was a kind gift from Prof. D.W. Ray (University of 
Manchester, UK) and previously described (Ray et al. 1999). The pMT-PR-B (PR) plasmid 
constitutively expresses the full length and untagged human PR-B isoform cloned into the pMT 
vector and was obtained from Prof. S. Okret (Karolinka Institute, Sweden).  The pRS-hMR 
(MR) plasmid constitutively expresses the full length and untagged human MR cloned into the 
pRS vector and was obtained from Prof. R.M. Evans (University of California, USA) and has 
been described previously (Arriza et al. 1987). The pSV-hAR (AR) plasmid was a gift from 
Prof. F. Claessens (Catholic University of Leuven, Belguim) and constitutively expresses the 
full length and untagged human AR cloned into the pSV vector and previously described 
(Brinkmann et al. 1999). The pSG5-hER (ER) plasmid constitutively expresses the full length 
and untagged human ER cloned into the pSG5 vector and was obtained from Prof. F. Gannon 
(European Molecular Biology Laboratory, Germany) and previously described (Zhou & Chen 
2001). The ERE-luc luciferase reporter gene plasmid contains the estrogen response element 
(ERE) and was also obtained from Prof. S. Okret (Karolinka Institute, Sweden). The 
pCMV4-3HA-Vpr (HA-Vpr) plasmid expresses a HA tagged variant of Vpr protein obtained 
from the HIV-1 type B NL4-3 clone and is under control of a constitutive CMV promoter in the 
CMV4 vector plasmid. It was obtained from Dr. W. Greene (University of California, San 
Francisco) and has been described previously (Sherman et al. 2000). The pSVtat72 (Tat) 
plasmid expresses Tat protein (residues 1-72) and is controlled by the SV40 early promoter 
(Frankel & Pabo 1988). The pBlue3’LTR-luc (HIV-1 LTR-luc) luciferase reporter gene 
plasmid expresses LTR for HIV-1 subtypes A, C, D, E, F, and G (Jeeninga et al. 2000). Both 
the Tat and HIV-1 LTR-luc plasmids were obtained from NIH AIDS Research and Reference 
Reagent Program (Germantown, MD, USA).  The p1168hu-IL-6P-luc (IL-6 full length 
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reporter) reporter gene plasmid expresses the full length human IL-6 promoter while the 
p(IL-6κB)3-50hu.IL-6P-luc (IL-6 minimal reporter) reporter gene plasmid is a derivative of 
the IL-6 full length reporter plasmid and only contains three motifs of the NFκB binding 
sites. Both the IL-6 full length reporter and IL-6 minimal reporter plasmids were obtained 
from Prof. G. Haegeman (University of Ghent, Belgium) (Plaisance et al. 1997). The 
following pseudovirus constructs pDU151A (encoding the HIV-1 envelope (env) which 
displays R5 tropism) (Williamson et al. 2003)), pSg3E- (containing the HIV-1 genomic 
sequences with a mutated env gene) (Andjelic et al. 2008), pLET-LAI (encoding the HIV-1 
env which displays X4 tropism), pNL4-3.E- (containing the HIV-1 genomic sequences with a 
mutated env gene) and pNL4-3.E-R- (containing the genomic sequences with a mutated env 
and vpr gene) were obtained from the NIH AIDS Research and Reference Reagent program. 
3.3  Plasmid transformation and preparation 
Plasmids were prepared by transformation into competent Escherichia coli DH5α bacterial 
cells. This was done as described in Sambrook et al. but briefly, to 100 µl of competent cells 
50 ng plasmid DNA was added and mixed, without vortexing (Sambrook et al. 1989). The 
mixture was then incubated on ice for 20 mins, heat shocked for 45 secs at 42°C and placed 
back on ice for 5 mins.  Thereafter 1 ml SOC medium [2% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM glucose] was added and 
then placed at 37°C for 60 mins, shaking. Then, 200 µl of the mixture was plated out on a 
LB-AMP selection plate [1% (w/v) tryptone, 0.5% yeast extract, 1% NaCl and 1.5% agarose 
containing 50 µg/ml ampicillin]. The remainder was centrifuged, the supernatant was 
discarded, while the pellet was resuspended in 200 µl SOC and plated on a selection plate. 
The selection plates were incubated overnight at 37°C. A day culture was prepared by 
inoculating a bacterial colony in 5 ml LB medium [1% (w/v) tryptone, 0.5% yeast extract and 
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1% NaCl] with ampicillin (100 ng/µl), and placed at 37°C. After approximately 8 hrs, 1 ml of 
the day culture was inoculated in 100 ml LB with ampicillin (100 ng/µl) and placed at 37°C 
overnight for preparation of plasmid DNA. The DNA was purified using the Promega® 
Midiprep system catalogue no. A2492 (Promega, USA) following manufacturer’s protocol. 
The purified DNA was quantified using a NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies).  
3.4  Restriction enzyme digest 
Restriction enzyme digests of plasmid DNA were performed to ensure the correct plasmid 
was purified and that the plasmid was in the proper conformation (i.e. supercoiled). A 
standard 50 µl reaction consisting of 1 unit enzyme, 5 µl (10X) enzyme buffers, 300 ng DNA 
and distilled water was set up for each digest. The control (undigested) reaction for each 
plasmid contained only 300 ng DNA and distilled water. After a reaction time of 1 hr at 
37°C, the RE digest samples were electrophorated on a 10 µg/ml ethidium bromide (EtBr) 
stained 0.8% agarose gel in 1X TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, 
pH 8) at 90 V for 45 mins and visualized under short wavelength ultraviolet light using a 
Syngene, G:Box (Vacutec).  
3.5  Cell culture  
Human epithelial cervical cancer cells (HeLa), monkey kidney fibroblast cells (COS-1) and 
human embryonic kidney cells (HEK293T) were purchased from the American Type Culture 
Collection (ATCC, USA). TZM-bl (HeLa cells modified to contain a stably integrated HIV-1 
LTR-luc and express CD4, CXCR4 and CCR5) cells were obtained from the NIH AIDS 
Research and Reference Reagent program. The above mentioned cell lines were cultured in 
75 cm2 flasks (Greiner Bio-one International, Austria) in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich, South Africa) supplemented with 10% (v/v) fetal calf 
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serum (FCS) (Highveld Biological, South Africa) 100 IU/mL penicillin and 100 μg/mL 
streptomycin (Gibco, Invitrogen, UK). 
Human endocervical cells immortalized with human papillomavirus 16 E6/E7 (End1/E6E7) 
(Fichorova et al. 1997) were obtained from Dr Fichorova, Brigham & Women’s Hospital, 
Boston, USA. The End1/E6E7 cells were cultured in 175 cm2 flasks (Greiner Bio-one 
International, Austria) in keratinocyte serum-free medium (ker-sfm) (Sigma-Aldrich, South 
Africa) supplemented with the provided keratinocyte growth supplement, 100 U/ml penicillin 
and 100 μg/ml streptomycin (Gibco, Invitrogen, UK).  
All cells were maintained at 37°C in a 5% CO2 incubator. Cells were passaged with 0.25% 
trypsin/0.1% EDTA in PBS (Highveld Biological, South Africa). Trypsinization was 
terminated with neutralization medium [DMEM (Sigma-Aldrich, South Africa), 10% (v/v) 
calf serum (Highveld Biological, South Africa), 100 U/ml penicillin and 100 μg/ml 
streptomycin (Gibco, Invitrogen, UK)]. The cell lines were regularly tested for mycoplasma 
infection by means of Hoechst staining (Freshney 1987), and only mycoplasma-negative cells 
were used in experiments. 
3.6  Reporter assays 
3.6.1 SRE promoter-reporter assay 
HeLa cells or End1/E6E7 cells were seeded into 24-well plates (Greiner Bio-one, Cellstar) at 
a density of 7.5 x 104 cells/well or 17.5 x 104 cells/well, respectively and incubated for 24 hrs. 
For the Vpr overexpression assays, the HeLa cells were transiently transfected with 82 
ng/well TAT-GRE and 125 ng/well HA-Vpr or empty vector. For the Vpr dose assays, the 
HeLa cells were transiently transfected with an increasing dose (25 ng, 125 ng and 300 
ng)/well of HA-Vpr. For the assays with the overexpressed SRs,  both cell lines were 
transfected with 82 ng/well TAT-GRE or 250 ng/well ERE-luc and 125 ng/well of either GR, 
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PR, AR, ER or MR expression vectors. For all assays the cells were transiently transfected 
using FuGENE™ 6 (Roche Applied Science, South Africa) according to manufacturer’s 
instructions and incubated for 24 hrs. On day three, cells were washed once with PBS and 
were treated with the respective compounds or vehicle (EtOH) in serum free DMEM medium 
for 24 hours. The cells were harvested by washing twice with PBS and lysed in 50 µl 1X 
Reporter lysis buffer (Promega, Madison, WI, USA). Luciferase activity in the lysates was 
measured using the Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus 
microplate luminometer (Turner Biosystems, Sunnyvale, CA, USA). The luciferase values 
obtained were normalized to protein content per well as determined by standard Bradford 
assay (Bradford 1976). It is important to note that prior to performing the reporter assays 
above and below, transfection conditions were optimized for both cell density and DNA 
amount. Cells were seeded to obtain an optimal confluency of 60% - 70% for transfection. 
DNA concentration was optimized for each reporter plasmid by adding increasing amounts of 
plasmid DNA (15 ng, 47 ng, 82 ng, 125 ng and 250 ng)/well and assessing for optimal 
reporter activity.  
3.6.2 HIV-1 LTR promoter-reporter assay 
HeLa cells were seeded into 24-well plates (Greiner Bio-one, Cellstar) at a density of 7.5 x 
104 cells/well. The next day, the cells were transiently transfected with 47 ng/well HIV-1 
LTR-luc, 125 ng/well Tat and 125 ng/well Vpr or empty vector. The cells were transfected 
using FuGENE™ 6 (Roche Applied Science, South Africa) according to manufacturer’s 
instructions and incubated for 24 hrs. On day three, the cells were washed once with PBS and 
were treated with the respective compounds or vehicle (EtOH) in serum free DMEM medium 
for 24 hours. The cells were harvested by washing twice with PBS and lysed in 50µl 1X 
Reporter lysis buffer (Promega, Madison, WI, USA). Luciferase activity in the lysates was 
measured using the Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus 
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microplate luminometer (Turner Biosystems, Sunnyvale, CA, USA). The luciferase values 
obtained were normalized to protein content per well as determined by standard Bradford 
assay (Bradford 1976). 
3.6.3 IL-6 full length and minimal promoter-reporter assays 
HeLa cells were seeded into 24-well plates (Greiner Bio-one, Cellstar) at a density of 7.5 x 
104 cells/well. The next day, the cells were transiently transfected with 250 ng/well IL-6 full 
length reporter plasmid or IL-6 minimal reporter plasmid. The cells were transfected using 
FuGENE™ 6 (Roche Applied Science, South Africa) according to manufacturer’s 
instructions and incubated for 24 hrs. On day three, cells were washed once with PBS and 
were treated with the respective compounds or vehicle (EtOH) in serum free DMEM medium 
for 24 hours. The cells were harvested by washing twice with PBS and lysed in 50 µl 1X 
Reporter lysis buffer (Promega, Madison, WI, USA). Luciferase activity in the lysates was 
measured using the Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus 
microplate luminometer (Turner Biosystems, Sunnyvale, CA, USA). The luciferase values 
obtained were normalized to protein content per well as determined by standard Bradford 
assay (Bradford 1976). 
3.7  Western blotting 
3.7.1 Preparation of protein control samples 
For the SR controls, COS-1 cells were seeded into 12-well plates (Greiner Bio-one, Cellstar) 
at a density of 25 x 104 cells/well. The next day the cells were transfected with 1 µg/well of  
GR, AR, PR or empty vector and 2 µg/well of MR or ERα using FuGENE™ 6 (Roche 
Applied Science, South Africa). After 24 hrs, the cells were washed once with PBS and lysed 
with 50 µl 2X SDS sample buffer (diluted from 5X SDS sample buffer: 100 mM Tris-Cl pH 
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6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% ß-mercaptoethanol and 0.1% (w/v) bromophenol-
blue) and boiled for 10 min at 100°C.  
3.7.2 Preparation of samples from the reporter assays 
For the reporter experiments, after the transactivation and Bradford assays were done, 7.5 µl 
of 5X SDS sample buffer was added to the 30 µl HeLa cell lysates and boiled for 10 min at 
100°C.   
3.7.3   Preparation of samples for other applications 
HeLa and End1/E6E7 cells were plated into 12-well plates at different amounts of cells/well, 
as indicated in the figure legends and treated with test compound or vehicle (EtOH), as 
indicated in the figure legends. After ligand stimulation the cells were washed twice with 
PBS and harvested in 50 µl 2X SDS sample buffer and boiled 10 min at 100°C.  
3.7.4 Western blot analysis and quantification 
Equal amounts of sample were loaded and resolved on a 6%, 8% or 10% SDS 
polyacrylamide gel (250 mM Tris-Cl pH 8, 0.1 (w/v) SDS, 0.1% (w/v) APS and 6%, 8% or 
10% (v/v) acrylamide) in running buffer (25 mM Tris-Cl pH 8; 250 mM glycine and 0.1% 
(w/v) SDS). The protein molecular weights were estimated using the Pageruler™ Prestained 
protein ladder SM0671 (Fermentas Life Sciences). The separated proteins were transferred 
onto a Hybond-ECL nitrocellulose membrane (Amersham, South Africa) in transfer buffer 
(25 mM Tris, 250 mM glycine and 20% (v/v) methanol) using the Mini Protean III blotting 
system (Bio-Rad, South Africa) for 1 hr at 0.18 A. Membranes were blocked in 4% ECL 
blocking buffer [4% (w/v) ECL blocking powder (Amersham, South Africa) and 1X TBST 
(0.1% (v/v) Tween in 1X TBS)] for 1 hr at room temperature, followed by incubation with 
primary antibody in 4% ECL blocking buffer overnight at 4°C. Membranes were then 
washed twice with 1X TBST for 10 mins and 5 mins, followed by incubation with the 
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appropriate secondary antibody in 5% fat-free milk powder buffer [5% (w/v) fat-free milk 
powder and 1X TBST] for 1 hr at room temperature. Thereafter the membranes were washed 
twice with 1X TBST for 10 mins and 5 mins and exposed to X-ray film. For antibody dilution 
see Table 3.1 below. The proteins were visualized using Pierce® ECL western blotting 
substrate (Thermo Scientific, South Africa), according to the manufacturer’s protocol, and 
Hyperfilm MP high performance autoradiography film (Amersham, South Africa). Bands on 
the X-ray film were scanned and quantification was done using AlphaEaseFC FluorChem 
5500 (Alpha Innotech). 
Table 3.1: Antibody concentrations used in Western blot analysis 
Primary Antibody Dilution 
GR (H-300)* 1:4000 
PR (C-20)* 1:1000 
AR (441)** 1:1000 
ERα (MC-20)** 1:1000 
MR (MCR, H-300)* 1:1500 
HA (12CA5)** 1:2000 
GAPDH ** 1:20 000 
Secondary antibodies are indicated by * and ** for  
anti-rabbit (1:10 000) and anti-mouse (1:2000), respectively. 
3.8  RNA isolation and cDNA synthesis 
HeLa or End1/E6E7 cells were seeded into 12-well plates at a density of 15 x 104 cells/well 
and 35 x 104 cells/well, respectively for 24 hrs and treated with test compound or vehicle 
(EtOH) for 4 hrs or 24 hrs. For the Vpr overexpression studies, prior to treatment with test 
compounds, the HeLa cells were transiently transfected with 1 µg HA-Vpr or an increasing 
dose (50 ng, 250 ng, 600 ng and 1 µg)/well  HA-Vpr using FuGENE™ 6 (Roche Applied 
39 
 
Science, South Africa) according to manufacturer’s instructions and incubated for 24 hrs. 
Thereafter, the cells were washed twice with PBS and harvested. Total RNA was isolated 
from cells using TRI Reagent® (Sigma-Aldrich, South Africa) according to the 
manufacturer's instructions. The isolated RNA was quantified using a NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies). The integrity of the RNA (presence of intact 
18S and 28S ribosomal bands) was confirmed by denaturing agarose gel electrophoresis. 
Briefly, 15 µl sample loading buffer [12% (v/v) DEPC water, 5% (v/v) bromophenol blue 
solution, 7% (v/v) glycerol, 10% (v/v) 10X MOPS buffer (0.2 M MOPS in DEPC water, 0.05 
M CH3COONa and 0.01 M EDTA), 17% (v/v) 12.3 M formaldehyde and 49% (v/v) 
formamide] with 20 µg/ml EtBr was added to 0.5 µg of total RNA of each sample, then 
electrophorated on a 1% agarose gel [1% (w/v) agarose, 70% (v/v) DEPC water, 10% (v/v) 
10X MOPS buffer and 20% (v/v) formaldehyde] at 65 V for 40 mins. Total RNA (500 ng) 
was reverse transcribed using the anchored oligo-dT method provided in the Transcriptor 
First Strand cDNA synthesis kit (Roche Applied Science, South Africa) according to the 
manufacturer's instructions. 
3.9 Real-time quantitative reverse transcription PCR (qRT-PCR) 
Equal volumes of synthesised cDNA were used for real-time qRT-PCR using the Sensi-Mix 
SYBR Green I system (Celtic Diagnostics, South Africa) and the Rotor-gene, RG-3000A 
(Corbett Research). For the inflammatory gene expression analysis; IκBα, IL-6, IL-8, and 
RANTES gene expression were measured using mRNA specific primer sets (Table 3.2) at a 
final concentration of 0.25 µM. GILZ gene expression were measured using QuantiTect 
Primer Assay (catalogue no. QT00091035) a validated primer set purchased from Qiagen, 
South Africa at a final concentration of 1X assay solution. GAPDH (Table 3.2) which served 
as the ‘housekeeping gene’ was used at a final concentration of 0.1 µM. Briefly, the 20 µl 
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PCR reaction mix contained 10 µl Sensi-Mix SYBR Green I system (Celtic Diagnostics, 
South Africa), 1 µl cDNA, 1 µl sense primer, 1 µl anti-sense primer and 7 µl PCR grade 
water. Melting curve analysis and gel electrophoresis was performed to confirm the generated 
amplicon in each sample. Standard curves were used to determine the efficiency of each 
primer set and relative transcript levels were calculated by the method described by Pfaffl and 
was normalized to relative GAPDH transcript levels (Pfaffl 2001). GAPDH has been shown 
by others in the laboratory to be a suitable housekeeping gene in these cells since it is not 
regulated by the hormones tested.  
 
Table 3.2: Primer sequences of inflammatory genes investigated 






GILZ Qiagen Proprietary Information forward 60 Qiagen, 
South 
Africa 
Qiagen Proprietary Information reverse 
IκBα ACTCGTTCCTGCACTTGGCC forward 60 Emmerich 
et al. 2011 TGCTCACAGGCAAGGTGTAG reverse 
IL-6 TCTCCACAAGCGCCTTCG forward 60 Wolf et al. 
2002 CTCAGGGCTGAGATGCCG reverse 
IL-8 TGCCAAGGAGTGCTAAAG forward 60 Wolf et al. 
2002 TGCCAAGGAGTGCTAAAG reverse 
RANTES TACCATGAAGGTCTCCGC forward 60 Wolf et al. 
2002 GACAAAGACGACTGCTGG reverse 
GAPDH TGAACGGGAAGCTCACTGG forward 55 Ishibashi 




For the SR mRNA screen; GR, PR-AB, AR, ERα and MR specific primer sets (Table 3.3) 
were used at a final concentration of 0.25 µM. 20 µl PCR reaction mixes were set up (as 
described above) followed by gel electrophoresis to confirm the generated amplicon in each 
sample. 10 ng SR plasmid DNA was used as PCR positive controls.  
 
Table 3.3: Primer sequences of the SRs 








GR TGCTGTGTTTTGCTCCTGATCTG forward 53 299 Tomasicchio 
et al. 2013 TGTCAGTTGATAAAACCGCTGCC reverse 
PR-
AB 
GTGCTCAAGGAGGGCCTGCCG forward 60 214 
TGTGCTGCCCTTCCATTGCCC reverse 
AR CAGGAAAGCGACTTCACCGCACC forward 60 209 
ATCAGGCAGGTCTTCTGGGGTGG reverse 
ERα TCGACGCCAGGGTGGCAGAG forward 60 218 
TGGTGCACTGGTTGGTGGCTGG reverse 
MR GAGCAGTGGAAGGGCAACAC forward 60 182 
TGGCTGCTCCTCGTGAATCC reverse 
 
3.10 Small interference RNA (siRNA) transfections 
End1/E6E7 cells were seeded in 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transfected with 10 nM validated GR 
HS_NR3C1_5 (GR5) (catalogue no. SI02654757) (Qiagen, South Africa) siRNA directed 
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against the human GR or validated non-silencing scrambled sequence control (NSC) siRNA 
(catalogue no. 1027310) (Qiagen, South Africa) using HiPerfect transfection reagent 
(Qiagen) as per the manufacturer’s instructions. Briefly, specific or NSC siRNA was diluted 
in pre-warmed Optimem medium with GlutaMAX™ (Gibco-BRL Life Technologies) to 
which 3.5 µl transfection reagent was added. The transfection mixture was incubated at room 
temperature for 10 min and then added drop-wise to the cells to a final concentration of 10 
nM. Cells were incubated for 48 hrs before being treated with 100 nM test compounds for 24 
hrs. RNA was then harvested and mRNA levels were analysed by qRT-PCR, as described 
above. Cells which were transfected in parallel were analysed by Western blotting as 
described above to verify the protein knockdown. 
3.11 Luminex 
Supernatants were collected from the siRNA experiments prior to cell harvest. Thereafter, 
human cytokine protein levels were measured using a 27-plex assay kit according to 
manufacturer’s protocol (Biorad, South Africa). 
3.12 MSD® singleplex cytokine assay 
Supernatants were collected from the dose response experiments prior to cell harvest. 
Samples were frozen at -80°C and shipped to the Fichorova laboratory (Brigham & Women’s 
Hospital, Boston, USA). Thereafter, cytokine protein levels were measured using singleplex 
assay kits for human IL-6, IL-8 and RANTES according to manufacturer’s protocol (Meso 
Scale Discovery (MSD®), USA). 
3.13 Chromatin immunoprecipitation (ChIP) assay 
ChIP was performed as described in Verhoog et al. with modifications (Verhoog et al. 2011). 
HeLa cells were plated at 3 x 106 cells/dish in 15 cm dishes and grown for 24 hrs in full 
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DMEM.  Cells were then washed twice with PBS and incubated in phenol-free DMEM 
(Sigma-Aldrich, South Africa) for another 24 hrs. Thereafter, the cells were washed twice 
with PBS and incubated with serum-free, phenol-free DMEM for 2 hrs, before treatment with 
100 nM DEX, MPA, P4 and NET-A for 1 hr. Cells were crosslinked for 10 min at 37°C by 
addition of formaldehyde to a final concentration of 1%. Crosslinking was stopped by 
addition of glycine to a final concentration of 0.1 mM for 5 min, shaking at room 
temperature. Cells were scraped in PBS, pelleted by centrifugation at 1200 x g for 10 min and 
resuspended in 300 µl nuclear lysis buffer (1% SDS, 50 mM Tris-HCL, pH 8.0, 10 mM 
EDTA, 1X Complete Mini Protease Inhibitor Cocktail (Roche Applied Science, South 
Africa)). Chromatin was sheared by sonication (Misonix Sonicator 3000) with a microtip (20 
s on//40 s off //10 cycles) before centrifugation at 15 000 x g for 10 min. For 
immunoprecipitation 100 µg chromatin was diluted with 900 µl IP dilution buffer (0.01% 
SDS, 20 mM Tris-HCL, pH 8.0, 1.1% Triton X-100, 167 mM NaCl, 1.2 mM EDTA, 1X 
Complete Mini Protease Inhibitor Cocktail). This solution was pre-cleared with 20 µl pre-
blocked protein A/G agarose beads (sc-2003, Santa Cruz Biotechnology, USA) for 1 hr, 
rotating at 4°C. Beads were spun down and 2 µg anti-GR (H300) (Santa Cruz Biotechnology, 
USA) or 2 µg anti-goat (Santa Cruz Biotechnology, USA) for IgG control was added to the 
supernatant, which was incubated on a rotator at 4°C overnight. The following day, 40 µl pre-
blocked protein A/G agarose beads were added, and tubes were incubated on a rotator for 6 
hrs at 4°C. Beads were washed sequentially with 1 ml each of wash buffer I [0.1% (w/v) 
SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris–Cl pH 8, and 150 mM NaCl], wash 
buffer II [(0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris–Cl pH 8, and 
500 mM NaCl] and wash buffer III [(1% (v/v) NP-40, 1% (v/v) sodium deoxycholate, 500 
mM LiCl, 1 mM EDTA, 10 mM Tris–Cl pH 8]. Beads were then washed three times with 1 
ml TE buffer [10 mM Tris pH 8, 0.1 mM EDTA]. Proteins were eluted from the beads by 
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addition of 300 µl elution buffer (1% SDS, 100 nM NaHCO3) for 30 min at room 
temperature on a rotator. NaCl was added to a final concentration of 300 nM. Tubes where 
then incubated at 65°C overnight to reverse crosslinks. The following day EDTA (final 
concentration 15 nM), Tris-HCl pH 6.5 (final concentration 125 nM) and proteinase K (final 
concentration 60 ng/µl) (Roche Applied Science, South Africa) were added and samples were 
then incubated at 45°C for 1 hr. DNA was purified using the QIAquick® PCR purification kit 
(Qiagen, USA) according to manufacturer’s instructions. Real-time qRT-PCR was performed 
on a Corbett Rotorgene, using the Sensi-Mix SYBR Green I system (Celtic Diagnostics, 
South Africa). ChIP primers used were for the GRE region of the GILZ promoter, AP-1 
region of the IL-6 promoter and NF-κB region of the IL-8 promoter (Table 3.4). Each real-
time qRT-PCR reaction contained the following: template DNA 2 µl for input or 4 µl for 
immunoprecipitated samples, 1 µl forward primer (0.5 µM final concentration), 1 µl reverse 
primer (0.5 µM final concentration), 10 µl Sensi-Mix SYBR Green I system (Celtic 
Diagnostics, South Africa) and PCR grade water to make a final volume of 20 µl. Melting 
curve analysis and gel electrophoresis was performed to confirm the generated amplicon in 
each sample. Relative protein recruitment was determined using real-time qRT-PCR and 
calculated by the method described by Pfaffl et al. 2001 and normalized to input, which was 











Table 3.4: Sequences the ChIP primer sets 















IL-6 TCTACAACAGCCGCTCACAG forward 45 162 Govender 
et al. 2014 AGCGTTCCAGTTAATTTGTAT
TTGT 
reverse 
IL-8 GGGCCATCAGTTGCAAAT forward 53 186 Garside et 
al. 2004 TTCCTTCCG GTG GTTTCTTC reverse 
 
3.14  Preparation and titration of HIV-1 pseudovirus  
Three different HIV-1 pseudoviruses were prepared to investigate different questions. In 
order to investigate the role of GR in LTR transcription, HIV-1 wildtype (wt) pseudovirus 
was prepared using pDU151A env and pSg3E- packaging plasmids. In order to investigate the 
role of Vpr in inflammatory gene and LTR regulation HIV-1 wt and HIV-1 with a mutated 
vpr gene (HIV-1 ΔVpr) were prepared. This HIV-1 wt pseudovirus was prepared using 
pLET-LAI env and pNL4-3.E- packaging plasmids and the HIV-1 ΔVpr pseudovirus was 
prepared using pLET-LAI env and pNL4-3.E--R- packaging plasmids. All three pseudoviruses 
were prepared as follows; HEK293T cells were seeded into 6-well plates at a density of 80 x 
104 cells/well and incubated for 24 hrs. Thereafter, the cells were transiently co-transfected 
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with an env expressing plasmid and corresponding packaging plasmid using Xtreme-GENE 9 
DNA transfection reagent (Roche Applied Science, South Africa) according to 
manufacturer’s instructions. Cells were incubated for 3 days at 37°C. Thereafter the 
supernatants were collected, centrifuged at 1200 rpm for 5 min and passed through a 0.22 
mM filter and charcoal stripped (cs) FCS (Highveld Biological, South Africa) was added to a 
final concentration of 40%. The viral stocks were aliquotted and stored at -80 °C until use. 
The titre of the pseudotyped viruses was determined using the Reed-Muench method in 
TZM-bl cells  to obtain TCID50  expressed as log10 values (Reed & Muench 1938; Janas & Li 
2010) . Thereafter, virus stocks were calculated from the TCID50 values and expressed as 
infectious units/ml (IU/ml).  
3.15 HIV-1 pseudovirus infection assays 
TZM-bl cells were seeded into 96-well plates at a density of 1 x 104 cells/well and incubated 
for 24 hrs. Cells were infected with either HIV-1 wt or HIV-1 ΔVpr, as indicated in the figure 
legends, and incubated for 72 hrs. Pseudovirus was added to obtain a multiplicity of infection 
(MOI) (0.0001, 0.0005 or 0.001) also as indicated in the figure legends. To calculate the 
volume of virus used at a specific MOI, the following equation was used; MOI = [(virus 
stock IU/ml) × (volume of virus used)]/ (number of cells in infection) (Janas & Li 
2010).Thereafter the virus medium was removed and the cells were washed twice with PBS 
to remove extracellular virus. Then, the cells were treated with test compounds in serum free 
DMEM medium for 24 hrs. The cells were then harvested with Bright-Glo™ (Promega, 
Madison, WI, USA) according to manufacturer’s specifications. Luciferase activity was 
measured using a Modulus microplate luminometer (Turner Biosystems, Sunnyvale, CA, 
USA). Luciferase activity was normalized to cell viability as determined using the Thiazolyl 
Blue Tetrazolium Bromide (MTT) cell determination kit (catalogue no. CGD1, Sigma-
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Aldrich, South Africa) according to manufacturer’s instructions. Figure 3.1 shows a brief 
overview of the pseudovirus strategy. 
 
 
Figure 3.1 Brief overview of the HIV-1 Pseudovirus Strategy. Envelope plasmid 
represents pDU151A or pLET-LAI and packaging plasmid represents pSg3E-, pNL43.E- or 
pNL4-3.E-R-. 
 
3.16 Primary endocervical cells 
Primary endocervical cells (VEN-100) were bought from MatTek Corporation (USA). Upon 
arrival, the cells were incubated overnight in VEN-100-MM medium (MatTek Corporation, 
USA) at 37°C in a 5% CO2 incubator. The following day cell viability was determined using 
the Thiazolyl Blue Tetrazolium Bromide (MTT) cell determination kit (catalogue no. CGD1, 
Sigma-Aldrich, South Africa) according to the manufacturer’s instructions. At this time, 
some cells were washed with PBS and either lysed with a N-[Tris(hydroxymethyl)- methyl]-
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3-aminopropanesulfonic acid (TAPS) buffer (0.1 M TAPS, pH 9.5) on ice to perform western 
blotting as described above or with TRIzol® (for RNA isolation, cDNA synthesis and qRT-
PCR as described above). Having established the viability of the cells, the majority of the 
VEN-100s were incubated in VEN-100-ASY-HCF hydrocortisone free assay medium 
(MatTek Corporation, USA) and 100 nM test compound for 48 hours, before performing an 
additional MTT assay. 
3.17 Statistical analysis 
Results were analysed with GraphPad PRISM™ (version 5) software from GraphPad 
Software Inc., using One-way ANOVA, with a Dunnett’s post-test when comparing all 
treatments to a single control, a Bonferroni’s or Newman-Keul’s post-test when comparing 
all treatments to each other and a post-test for linear trend. In addition, P values for 
comparison of 2 treatments were obtained by using the t-test (paired and unpaired) as 
indicated in the figure legends. Statistical significance of difference is denoted by *, ** or 




Chapter 4: Inflammatory gene regulation in human endocervical cells by 




The main aim of this present study was to investigate the hypothesis that MPA, P4 and NET-
A differentially regulate inflammatory gene expression in the cervical mucosa and that the 
MPA-mediated gene regulation occurs via the GR. More specifically the goals were to (i) 
determine whether the synthetic progestins and P4 differentially regulate inflammatory gene 
expression in the End1/E6E7 human endocervical cell line (ii) determine whether the 
differential regulation of the genes by the synthetic progestins is mediated via the GR (iii) 
further investigate the GR mechanism of action and (iv) confirm the differential regulation of 
the inflammatory genes by the synthetic progestins in human primary cervical cells. 
Results 
4.1 DEX- and MPA-mediated regulation of the inflammatory genes is dose- and 
time-dependent 
In order to both determine whether the synthetic progestins and P4 differentially regulate 
inflammatory gene expression in the cervical mucosa and to determine whether this 
regulation is in a dose- and/or time-dependent manner, experiments were performed in the 
End1/E6E7 cell line. This was done by treating the cells with an increasing dose (1 nM, 10 
nM, 100 nM and 1 µM) of DEX, MPA, P4 and NET-A for 4 hrs and 24 hrs, respectively. 
Thereafter, gene expression was measured by qRT-PCR. Figure 4.1 A and B shows that 
DEX- and MPA-dose dependently induced GILZ mRNA expression, while P4 and NET-A 
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appear to have no affect on GILZ gene expression at any of the concentrations or time-points. 
It also appears that the maximal response for MPA and DEX regulation of GILZ mRNA 
levels does not change between 4 and 24 hrs. DEX and MPA, unlike P4 and NET-A, repress 
IL-6 mRNA levels dose-dependently at both 4 hrs and 24 hrs (Figure 4.1 C and D). The 
DEX-mediated repression of IL-6 mRNA at 24 hrs is more potent than the repression at 4 hrs 
whereby DEX has an EC50 (potency) of ~11 nM at 4hrs and ~3 nM at 24 hrs. In addition, 
MPA appears to have a greater maximal repression of IL-6 mRNA levels at 24 hrs than 4hrs. 
It also appears that NET-A (100 nM and 1 µM) upregulates IL-6 mRNA while 10 nM NET-
A represses IL-6 mRNA at 24 hrs; however this is not statistically significant. Figure 4.1 E 
and D shows that DEX and MPA dose-dependently repress IL-8 mRNA levels; however both 
the DEX- and MPA-mediated repression are more potent at 24 hrs. At 4 hrs, P4 appears to 
upregulate and NET-A appears to dose-dependently upregulate IL8 mRNA levels while at 24 
hrs they both appear to repress IL-8 mRNA (Figure 4.1 E and F). The regulation of RANTES 
at 4 hrs appears to be inconclusive and no repression of RANTES is apparent (Figure 4.1 G).  
At 24 hrs, both DEX and MPA dose-dependently repressed RANTES mRNA (Figure 4.1 H). 
Although not statistically significant, both P4 and NET-A show a trend for repression of 
RANTES mRNA levels (Figure 4.1 H). The MPA- and DEX-mediated dose and time 
dependent regulation of these genes are more apparent on the dose response plots in Figure 
4.2. MPA appears to have a potency of ~24 nM for transactivation of GILZ and a potency of 




Figure 4.1: DEX- and MPA-mediated transactivation and transrepression is dose- and 





Figure 4.1: DEX- and MPA-mediated transactivation and transrepression is dose- and 
time dependent. (figure legend to follow on next page) 
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End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were treated with increasing amounts (1 nM, 10 
nM, 100 nM and 1 µM) of DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 4 hrs and 
24 hrs, respectively. Thereafter, the cells were washed twice with PBS and harvested for total 
RNA with TRIzol® and 500 ng RNA was reverse-transcribed. Relative GILZ (A, B), IL-6 
(C, D), IL-8 (E, F) and RANTES (G, H) gene expression was measured by qRT-PCR and 
normalised to GAPDH mRNA expression. In addition, relative gene expression was 
normalized to basal activity (EtOH) set to 1 to obtain relative fold expression. Graphs 
represent pooled results of at least three independent experiments and are plotted as mean +/- 
SEM. Statistical analysis was carried out using GraphPad Prism™ software (version 5) using 
a one-way ANOVA with either Dunnett post-test or paired t-test. Statistical significance is 





Figure 4.2: DEX- and MPA-mediated regulation of inflammatory genes is more potent 
at 24 hrs than 4 hrs. (figure legend to follow on next page) 
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End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were treated with increasing amounts (1 nM, 10 
nM, 100 nM and 1 µM) of DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 4 hrs and 
24 hrs, respectively. Thereafter, the cells were washed twice with PBS and harvested for 
either total RNA with TRIzol® and 500 ng RNA was reverse-transcribed. Relative (A, B) 
GILZ, (C, D) IL-6, (E, F) IL-8 and (G, H) RANTES gene expression was measured by qRT-
PCR and normalised to GAPDH mRNA expression. In addition, relative GILZ gene 
expression was normalized to 1 µM DEX set to 100% in order to obtain % partial agonist 
activity. Relative IL-6, IL-8 and RANTES expression was normalized to basal activity 
(EtOH) set to 100 in order to obtain % repression. 
 
The Western blots in Figure 4.3 A and B show the effect of the ligands on the expression of 
endogenous GR protein levels at 4 hrs and 24 hrs, respectively. At 4 hrs, the ligands appear to 
have no effect on GR protein levels (Figure 4.3 A), while at 24 hrs, only DEX (10 nM, 100 
nM and 1 µM) and MPA (1 nM) reduced GR protein levels (Figure 4.3 B).  
           




End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were treated with increasing amounts (1 nM, 10 
nM, 100 nM and 1 µM) of DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 4 hrs (A) 
and 24 hrs (B), respectively. Thereafter, the cells were washed twice with PBS and harvested 
with 5X SDS sample buffer. Equal amounts of whole cell lysates were loaded on SDS page 
gels and analyzed by Western blotting with antibodies specific for GR and GAPDH (loading 
control). Single representative blots are shown for each time point. 
 
In order to determine whether the differential gene regulation by the ligands is mimicked at 
the protein level, cytokine protein levels were measured. This was done by collecting the 
supernatants from the 24 hr experiments prior to cell harvest. Thereafter the cytokine 
secretions were measured by MSD® singleplex cytokine assays. Figure 4.4 A and B shows 
that DEX dose-dependently repressed both IL-6 and IL-8 protein levels at 24 hrs. The trend 
of the MPA dose appears to repress IL-6 protein levels; however this trend is not statistically 
significant (Figure 4.4 A). MPA does not appear to repress IL-8 protein at 24 hrs (Figure 4.4 
B). Although not statistically significant, P4 appears to repress IL-6 protein levels but not IL-
8 protein at 24 hrs. Interestingly, NET-A dose-dependently upregulates both IL-6 and IL-8 
protein levels at 24 hrs (Figure 4.4 A and B). Although the regulation of RANTES protein by 
the ligands at 24 hrs is not statistically significant, there appears to be a trend of 
downregulation with DEX and MPA, while the trend with P4 appears to be inconclusive 
(Figure 4.4 C). Also, there appears to be a trend of upregulation with the NET-A. Due to the 
large data-sets, statistical significance could not be determined for some of the mRNA and 
protein results. Taken together, results indicate that MPA, unlike NET-A and P4, represses 
mRNA levels and possibly protein levels of the inflammatory genes. In addition, the 
regulation of these inflammatory genes by MPA is dose-and time-dependent and it is similar 
to the GR agonist, DEX. Furthermore, NET-A dose-dependently upregulates the mRNA and 




Figure 4.4: DEX dose-dependently represses IL-6, IL-8 and RANTES protein levels. 
End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were treated with increasing amounts (1 nM, 10 
nM, 100 nM and 1 µM) of DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 24 hrs. 
Then, supernatants were collected prior to cell harvest and cytokine protein levels for (A) IL-
6, (B) IL-8 and (C) RANTES were determined by MSD® singleplex cytokine assays. 
Relative protein expression was normalized to basal activity (EtOH) set to 100% to obtain 
relative fold repression. Graphs represent pooled results of at least two independent 
experiments and are plotted as mean +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA followed by a linear trend 
post-test and a paired t-test. Statistical significance is denoted by *, ** or *** to indicate P< 





4.2 DEX and MPA regulation of the inflammatory genes is mediated via the GR 
Given the differential SR selectivity of P4 and the synthetic progestins, it was investigated 
whether the GR, AR, PR, MR or ERα are expressed in the End1/E6E7 endocervical cell line. 
The End1/E6E7 cells were assessed for SR mRNA content by qRT-PCR using primer pairs 
designed specifically for each receptor followed by gel electrophoresis. The endocervical 
cells were also assessed for endogenous SR protein content by Western blotting. Western 
blotting controls were made by transiently transfecting COS-1 cells with the different SR 
expression vectors or empty vector to produce positive and negative controls, respectively. 
Figure 4.5 A indicates that the End1/E6E7 cells contain only GR mRNA and Figure 4.5 B 
shows that the End1/E6E7 cells express GR protein only. Although it appears that the 
End1/E6E7 cells contain MR protein (Figure 4.5 B) it is highly unlikely that this is true since 
the End1/E6E7 cells do not express MR mRNA. On further examination, it is evident that 





      
Figure 4.5: End1/E6E7 cells only express detectable GR mRNA and protein. (A) 
End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, cells were washed once with PBS and harvested with 
TRIzol. Total RNA was isolated and 500 ng RNA was reverse-transcribed. Steroid receptor 
gene expression was measured by qRT-PCR with receptor specific and GAPDH (loading 
control) primers, followed by gel electrophoresis to confirm the PCR products. (B) 
End1/E6E7 cells were seeded into 12-well plates and incubated for 24 hrs. Thereafter, cells 
were washed once with PBS and were lysed with 2X SDS sample buffer. COS-1 cells were 
seeded into a 12-well plate. After 24 hrs, the cells were transiently tranfected with 1 µg/well 
pcDNA3 (empty vector) which served as negative control (-CTRL) or with 1 µg/well steroid 
receptor expression vectors (pcDNA3-hGR, pMT-PR-B, pSV-hAR, pRS-hMR and pSG5-
hER) which served as positive controls (+CTRL). After 24 hrs, the COS-1 cells were washed 
once and lysed with 2X SDS sample buffer. Equal volumes of lysate were analysed by 
Western blotting with steroid receptor specific antibodies and GAPDH specific antibody as 
loading control.  
 
In order to confirm that the GR is involved in the regulation of the inflammatory genes in 
response to the synthetic progestin MPA, GR knockdown experiments were performed in the 
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End1/E6E7 cell line. This was carried out by transfecting 10 nM GR or NSC siRNA for 48 
hrs. Then the cells were treated with 100 nM DEX, MPA, P4 and NET-A for 24 hrs. 
Thereafter, gene expression was measured by qRT-PCR. As expected DEX and MPA 
upregulated GILZ mRNA, while P4, NET-A and NET do not (Figure 4.6 A). Notably, NET 
was included in this experiment as a control to exclude the possibility that the acetate form 
(NET-A) would regulate the genes differently. Figure 4.6 A also shows that both the DEX- 
and MPA-induced upregulation of GILZ is diminished when GR is knocked down. Figure 4.6 
B shows that DEX induces IκBα gene expression and this induction is repressed when GR is 
knocked down. Here the MPA induction of IκBα is not significant; therefore a loss of 
induction is not apparent with the knockdown. Once more, P4, NET-A and NET do not affect 
the expression of IκBα. To verify the successful knock down of GR protein in the cells, cell 
lysates were prepared and Western blotting was performed (Figure 4.6 C).  The average 
percentage knock down achieved was ~40% (Figure 4.6 D). This was the best GR protein 
knockdown achievable in this cell line while preserving cell viability. 
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Figure 4.6: MPA- and DEX-mediated induction of anti-inflammatory genes are 
mediated by the GR. End1/E6E7 cells were seeded into 12-well plates at a density of 40 x 
104 cells/well and incubated for 24 hrs. Thereafter, the cells were transfected with 10 nM  GR 
siRNA (GR5) or non-silencing control (NSC) siRNA for 48 hrs (A-D) and then treated with 
100 nM DEX, MPA, P4, NET-A, NET or EtOH (0.1% v/v, vehicle) for 24 hrs. Then, the 
cells were washed twice with PBS and harvested for total RNA with TRIzol and 500 ng RNA 
was reverse-transcribed. Relative (A) GILZ and (B) IκBα gene expression was measured by 
qRT-PCR and normalised to GAPDH mRNA expression. Relative gene expressions were 
normalized to basal activity (EtOH) in order to obtain relative fold expression. Graphs in (A) 
and (B) represent pooled results of at least three independent experiments and are plotted as 
mean +/- SEM, while for verification of GR knockdown a representative blot is shown in (C). 
Cells were harvested with 2X SDS sample buffer and equal volumes of lysate were analysed 
by Western blotting with an antibody specific for GR and GAPDH (loading control). (D) 
Western blots of at least three independent experiments were quantified to determine the 
relative GR protein expression and is plotted as mean +/- SEM. Statistical analysis was 
carried out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with a 
Dunnett post-test, followed by a student’s t-test to compare specific conditions to each other. 




Again, as expected DEX and MPA repress IL-6 mRNA expression (Figure 4.7 A), while P4 
and NET-A appear to have no effect on IL-6 mRNA expression (Figure 4.7 A). Although not 
statistically significant, NET does appear to induce IL-6 mRNA. However, this induction is 
not reflected in the IL-6 protein expression (Figure 4.7 A and B, respectively). The DEX- and 
MPA-mediated repression of IL-6 mRNA expression is lifted when GR is knocked down. In 
addition, DEX-mediated repression is also seen on IL-6 protein levels (Figure 4.7 B). 
Interestingly, it appears that MPA and P4 repress IL-6 protein levels and the repression is 
lifted in the knockdown, however these results were not statistically significant. A similar 
result is seen in the regulation of IL-8 mRNA expression by DEX and MPA (Figure 4.7 C). 
Figure 4.7 D shows that DEX appears to repress IL-8 protein levels and the knockdown lifts 
basal IL-8, thereby lifting the DEX repression. RANTES mRNA level are also repressed by 
DEX and MPA, but not by P4 and NET-A, in a GR-dependent manner (Figure 4.7 E). 
Although not statistically significant, NET appears to upregulate RANTES mRNA levels 
(Figure 4.7 E). It appears that the RANTES protein levels (Figure 4.7 F) are not regulated by 
any of the ligands, however this could possibly be due to its instability in the medium. Again, 
the lack of statistical significance for some of the mRNA and protein results could be due to 
the large number of variables in the data-sets. Taken together, these results confirm the 
differential regulation of the inflammatory genes by P4 and the synthetic progestins, MPA 
and NET-A occurs on both the mRNA and protein level. In addition, it shows that both the 




Figure 4.7: MPA- and DEX-mediated repression of pro-inflammatory cytokine genes 
are mediated via the GR. End1/E6E7 cells were seeded into 12-well plates at a density of 
40 x 104 cells/well and incubated for 24 hrs. Thereafter, the cells were transfected with 10 nM  
GR siRNA (GR5) or non-silencing (NSC) siRNA for 48 hrs (A-F) and then treated with 100 
nM DEX, MPA, P4, NET-A, NET or EtOH (0.1 % v/v, vehicle) for 24 hrs. Thereafter, the 
cells were washed twice with PBS and harvested for total RNA with TRIzol® and 500 ng 
RNA was reverse-transcribed. Relative (A) IL6 (C) IL8 and (E) RANTES gene expression 
was measured by qRT-PCR and normalised to GAPDH mRNA expression. In addition, 
relative gene expressions were normalized to basal activity (EtOH) in order to obtain fold 
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expression. The corresponding cytokine protein levels were determined by Luminex of 
supernatants collected prior to cell harvest, (B) IL6 protein levels, (D) IL8 protein levels and 
(F) RANTES protein levels. Graphs represent pooled results of at least three independent 
experiments and are plotted as mean +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA, with either a Dunnett 
post-test or paired t-test. Statistical significance is denoted by * or ** to indicate P< 0.05 or 
P< 0.001, respectively.  
 
4.3 Inhibition of protein synthesis supports a mechanism of partially direct 
regulation by the GR of the inflammatory genes 
In order to investigate the mechanism of gene regulation, cycloheximide (CHX; de novo 
protein synthesis inhibitor) experiments were performed in the End1/E6E7 cells to determine 
whether the GR-mediated regulation of the cytokine genes require new protein synthesis. 
This was done by pre-treating the cells with 1 µg/ml CHX for 30 min and then treating with 
100 nM DEX, MPA, P4 and NET-A for 24 hrs.  Figure 4.8 A shows the expected induction 
of GILZ mRNA in response to DEX and MPA. The addition of CHX appears to partially 
reverse the DEX induction of GILZ mRNA and fully reverses the MPA induction. The effect 
of the ligands on IκBα mRNA expression is not reversed by CHX (Figure 4.8 B). Figure 4.8 
C shows that DEX- and MPA-mediated repression of IL-6 mRNA is not influenced by pre-
treatment with CHX. Similarly, in Figure 4.8 D, IL-8 mRNA is repressed by DEX and this 
repression is not reversed by CHX. However, for this gene the results for MPA were 
inconclusive. In contrast, the DEX-mediated repression of RANTES mRNA is partially 
reversed by CHX (Figure 4.8 E). However, the MPA-mediated repression of RANTES 
mRNA is not reversed. To confirm that the CHX inhibited de novo protein synthesis, 
End1/E6E7 cells were pre-treated with 1 µg/ml CHX and then treated with 100 nM DEX for 
24 hrs, thereafter cell lysates were prepared and western blotting was performed (Figure 4.8 
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F). It is worth noting (to prevent confusion), that in this thesis IκBα was used for a dual 
purpose. In addition to GILZ, the IκBα gene was used as a GR transactivation model while 
IκBα protein levels were used as a positive control for the CHX experiments. IκBα protein 
levels were measured since this protein has been shown to have a high turnover (Kogan et al. 
2012). In addition, DEX induces IκBα protein levels and if new protein synthesis is inhibited 
by CHX this DEX-induction will be lost and thereby is an indicator of new protein synthesis 
inhibition. As seen in Figure 4.8 G, the 2-fold DEX induction is lost with the addition of 
CHX. These results suggest that upregulation of GILZ mRNA levels is only partially 
dependent on transactivation by the GR and it is also in part dependent on synthesis of 
another protein. IκBα mRNA upregulation appears to be independent of new protein 
synthesis and thereby suggests that the induction of the gene in these cells are predominantly 
dependent on transactivation of the GR. Given that the GR-mediated repression of IL-6, IL-8 
and RANTES is either not reversed or only partially reversed by CHX; these results indicate 
that the GR-mediated regulation may partially require new protein synthesis for some of 
these pro-inflammatory genes. In summary, results indicate that under conditions where CHX 
is shown to inhibit new protein synthesis, all the anti-inflammatory and pro-inflammatory 
genes investigated are at least in part regulated by direct effects of DEX without a 
requirement for new protein synthesis, and where this could be established, similar trends are 





Figure 4.8: The GR at least in part directly regulates mRNA levels of the inflammatory 
genes. (figure legend to follow on next page) 
67 
 
End1/E6E7 cells were seeded into 12-well plates at a density of 35 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were pre-treated with 1 µg/ml cycloheximide 
(CHX) then treated with 100 nM DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 24 
hrs. Thereafter, the cells were washed twice with PBS and harvested for total RNA with 
TRIzol® and 500 ng RNA was reverse-transcribed. Relative (A) GILZ (B) IκBα, (C) IL-6, 
(D) IL-8 and (E) RANTES gene expressions was measured by qRT-PCR and normalised to 
GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal 
activity (EtOH) in order to obtain relative fold expression. Graphs represent pooled results of 
at least three independent experiments and are plotted as mean +/- SEM. To verify that the 
CHX inhibited de novo protein synthesis. End1/E6E7 cells were seeded into 12-well plates 
and incubated for 24 hrs. Thereafter, the cells were pre-treated with 1 µg/ml cyclohexamide 
(CHX) then treated with 100 nM DEX or EtOH (0.1% v/v, vehicle) for 24 hrs. (F) Cells were 
harvested with 2X SDS sample buffer and equal volumes of lysate were analysed by Western 
blotting with an antibody specific for IκBα and GAPDH (loading control). (G) Western blots 
of four independent experiments were quantified to determine the relative GR protein 
expression. Statistical analysis was carried out using GraphPad Prism™ software (version 5) 
using a one-way ANOVA with either a Dunnett post-test or a paired t-test. Statistical 
significance is denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or P< 0.0001, 
respectively.  
 
4.4 DEX and MPA recruit GR to the promoters of the IL-6 and IL-8 gene  
Having shown that GR directly regulates expression of the inflammatory genes, a further 
investigation into the mechanism of transcriptional regulation of these genes via the GR was 
performed. Attempts to perform ChIP assays in the End1/E6E7 cells using the same 
conditions as described below were unsuccessful. This may be due to high background and 
low sensitivity for ChIP signals in these cells. Concurrent experiments with synthetic 
progestins were done in the HeLa cell line to investigate the hypothesis that HIV-1 Vpr acts a 
GR co-activator (as described in Chapter 5) and it was established that the HeLa cells contain 
functional GR. It was therefore decided to perform the ChIP assays in the HeLa cell line. 
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HeLa cells were stimulated for 1 hr with 100 nM DEX, MPA, P4 and NET-A, and ChIP 
assays were performed using an anti-GR antibody for immunoprecipitation. In addition, gene 
expression experiments at a 4 hr time point with 100 nM of ligands were done in the HeLa 
cells and it was determined that the effects of the ligands on gene expression of GILZ, IL-6 
and IL-8 were similar to that obtained in the End1/E6E7 cell line (Addendum Figure 1). 
Figure 4.9 A, shows that stimulation with DEX, but not MPA resulted in the recruitment of 
the GR to the GILZ promoter. Furthermore, DEX and MPA stimulation resulted in the 
recruitment of the GR to the IL-6 and IL-8 promoters (Figure 4.9 B and C). Interestingly, it 
appears that the level of GR recruitment in response to the ligands is gene-specific. Figure 4.9 
B shows that stimulation with DEX and MPA recruit similar amount of GR to the IL-6 
promoter, whereas Figure 4.9 C shows that stimulation with DEX recruits more GR to the IL-
8 promoter than MPA. In summary these results strongly suggest that both DEX and MPA 
suppress inflammation in the cervical cells by a mechanism of activating and thereby 
recruiting the GR to promoters of these genes and consequently inducing transcription of the 
anti-inflammatory gene GILZ, while repressing transcription of the pro-inflammatory genes 




Figure 4.9: DEX and MPA recruit GR to the IL-6 and IL-8 cytokine gene promoters. 
HeLa cells were seeded into 10 cm dishes at a density of 300 x 104 cells/well and incubated 
for 24 hrs. Thereafter, the cells were serum starved for 2 hrs and then treated with 100 nM 
DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle) for 1 hr. ChIP was carried out using an 
anti-GR antibody to immnoprecipitate endogenous GR and an anti-IgG antibody as a 
negative control. qRT-PCR was performed on input and immunoprecipitated DNA with 
primers specific for endogenous (A) GILZ, (B) IL-6 and (C) IL-8 promoters. GR recruitment 
was measured relative to input. Graphs represent pooled results of at least three independent 
experiments and are plotted as mean +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA with Dunnett post-test. 





4.5 Effect of synthetic progestins on inflammatory gene regulation in a primary 
endocervical model (VEN-100) 
Having shown that the progestogens differentially regulate the immune response genes in two 
cervical cell lines, gene regulation in a more physiologically relevant model was next 
investigated. The model used consisted of a bio-engineered multilayer of a primary 
endocervical cells (VEN-100) purchased from MatTek Corporation (Ashland, MA, USA). 
Upon arrival of the cells, they were incubated for 24 hrs and then treated with 1 nM, 10 nM 
and 100 nM DEX or MPA for 48 hrs. Thereafter, gene expression was measured by qRT-
PCR. In Figure 4.10 A it appears that neither DEX nor MPA induced GILZ gene expression 
in the VEN-100. In order to determine viability of the cells a MTT based cell growth 
determination test was done on both day of treatment and day of harvest. Figure 4.10 B 
shows that the cells were viable on day of treatment. However, on day of harvest the viability 
of the cells had significantly decreased (Figure 4.10 B).  
 
Figure 4.10: The primary cells were unresponsive and non-viable on day of harvest (A) 
VEN-100 cells were incubated for 24 hrs. Thereafter, the cells were either treated with an 
increasing dose (1 nM, 10 nM and 100 nM) of DEX, MPA or with EtOH (0.1% v/v, vehicle) 
for 48 hrs. Then, the cells were washed twice with PBS and harvested for total RNA with 
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TRIzol® and 500 ng RNA was reverse-transcribed. Relative GILZ gene expression was 
measured by qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative 
gene expressions were normalized to basal activity (EtOH) in order to obtain relative fold 
expression. Graph represent results of at least three independent experiment performed in 
duplicate and are plotted as mean +/- SEM. (B) VEN-100 cells were either incubated for 24 
hrs (treatment day) or 72 hrs (end of treatment day). Then, a cell-growth determination (MTT 
based) assay was performed. Absorbance readings were measured at wavelength at 570 nm. 
Cell culture media served as the CTRL (control). CTRL for each day was set to 1 to obtain 
relative fold induction of cell viability. Graph represent results of at least three independent 
experiments and are plotted as mean +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA with Dunnett post-test and 
an unpaired t-test. Statistical significance is denoted by * or *** to indicate P< 0.05 or P< 
0.0001, respectively. 
 
Concurrent to the dose experiment, the effect of the synthetic progestins in the presence of 
the GR/PR agonist (RU-486) was also investigated. In Figure 4.11 A, it appears that all the 
ligands induce expression of GILZ mRNA, but this was not statistically significant. The 
treatment with RU-486 does not appear to affect the ligand-mediated induction of GILZ; 
however this was not significant (Figure 4.11 A). NET-A appears to upregulate IL-6 gene 
expression (Figure 4.11 B). However, DEX, MPA and P4 do not appear to regulate IL-6. For 
IL-6, the treatment with RU-486 appears to upregulate basal gene expression. It appears that 
the combination of ligands with RU-486 also upregulates gene expression (Figure 4.11 B). 
Again, it is not surprising that the cells did not respond as expected since the viability of the 
cells did decrease significantly by the time they were harvested for analysis. Therefore, 




Figure 4.11: The primary cells appear to respond non-specifically to ligand treatment. 
VEN-100 cells were incubated for 24 hrs. Thereafter, the cells were treated with or without 1 
μM RU-486 and 100 nM DEX, MPA, P4, NET-A or EtOH (0.1% v/v, vehicle). Then, the 
cells were washed twice with PBS and harvested for total RNA with TRIzol® and 500 ng 
RNA was reverse-transcribed. Relative (A) GILZ and (B) IL-6 gene expression was 
measured by qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative 
gene expressions were normalized to basal activity (EtOH) in order to obtain relative fold 
expression. Graphs represent results of one independent experiment performed in duplicate 
and are plotted as mean +/- SEM. 
 
4.6 Primary endocervical cells (VEN-100) express endogenous GR, MR and ER 
mRNA and GR protein  
Although the gene regulation experiments in the primary model were not conclusive, the SR 
content of the VEN-100 model was examined since the cells were still viable at this time-
point. Upon arrival of the cells, they were harvested for total RNA and screened for SR 
mRNA by qRT-PCR using primer pairs designed specifically for each receptor followed by 
gel electrophoresis. In addition, the cells were harvested for assessment by Western blotting. 
For the Western blotting analysis, COS-1 cells were transiently transfected with GR or empty 
vector to produce positive and negative controls, respectively. Figure 4.12 A shows, for the 
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first time, that the VEN-100 primary cells contain endogenous GR, MR and ERα mRNA. In 
addition, these primary cells contain endogenous GR protein (Figure 4.12 B). 
 
 
Figure 4.12: VEN-100 primary cells contain GR, AR, MR and ER mRNA and GR 
protein. (A) Upon arrival the VEN-100 cells were incubated for 24 hrs. Thereafter, cells 
were washed once with PBS and harvested with TRIzol®. Total RNA was isolated and 500 
ng RNA was reverse-transcribed. Steroid receptor gene expression was measured by qRT- 
PCR with receptor specific and GAPDH (loading control) primers, followed by gel 
electrophoresis to confirm the PCR products.  (B) For the controls, COS-1 cells seeded into a 
12-well plate. After 24 hrs, the cells were transiently transfected with 1 µg/well pcDNA3 
(empty vector) which served as negative control (-CTRL) or with 1 µg/well GR expression 
vector which served as positive control (+CTRL). 24 hrs later, the COS-1 cells were washed 
once and lysed with 2X SDS sample buffer. VEN-100 cells were incubated for 24 hrs. 
Thereafter, cells were washed once with PBS and were lysed with 2X SDS sample buffer. 
Equal volumes of lysate were analysed by Western blotting with antibodies against anti-GR 




Chapter 5: An investigation into the role of HIV-1 Vpr in GR-mediated 




The aim of this chapter was to investigate the hypothesis that HIV-1 Vpr acts as a co-
activator of the GR and results in the modulation of GR-regulated inflammatory genes in the 
presence of DEX and the synthetic progestins. In order to investigate this hypothesis the main 
goals were to (i) determine whether the P4 and the synthetic progestins differentially regulate 
GR-regulated reporter and inflammatory endogenous genes in the HeLa cell line as found for 
the End1/E6E7 cell line, (ii) determine whether Vpr modulates GR-regulated reporter and 
inflammatory endogenous genes in the presence of DEX and the progestogens.  
 
Results 
5.1  The GR is the predominant SR protein expressed in the cervical cell lines 
As mentioned in the previous chapter, the synthetic progestins and P4 display differential SR 
selectivity. In order to determine whether the ligands differentially regulate GR-regulated 
genes in the HeLa cells similar to that of the End1/E6E7 cells and to determine whether Vpr 
plays a role in GR-mediated gene regulation in the HeLa and TZM-bl cell lines, the SR 
content of both the cell lines had to be first examined. Cell lysates were prepared and the SR 
mRNA and protein levels were detected by qRT- PCR and Western blotting, respectively. 
Figure 5.1 A indicates that both HeLa and TZM-bl cells contain GR, AR and MR mRNA. 
However, it is shown in Figure 5.1 B that the HeLa cells express only GR protein while the 
TZM-bl cells express GR and AR protein.  It appears that the HeLa and TZM-bl cells contain 
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MR protein (Figure 5.1 B) however this is a non-specific band that also appears in the 
negative control. Still, it is possible that the HeLa cells do contain small amount of the AR 
and MR protein that is beyond the detection level of the Western blots.  
 
 
Figure 5.1: HeLa cells only express detectable GR protein, while TZM-bl cells express 
GR and AR protein. (A) HeLa and TZM-bl cells were seeded into 12-well plates at a 
density of 15 x 104and 10 x 104 cells/well, respectively and incubated for 24 hrs. Thereafter, 
cells were washed once with PBS and harvested with TRIzol. Total RNA was isolated and 
500 ng RNA was reverse-transcribed. Steroid receptor gene expression was measured by 
qRT-PCR with receptor specific and GAPDH (loading control) primers, followed by gel 
electrophoresis to confirm the PCR products.  (B) HeLa and TZM-bl cell lines were seeded 
into 12-well plates and incubated for 24 hrs. Thereafter, cells were washed once with PBS 
and were lysed with 2X SDS sample buffer. COS-1 cells were seeded into a 12-well plate. 
After 24 hrs, the cells were transiently tranfected with 1 µg/well pcDNA3 (empty vector) 
served as negative control (-CTRL) or with 1 µg/well steroid receptor expression vectors 
(pcDNA3-hGR, pMT-PR-B, pSV-hAR, pRS-hMR and pSG5-hER) served as positive 
controls (+CTRL). After 24 hrs, the COS-1 cells were washed once and lysed with 2 X SDS 
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sample buffer. Equal volumes of lysate were analysed by Western blotting with antibodies 
against steroid receptor specific antibodies and GAPDH specific antibody as loading control.  
 
It was next determined if the endogenously expressed GR, AR and MR in the HeLa cells are 
functional. Luciferase reporter assays were performed using overexpressed SRs which served 
as positive controls for a transactivation response via the respective receptor-specific 
agonists. Figure 5.2 A shows that when HeLa cells were stimulated with the GR agonist, 
DEX, a significant transactivation response occurs and the addition of exogenous GR 
produced a greater DEX-induced response. However, when the HeLa cells were stimulated 
with AR and MR specific agonists (MIB and ALD, respectively) no significant response was 
detected (Figure 5.2 B and C). As expected, when the cells were transfected with either AR 
or MR and then stimulated with MIB and ALD, transactivation occurred (Figure 5.2 B and 
C). These results indicate that in the HeLa cells only endogenous GR is functional. In order to 
confirm that the expressed SRs in the HeLa cells are functional, endogenous transactivation 
(GILZ) and transrepression (IL-6 and IL-8) models were used. HeLa cells were stimulated 
with SR specific agonists (DEX, MIB and ALD) and gene expression was measured by qRT-
PCR. Figure 5.2 D indicates that when HeLa cells were stimulated with the SR agonists, only 
DEX-induced a significant transactivation of GILZ which is consistent with the endogenous 
GR being active. In addition, only DEX significantly repressed IL-6 gene expression (Figure 
5.2 E). Although not statistically significant, it appears that ALD may upregulate IL-6 
expression (Figure 5.2 E). In Figure 5.2 F, although it appears that DEX may repress IL-8, 
statistical significance was not established. ALD significantly induces IL-8 mRNA 
expression and although it appears that MIB also induces IL-8 mRNA expression, this 
induction is not statistically significant (Figure 5.2 F).  These results are consistent with the 
reporter-promoter assay results and show that endogenous GR is functional. In addition, it 
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shows that only the GR-specific agonist could induce the transactivation of GILZ mRNA and 
transrepression of IL-6 mRNA and possibly IL-8 mRNA. Furthermore, the significant 
induction of IL-8 mRNA by the MR agonist indicates that the MR is also functional. 
 
Figure 5.2:  Receptor-specific agonists induced changes in mRNA levels indicate that 
the GR is functional in the HeLa cells.  HeLa cells (A-C) were seeded into 24-well plates at 
a density of 7.5 x 104 cells/well and incubated for 24 hrs. Thereafter, cells were transiently 
transfected for 24 hrs with 82 ng/well TAT-GRE, 125 ng/well pcDNA-3 (empty vector) and 
either125 ng/well of (A) pcDNA3-hGR, (B) pSV-hAR or (C) pRS-hMR. Then, the cells were 
treated with 100 nM DEX, 100 nM MIB, 10 nM ALD or EtOH (0.1% v/v; vehicle) for 24 
hrs. Thereafter, the cells were washed twice with PBS and lysed with 1X reporter lysis buffer 
and the luciferase activity was measured. Luciferase activity was normalized to protein 
content per well as determined by Bradford assay. In addition, the ligand stimulated 
responses were normalized with the basal activity (EtOH) in order to obtain a relative fold 
induction. HeLa cells (D-F) were seeded into 12-well plates at a density of 15 x 104 cells/well 
and incubated for 24 hrs. Thereafter, the cells were treated for 4 hrs with 100 nM DEX, 100 
nM MIB, 10 nM ALD or EtOH (0.1% v/v; vehicle). Then, the cells were washed once with 
PBS and harvested with TRIzol. Total RNA was isolated and 500 ng RNA was reverse-
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transcribed. Relative (D) GILZ (E) IL-6 and (F) IL-8 gene expression was measured by qRT-
PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions 
were normalized to basal activity (EtOH) in order to obtain fold expression. Graphs (A-C) 
represent pooled results of at least three independent experiments, performed in triplicate and 
are plotted as mean +/-SEM. Graphs (D-F) represent pooled results of at least three 
independent experiments and are plotted as mean +/- SEM. Statistical analysis was carried 
out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with Dunnett 
post-test. Statistical significance is denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or 
P< 0.0001, respectively. 
 
 
5.2  MPA, unlike NET-A and P4, acts like a GR partial agonist for 
transactivation of a GRE reporter gene in the HeLa cell line 
Having established that the HeLa cells contain functional endogenous GR protein, it was next 
investigated whether the synthetic progestins would differentially regulate GR-regulated 
GRE-and IL-6 reporter genes in the HeLa cell line. HeLa cells were transiently transfected 
with either TAT-GRE, IL-6-luc minimal promoter or IL-6-luc full length promoter reporter 
constructs. For the TAT-GRE reporter assay, the cells were treated with saturating 
concentrations of progestins MPA, P4 and NET-A and the GR agonist DEX for 24 hrs. For 
the IL-6-luc minimal and IL-6-luc full length reporter assays, the cells were treated with 
saturating concentrations of progestins DEX, MPA, P4 and NET-A but in the presence and 
absence of TNF-α. Thereafter, luciferase activity was measured. As expected, DEX induced 
the highest transcriptional response of the TAT-GRE reporter (~80 fold) followed by partial 
agonist MPA (~13 fold) while P4 and NET-A produced a response similar to basal (Figure 
5.3 A). However, unexpectedly, DEX did not repress the transcriptional activity of basal or 
TNF-α-induced IL-6-luc minimal and IL-6-luc full length promoter reporters (Addendum 
Figure 2). In addition, the ligands did not produce a typical response on the IL-6-luc minimal 
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promoter or IL-6-luc full length reporter genes (Addendum Figure 2). It was therefore 
decided that these IL-6-luc reporter genes were not an ideal transrepression model in this cell 
line, while the GR transactivation model experiments indicate that P4 and the synthetic 
progestins MPA and NET-A differentially regulate the expression of the GRE-reporter gene. 
 
 
Figure 5.3: MPA, unlike P4 or NET-A, induces transactivation of a GRE-reporter gene. 
(A) HeLa cells were seeded into 24-well plates at a density of 7.5 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transiently transfected with 82 ng/well TAT-
GRE. After 24 hrs, the cells were treated with 100 nM DEX, 1 µM MPA, 10 µM P4, 10 µM 
NET-A or EtOH (0.1% v/v; vehicle) for 24 hrs.  Then, the cells were washed twice with PBS 
and lysed with 1X reporter lysis buffer and the luciferase activity was measured. Luciferase 
activity was normalized to protein content per well as determined by Bradford assay. In 
addition, the ligand stimulated responses were normalized with the basal activity (EtOH) in 
order to obtain a fold induction. Effect of progestins on GR protein expression. (B) After 
transactivation assays the remaining HeLa cell lysates were prepared for Western blotting 
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analysis by adding 5X SDS sample buffer. Then equal amounts of sample were loaded on 
SDS page gels and analyzed by Western blotting with antibodies specific for GR as well as 
GAPDH (loading control). The Western blot shown is a single representative blot. (C) GR 
protein levels were quantified and normalized to GAPDH protein levels; additionally the 
ligand stimulated responses were normalized to basal activity (EtOH). Graph (A) represents 
pooled results of at least two independent experiments, performed in triplicate, and are 
plotted as means +/- SEM. Relative protein expression graph (C) represents pooled results of 
at least two independent experiments and are plotted as means +/- SEM. Statistical analysis 
was carried out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with 
Dunnett post-test and a paired t-test. Statistical significance is denoted by * or *** to indicate 
P< 0.05 or P< 0.0001, respectively. 
 
Having shown that the progestogens differentially regulate a GR transactivation reporter 
model gene in the HeLa cells, Western blotting was next used to determine whether the 
ligands would differentially regulate GR protein levels. This was done by re-suspending the 
cell lysates after the transactivation assays with 5X SDS sample buffer and assessment of the 
samples by western blotting. From Figure 5.3 B it appears that all the ligands reduce the GR 
levels as compare to vehicle (EtOH). However, stimulation with P4 and NET-A may have an 
effect on cell numbers/cell death as seen by the loading control GAPDH (Figure 5.3 B). After 
quantification and normalization (Figure 5.3 C) it appears that DEX and NET-A reduces GR 
protein levels, which is an indication of GR protein turnover, more than P4 and MPA. It is 
worth noting that the concentration (10 µM) of P4 and NET-A used may be toxic to the cells 
as indicated by the lower levels of GAPDH protein in comparison to the EtOH (control) lane 
shown in Figure 5.3 B.  It is suggested that the lower levels of GAPDH could be due to cell 
death because prior to harvest the cells were viewed under the microscope and there were 
fewer cells in P4 and NET-A conditions compared to the control. In addition, equal volumes 
of harvested protein were loaded on the SDS page gel 
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5.3  Vpr co-activates the DEX- and MPA-mediated transactivation of a GRE 
reporter gene 
Having established that MPA, unlike P4 or NET-A, acts a partial agonist for the GR in the 
HeLa cell line, the hypothesis that Vpr acts a co-activator of the GR in the presence of DEX 
and the progestogens could now be investigated. HeLa cells were transiently transfected with 
TAT-GRE and HA-Vpr or empty expression vectors prior to treatment with saturated 
concentrations of ligands for 24 hrs. In the absence of Vpr, only DEX (~40 fold) and MPA 
(~8.3 fold) induce transactivation (Figure 5.4 A), which is consistent with the trend of the 
previous result (Figure 5.3 A). When Vpr protein was expressed, there was no change in 
basal activity (EtOH) but there was a significant increase in both the DEX-mediated 
transactivation (with a fold increase from ~40 to ~321) and MPA-mediated transactivation 
(with a fold increase from ~8.3 to ~67). Figure 5.4 B shows the expression of Vpr protein 





Figure 5.4: Vpr enhances DEX- and MPA- mediated transactivation of a GRE-reporter 
gene. (A) HeLa cells were seeded into a 24-well plate at a density of 7.5 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transiently transfected with 82 ng/well TAT-
GRE and 125 ng/well HA-Vpr or empty vector. After 24 hrs, the cells were treated with 100 
nM DEX, 1 µM MPA, 10 µM P4, 10 µM NET-A or EtOH (0.1% v/v; vehicle) for 24 hrs. 
The cells were then washed twice with PBS and lysed with 1X reporter lysis buffer and the 
luciferase activity was measured. Luciferase activity was normalized to protein content per 
well as determined by Bradford assay. In addition, the ligand stimulated responses were 
normalized with the –Vpr basal activity (EtOH) in order to obtain a fold induction. Relative 
GR protein expression. (B) After transactivation assays the remaining HeLa cell lysates 
were prepared for analysis by Western blotting by adding 5X SDS sample buffer. Then equal 
amounts of sample were loaded on SDS page gels and analyzed by Western blotting. The 
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blots were cut in strips and probed with antibodies specific for GR, HA- and GAPDH 
(loading control). The Western blot shown is a single representative blot. (C) GR protein 
levels were quantified and normalized to GAPDH protein levels; additionally the ligand 
stimulated responses were normalized to basal activity (EtOH). Graph (A) represents pooled 
results of at least two independent experiments, performed in triplicate, and are plotted as 
means +/- SEM. Relative protein expression graph (C) represents pooled results of at least 
three independent experiments and are plotted as means +/- SEM. Statistical analysis was 
carried out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with a 
Newman-Keuls Multiple Comparison Test and a paired t-test. Statistical significance is 
denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or P< 0.0001, respectively. 
 
5.4  Vpr does not affect the DEX- or MPA-mediated transactivation and 
transrepression of the endogenous inflammatory genes 
Having shown on a GRE-reporter gene that MPA acts like a GR agonist for transactivation 
and subsequently Vpr co-activates the DEX- and MPA-mediated transactivation, it was next 
confirmed if this occurs on endogenous GR-regulated inflammatory genes; GILZ, IκBα, IL-6, 
IL-8 and RANTES. HeLa cells were either transiently transfected with HA-Vpr or empty 
expression vectors and then treated with saturating concentrations of DEX, MPA, P4 and 
NET-A. Thereafter, mRNA expression was measured by qRT-PCR. The experiments to 
investigate the effects of the synthetic progestins on the regulation of the endogenous genes 
were done in parallel with the experiments to investigate the effect of Vpr on the modulation 
of the endogenous genes in the presence of the ligands. Thus, the results in the absence of 
Vpr will be reported first. Both DEX and MPA induced transactivation of GILZ and IκBα 
mRNA (Figure 5.5 A and B, respectively), however, P4 and NET-A had no affect on GILZ 




Figure 5.5:   Vpr does not affect DEX- and MPA-mediated transactivation of GILZ and 
IB HeLa cells were seeded into a 12-well plate at a density of 15 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transiently transfected with 1 µg/well HA-Vpr 
or empty vector. After 24 hrs, the cells were treated with 100 nM DEX, 1 µM MPA, 10 µM 
P4, 10 µM NET-A or EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, the cells were washed 
twice with PBS and harvested for total RNA with TRIzol® and 500 ng RNA was reverse-
transcribed. Relative (A) GILZ and (B) IB gene expression was measured by qRT-PCR 
and normalised to GAPDH mRNA expression. In addition, relative gene expression was 
normalized to –Vpr basal activity (EtOH) in order to obtain relative fold expression. Graphs 
represent pooled results of at least three independent experiments and are plotted as mean +/- 
SEM. Statistical analysis was carried out using GraphPad Prism™ software (version 5) using 
a one-way ANOVA, with Dunnett post-test. Statistical significance is denoted by *, ** or *** 
to indicate P< 0.05, P< 0.001 or P< 0.0001, respectively. 
 
Figure 5.6 A shows that MPA, like DEX, repressed the expression of basal IL-6. In contrast, 
although not statistically significant, P4 and NET-A appear to upregulate IL-6 mRNA 
expression. In Figure 5.6 B, although it appears that DEX may repress IL-8 expression, this is 
not statistically significant. Interestingly, P4 significantly upregulated IL-8 mRNA 
expression, while both MPA and NET-A did not affect mRNA expression (Figure 5.6 B). 
The ligands did not appear to regulate RANTES mRNA expression in the HeLa cells (Figure 
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5.6 C). However this could be due to low basal levels of RANTES in the HeLa cells (as 
indicated by real-time qRT-PCR Ct values, data not shown). The results on the endogenous 
gene models are consistent with the GRE-reporter gene results and shows that the synthetic 
progestins differentially regulate the expression of these genes. In addition, it confirms that 
MPA, unlike NET-A, acts like a GR partial agonist for transactivation on the endogenous 
genes; it also shows that MPA acts like a GR partial agonist for transrepression on the IL-6 
endogenous gene. 
The presence of Vpr did not affect basal regulation of GILZ or IκBα mRNA expression 
(Figure 5.5 A and B, respectively). Also, expression of Vpr protein did not affect the DEX- 
and MPA-mediated regulation of GILZ or IκBα. Similar results are obtained for RANKL 
mRNA expression (Addendum Figure 3). Similarly to the endogenous GR-transactivation 
genes, Vpr did not appear to affect the ligand-mediated regulation of IL-6 (Figure 5.6 A). 
Although it appears that Vpr may upregulate basal IL-6 mRNA expression, statistical 
significance could not be established in this multi-variable experiment. Similar to the results 
obtained on IL-6, it appears that Vpr upregulates basal expression and has no affect on the 
ligand-mediated regulation of IL-8 mRNA. In addition, like the other transrepression model 
genes, it appears that Vpr did not affect the regulation of RANTES mRNA in the presence of 
the ligands. Again, although not statistically significant, it appears Vpr upregulates basal 
RANTES mRNA expression. Figure 5.6 D shows the expression of Vpr protein (~20 kDa) in 
the cells and also shows that Vpr did not affect the levels of endogenous GR protein. In 
addition, it shows that the ligands do not regulate Vpr protein expression.  In summary, these 
results show that Vpr does not affect the ligand-mediated regulation of the endogenous 
transactivation or transrepression model genes. However, it appears that Vpr may regulate the 




Figure 5.6: Vpr does not affect DEX- and MPA-mediated repression of IL-6 HeLa cells 
were seeded into a 12-well plate at a density of 15 x 104 cells/well and incubated for 24 hrs. 
Thereafter, the cells were transiently transfected with 1 µg/well HA-Vpr or empty vector. 
After 24 hrs, the cells were treated with 100 nM DEX, 1 µM MPA, 10 µM P4, 10 µM NET-
A or EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, the cells were washed twice with PBS 
and harvested for either total RNA with TRIzol® and 500 ng RNA was reverse-transcribed or 
for whole cell lysate with 2X SDS sample buffer.  Relative (A) IL-6, (B) IL-8 and (C) 
RANTES gene expression was measured by qRT-PCR and normalised to GAPDH mRNA 
expression. In addition, relative gene expression was normalized to –Vpr basal activity 
(EtOH) in order to obtain relative fold expression. Relative protein expression. (D) Equal 
amounts of whole cell lysates were loaded on SDS page gels and analyzed by Western 
blotting. The blots were cut in strips and probed with antibodies specific for GR, HA- and 
GAPDH (loading control). Graphs (A-C) represent pooled results of at least three 
independent experiments and are plotted as mean +/- SEM. Statistical analysis was carried 
out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with a Dunnett 
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post-test and a paired t-test. Statistical significance is denoted by *, ** or *** to indicate P< 
0.05, P< 0.001 or P< 0.0001, respectively. 
 
5.5  Vpr dose-dependently enhances the DEX-mediated regulation of a GRE-
reporter gene 
Having shown that 125 ng of the Vpr expression vector enhanced DEX- and MPA-mediated 
induction of a GRE-reporter gene, while 1 µg of the Vpr expression vector did not affect 
ligand-mediated regulation of the endogenous genes, these results led to the hypothesis that 
the effect of Vpr on gene regulation may be dose-dependent. Therefore it was next 
investigated whether Vpr affected ligand-mediated gene regulation in a dose-dependent 
manner. This was done by transiently transfecting HeLa cells with TAT-GRE and increasing 
amounts of HA-Vpr (25 ng, 125 ng and 300 ng)/well, before treating with 100 nM DEX for 
24 hrs. Thereafter, luciferase activity was measured. As expected, DEX induced 
transactivation of the GRE-reporter gene (Figure 5.7 A). Figure 5.7 A, also shows that 
increasing amounts of Vpr dose-dependently enhanced the DEX-mediated induction of the 
reporter gene while having no affect on the basal levels of the gene. The expression of Vpr 
protein in the cells is shown in the Western blot (Figure 5.7 B). The smaller amounts of Vpr 
(25 ng and 125 ng) could not be detected using this method. This was unexpected since 125 
ng Vpr was detected by Western blot in earlier experiments (Figure 5.4 B). This discrepancy 
could be due to differences in transfection efficiency between the experiments. This 
suggestion is further supported by the differences in relative fold induction shown in Figure 
5.4 A and Figure 5.7 A.  In retrospect, a transfection control such as the Renilla luciferase 
control reporter vector should have been used to normalize luciferase activity. The Western 
blot also shows that increasing amounts of Vpr do not affect GR protein levels (Figure 5.7 B). 
In addition, Figure 5.7 B shows that GR protein levels are reduced by DEX. The result that 
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Vpr dose-dependently enhances DEX-mediated regulation of the GRE reporter gene is 
consistent with the hypothesis that Vpr is a co-activator of the GR. 
 
Figure 5.7: Vpr dose-dependently enhances DEX-mediated induction of a GRE-
reporter gene. (A) HeLa cells seeded into a 24-well plate at a density of 7.5 x104  cells/well 
and incubated for 24 hrs. Thereafter, the cells were transiently transfected with 82 ng/well 
TAT-GRE; 25, 125 or 300 ng/well HA-Vpr and relative amounts of empty vector. After 24 
hrs, the cells were treated with 100 nM DEX or EtOH (0.1% v/v; vehicle) for 24 hrs.  Then, 
the cells were washed twice with PBS and lysed with 1X reporter lysis buffer and the 
luciferase activity was measured. Luciferase activity was normalized to protein content per 
well as determined by Bradford assay. In addition, in order to obtain fold induction the ligand 
stimulated responses were normalized with the –Vpr basal activity (EtOH). Relative GR 
protein expression. (B) After transactivation assays the remaining HeLa cell lysates were 
prepared for analysis by Western blotting by adding 5X SDS sample buffer. Then equal 
amounts of sample were loaded on SDS page gels and analyzed by Western blotting. The 
blots were cut in strips and probed with antibodies specific for GR and GAPDH (loading 
control). Graph (A) represents pooled results of at least two independent experiments, 
performed in triplicate, and are plotted as means +/- SEM. Statistical analysis was carried out 
using GraphPad Prism™ software (version 5) using a one-way ANOVA, with a Dunnett 
post-test. Statistical significance is denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or 




5.6  Increasing amounts of Vpr do not affect the DEX-mediated regulation of the 
endogenous genes 
Having shown that Vpr dose-dependently co-activates the GR-mediated regulation of a 
reporter gene, it was next investigated whether this occurs on the endogenous genes. This was 
done again by transiently transfecting HeLa cells with increasing amounts of Vpr (50 ng, 250 
ng, 600 ng and 1 µg)/well and then treating the cells with 100 nM DEX for 24 hrs. 
Thereafter, mRNA expression was measured by qRT-PCR. DEX induced both GILZ and 
IκBα gene expression (Figure 5.8 A and B). Contrary to the reporter gene results, increasing 
amounts of Vpr did not affect basal or DEX-mediated induction of GILZ (Figure 5.8 A). In 
addition, Vpr (50 ng, 250 ng and 600 ng) did not appear to affect basal or DEX-mediated 
induction of IκBα (Figure 5.8 B).  However, although not statistically significant, it appears 
that 1 µg Vpr may upregulate basal IκBα mRNA levels (Figure 5.8 B). The Western blot in 
Figure 5.8 C shows the expression of Vpr protein in the cells and further confirms that 




Figure 5.8: Increasing amounts of Vpr do not affect the DEX-mediated induction of 
GILZ and IκBα. HeLa cells were seeded into a 12-well plate at a density of 15 x 104 
cells/well and incubated for 24 hrs. Thereafter, the cells were transiently transfected with 60 
ng, 250 ng, 600 ng or 1 µg /well HA-Vpr and relative amounts of empty vector. After 24 hrs, 
the cells were treated with 100 nM DEX and EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, 
the cells were washed twice with PBS and harvested for either total RNA with TRIzol® and 
500 ng RNA was reverse-transcribed or for whole cell lysate with 2X SDS sample buffer. 
Relative (A) GILZ and (B) IB gene expression was measured by qRT-PCR and 
normalised to GAPDH mRNA expression. In addition, relative gene expression was 
normalized to –Vpr basal activity (EtOH) in order to obtain relative fold expression. Relative 
protein expression. (C) Then equal amounts of sample were loaded on SDS page gels and 
analyzed by Western blotting. The blots were cut in strips and probed with antibodies specific 
for GR, HA- and GAPDH (loading control). Graphs (A-B) represent pooled results of at least 
three independent experiments and are plotted as mean +/- SEM. Statistical analysis was 
carried out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with 
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Dunnett post-test and a paired t-test. Statistical significance is denoted by * or *** to indicate 
P< 0.05 or P< 0.0001, respectively. 
 
DEX repressed both IL-6 and IL-8 mRNA expression (Figure 5.9 A and B). In addition, 
increasing amounts of Vpr do not appear to regulate the DEX-mediated repression of both IL-
6 and IL-8 (Figure 5.9 A and B). Although it appears that 600 ng and 1µg Vpr may 
upregulate basal IL-6, this is not significant (Figure 5.9 A), while in Figure 5.9 B, 1 µg Vpr 
significantly upregulated basal IL-8 mRNA expression. The results indicate that, unlike the 
reporter gene, increasing amounts of Vpr do not affect DEX-mediated regulation of the 
endogenous genes. However, the results indicate that Vpr may affect the basal levels of 
endogenous IL-6 and IL-8 mRNA in a ligand-independent manner. 
 
Figure 5.9: Increasing amounts of Vpr do not affect DEX-mediated repression of IL-6 
and IL-8. HeLa cells were seeded into a 12-well plate at a density of 15 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transiently transfected with 60 ng, 250 ng, 600 
ng or 1 µg /well HA-Vpr and relative amounts of empty vector. After 24 hrs, the cells were 
treated with  100 nM DEX and EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, the cells 
were washed twice with PBS and harvested for total RNA with TRIzol® and 500 ng RNA 
was reverse-transcribed. Relative (A) IL-6 and (B) IL-8 gene expression was measured by 
qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene 
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expression was normalized to basal activity (EtOH) in order to obtain relative fold 
expression. Graphs represent pooled results of at least three independent experiments and are 
plotted as mean +/- SEM. Statistical analysis was carried out using GraphPad Prism™ 
software (version 5) using a one-way ANOVA, with Dunnett post-test and a paired t-test. 
Statistical significance is denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or P< 0.0001, 
respectively. 
 
Having shown by transient transfection experiments using a Vpr expression vector that 
increasing amounts of Vpr do not affect ligand-mediated regulation of the endogenous genes, 
the affect of Vpr on endogenous gene regulation was next investigated using HIV-1 
pseudovirus to deliver Vpr. The HIV-1 pseudovirus experiments were performed in the 
TZM-bl cell line which is a HeLa cell line modified to express the co-receptors, CCR5 and 
CXCR4, which are required for HIV-1 infection. TZM-bl cells were infected with increasing 
amounts of HIV-1 wt (wild-type) or HIV-1 ΔVpr (Vpr deletion mutant) and incubated for 72 
hrs. The cells were then treated with 100 nM DEX for 24 hrs. Thereafter, mRNA expression 
was measured by qRT-PCR. As expected, DEX induced both GILZ and IκBα mRNA levels, 
while the increasing amounts of HIV-1 wt did not affect basal or DEX-induced expression of 
GILZ and IκBα (Figure 5.10 A and B).  The absence of Vpr (HIV-1 ΔVpr), also did not 




Figure 5.10: Vpr delivered by HIV-1 pseudovirus does not affect DEX-mediated 
induction of GILZ and IκBα. TZM-bl cells were seeded into 12-well plates at a density of 
10 x 104 cells/well and incubated for 24 hrs. Thereafter, the cells were infected for 72 hrs 
with either virus control (Vctrl), increasing MOI (0.0001, 0.0005 and 0.001) of HIV-1 wt 
(pNL4-3.E- and pLET-LAI) or HIV-1 ΔVpr (pNL4-3.E-R- and pLET-LAI). Then, the cells 
were treated with 100 nM DEX and EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, the cells 
were washed twice with PBS and harvested for total RNA with TRIzol® and 500 ng RNA 
was reverse-transcribed. Relative (A) GILZ and (B) IB gene expression was measured by 
qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene 
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expression was normalized to V ctrl basal activity (EtOH) in order to obtain relative fold 
expression. Graphs represent pooled results of at least three independent experiments and are 
plotted as mean +/- SEM. Statistical analysis was carried out using GraphPad Prism™ 
software (version 5) using a one-way ANOVA), with Dunnett post-test and a paired t-test. 
Statistical significance is denoted by * or ** to indicate P< 0.05 or P< 0.001, respectively. 
 
Again, DEX repressed both IL-6 and IL-8 mRNA levels (Figure 5.11 A and B). In addition, it 
appears that HIV-wt did not affect DEX-mediated repression of either IL-6 or IL-8 mRNA 
levels (Figure 5.11 A and B). However, HIV-1 wt appears to upregulate basal IL-6 mRNA 
levels and this upregulation is lost with HIV-1 ΔVpr (Figure 5.11 A). HIV-1 wt does not 
appear to affect basal IL-8 mRNA levels, while the absence of Vpr (HIV-1 ΔVpr) appears to 
repress basal IL-8 (Figure 5.11 B). Again, statistical significance could not be established for 
most of the mRNA results due to the large number of variables in the pseudovirus 
experiment. These results are consistent with the Vpr transient transfection experiment results 
and suggest that Vpr does not affect the DEX-mediated regulation of the endogenous 
transactivation and transrepression model genes. Results also suggest that Vpr regulates the 





Figure 5.11: Vpr delivered by HIV-1 pseudovirus does not affect DEX-mediated 
repression of IL-6 and IL-8. TZM-bl cells were seeded into 12-well plates at a density of 10 
x 104 cells/well and incubated for 24 hrs. Thereafter, the cells were infected for 72 hrs with 
either virus control (V ctrl), increasing MOI (0.0001, 0.0005 and 0.001) of HIV-1 wt (pNL4-
3.E- and pLET-LAI) or HIV-1 ΔVpr (pNL4-3.E-R- and pLET-LAI). Then, the cells were 
treated with 100 nM DEX and EtOH (0.1% v/v; vehicle) for 24 hrs. Thereafter, the cells were 
washed twice with PBS and harvested for total RNA with TRIzol®and 500 ng RNA was 
reverse-transcribed. Relative (A) Il-6 and (B) IL-8 gene expression was measured by qRT-
PCR and normalised to GAPDH mRNA expression. In addition, relative gene expression was 
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normalized to V ctrl basal activity (EtOH) in order to obtain relative fold expression. Graphs 
represent pooled results of at least three independent experiments and are plotted as mean +/- 
SEM. Statistical analysis was carried out using GraphPad Prism™ software (version 5) using 
a one-way ANOVA, with Dunnett post-test and a paired t-test. Statistical significance is 




















Chapter 6: An investigation into the role of GR and Vpr in the regulation 
of HIV-1 LTR transcription in the presence of DEX, P4 and the synthetic 
progestins (Results).  
 
Aims 
The main aim of this chapter was to investigate the hypothesis that the GR and HIV-1 Vpr 
regulate HIV-LTR transcription in the presence of DEX, P4 and the synthetic progestins. In 
particular, the goals were to (i) determine whether P4 and the synthetic progestins regulate 
HIV-1 LTR transcription, (ii) determine whether the regulation of the HIV-1 LTR in the 
presence of the ligands is mediated via the GR, (iii) determine whether Vpr differentially 
regulates HIV-1 LTR transcription in the presence of ligands. 
Results 
6.1 The synthetic progestins, like DEX and P4, all repress HIV-1 LTR 
transcription 
In order to determine whether the synthetic progestins regulate HIV-1 LTR transcription, 
HeLa cells were transiently transfected with HIV-1 LTR-luc and Tat expression vectors. The 
cells were then treated with saturating concentrations of DEX, MPA, P4 and NET-A or 
treated with the combination of RU-486 and DEX for 24 hrs. Figure 6.1 shows that in the 
absence of Tat the LTR is not activated.  In addition, it is shown that all ligands; DEX, MPA, 
P4 and NET-A repressed Tat-activated LTR activity. The GR/PR antagonist, RU-486, also 
repressed LTR transcription. Interestingly, although it appears that the combination of DEX + 
RU-486 may additively repress LTR transcription there is no significant difference between 
DEX and DEX + RU-486. Since there is no significant difference between RU-486 and DEX 
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+ RU-486, the appearance of additive repression is possibly due to RU-486 alone and not the 
combination. 
Figure 6.1: The synthetic progestins, like DEX and P4, repress Tat-activated LTR 
reporter gene expression.  HeLa cells were seeded into 24-well plates at a density of 7.5 x 
104 cells/well and incubated for 24 hrs. Thereafter, the cells were transiently transfected with 
47 ng/well HIV-1 LTR-luc and 125 ng/well Tat and incubated for 24 hrs. Then the cells were 
either treated with 100 nM DEX, 1 µM MPA, 10 µM PROG, 10 µM NET-A, 1 µM RU-486, 
1 µM RU-486 and 100 nM DEX or EtOH (0.1% v/v; vehicle) for 24 hrs.  Thereafter, the cells 
were washed twice with PBS and lysed with 1X reporter lysis buffer and the luciferase 
activity was measured. Luciferase activity was normalized to protein content per well as 
determined by Bradford assay. In addition, the ligand stimulated responses were normalized 
with the -Tat basal activity (EtOH) in order to obtain fold LTR activity. Pooled results are 
shown of at least two independent experiments, performed in triplicate, and plotted as means 
+/- SEM. Statistical analysis was carried out using GraphPad Prism™ software (version 5) 
using a one-way ANOVA, with Dunnett post-test and an unpaired t-test. Statistical 
significance is denoted by * or ** to indicate P< 0.05 or P< 0.001, respectively. 
 
In order to confirm the ligand-mediated repression of the LTR in a cell line model with a 
stably integrated LTR as this would be more physiological than the transient transfection of 
an LTR expression vector, experiments were performed in the TZM-bl cell line. In addition, 
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to deliver viral proteins by means of a more physiological method than transient transfection 
of a Tat expression vector, HIV-1 pseudovirus experiments were done. TZM-bl cells were 
infected with HIV-1 wt pseudovirus for 72 hrs, and then treated with 100 nM of DEX, MPA 
and NET-A for 24 hrs. Thereafter, luciferase activity was measured. For all the HIV-1 
pseudovirus experiments luciferase activity was normalized to MTT activity. The MTT assay 
which measures viable cells with an active metabolism is a different method of normalization 
than the Bradford assay which measures total protein content of the cells (Sittampalam et al. 
2004). Figure 6.2 shows that in the absence of virus (V ctrl) the LTR is not activated. Similar 
to results from the transient transfection of Tat and LTR-luc experiments, Figure 6.2 shows 
that DEX, MPA, P4 and NET-A repressed transcription of the stably integrated LTR. These 
findings show that there is no differential ligand regulation of the LTR i.e. the synthetic 
progestins, like DEX and P4; all repress the LTR to a similar extent. Since the ligands 
similarly repress the LTR it is suggested that the ligand-mediated repression of the LTR 
might not be GR-specific.  
Figure 6.2: The synthetic progestins, like DEX and P4, all repress viral-activated LTR 
transcription. TZM-bl cells were seeded into 96-well plates at 1 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were infected with HIV-1 wt (pSg3E- and 
pDU151A) at a MOI of 0.0005 or virus control (V ctrl) for 72 hrs. Then, the cells were 
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washed twice with PBS and then treated with 100 nM DEX, MPA, P4, NET-A or EtOH 
(0.1% v/v; vehicle) in serum free DMEM for 24 hrs. Thereafter, the cells were lysed with 1X 
Bright-Glo™ and the luciferase activity was measured. In addition, a parallel experiment was 
done and MTT activity was measured. Luciferase activity was normalized to MTT activity. 
Furthermore, relative LTR activity/MTT was normalized to + HIV-1 wt basal activity (EtOH) 
set to 100% to obtain % LTR activity. Graphs represent pooled results of at least two 
independent experiments, performed in duplicate, and are plotted as means +/- SEM. 
Statistical analysis was carried out using GraphPad Prism™ software (version 5) using a one-
way ANOVA, with Dunnett post-test. Statistical significance is denoted by *, ** or *** to 
indicate P< 0.05, P< 0.001 or P< 0.0001, respectively. 
 
6.2  Rank order of the ligand-mediated HIV-1 LTR repression is indicative of a 
role for the GR 
In order to determine whether the ligand-mediated repression of the LTR involves the GR, 
GR knockdown experiments were done. This was performed by first transfecting the TZM-bl 
cells with GR or NSC siRNA for 48 hrs. Then the cells were infected with HIV-1 wt 
pseudovirus for 72 hrs. Next, the cells were treated with 100 nM DEX, MPA, P4, NET-A, 
NET and LNG for 24 hrs. Thereafter, luciferase activity was measured. Here, NET was 
included in this experiment as a control to exclude the possibility that the acetate form (NET-
A) would regulate the HIV-1 LTR transcription differently. In addition, a second generation 
synthetic progestin (LNG) with no reported GR activity was also included. Again, it is shown 
that in absence of virus (V ctrl) the LTR is not activated (Figure 6.3 A). Figure 6.3 A also 
shows that DEX, MPA, P4 and NET-A significantly repressed LTR transcription similar to 
the results in Figure 6.2. In addition, NET repressed LTR activity similar to NET-A (Figure 
6.3 A). Interestingly, LNG also repressed the LTR (Figure 6.3 A). There is a significant linear 
trend in the order of the ligand-mediated repression and it appears that there is a rank order in 
which the ligands repress LTR transcription is DEX>MPA>P4>NET-A>NET>LNG.  Figure 
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6.3 A shows that basal LTR transcription decreased considerably when the GR was knocked 
down. Surprisingly, the ligand-mediated repression is not lifted in the GR knockdown 
condition and the linear trend in the order of the ligand-mediated repression remains. The 
Western blot in Figure 6.3 B confirms successful knock down of GR protein in the cells and 
Figure 6.3 C shows that the average knockdown of GR protein is ~41%.  Although the GR 
knock down did not lift the ligand-mediated repression, the result in which the ligands repress 
the LTR in a rank order similar to that of the ligands potency for GR-mediated transactivation 
and transrepression of transcription suggests that GR is involved in the ligand-mediated LTR 
repression. In addition, 59% of GR protein is still present in cells which suggest that the 
ligands require a small amount of GR protein in the TZM-bl cells to mediate a repression 
response on the LTR gene. 
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Figure 6.3: The rank order of ligand-mediated LTR repression is indicative of a role for 
the GR. (A) TZM-bl cells were seeded into 10 cm dishes at a density of 100 x 104 cells/dish 
and incubated for 24 hrs. Thereafter, the cells were transfected with 10 nM GR or NSC 
siRNA for 48 hrs. Then, the cells were re-seeded into 96-well plates at a density of 1 x 104 
cells/well and incubated for 24 hrs. Thereafter, the cells were infected with HIV-1 wt (pSg3E- 
and pDU151A) at a MOI of 0.0005 or virus control (V ctrl) for 72 hrs. Then, the cells were 
washed twice with PBS and then treated with 100 nM DEX, MPA, P4, NET-A, NET, LNG 
or EtOH (0.1% v/v; vehicle) in serum free DMEM for 24 hrs. Thereafter, the cells were lysed 
with 1X Bright-Glo™ and the luciferase activity was measured. In addition, a parallel 
experiment was done and MTT activity was measured. Luciferase activity was normalized to 





basal activity (EtOH) set to 100% to obtain % LTR activity. Pooled results are shown of at 
least three independent experiments, performed in duplicate, and plotted as means +/- SEM. 
(B) For verification of GR knockdown, TZM-bl cells were seeded into 10 cm dishes and 
incubated for 24 hrs. Thereafter, the cells were transfected with 10 nM GR or NSC siRNA for 
48 hrs. Then, the cells were harvested with 5X SDS sample buffer. Equal amounts of sample 
were loaded on SDS page gels and analyzed by Western blotting with antibody specific for 
GR and GAPDH (loading control). A representative Western blot is shown. (C) Western 
blots of at least three independent experiments were quantified to determine the relative GR 
protein expression and plotted as mean +/- SEM.  Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA, with a Dunnett post-test, 
paired t-test and linear trend post-test. Statistical significance is denoted by *, ** or *** to 
indicate P< 0.05, P< 0.001 or P< 0.0001, respectively. 
 
6.3  Vpr does not play a role in GR-mediated regulation of HIV-1 LTR 
Having shown that the synthetic progestins, like DEX and P4, all repress LTR transcription 
and the GR may be involved in this repression; the role of Vpr in this ligand-mediated LTR 
repression was next investigated. HeLa cells were transiently transfected with HIV-1 LTR-
luc, Tat and HA-Vpr expression vectors. The cells were then treated with saturating 
concentrations of DEX, MPA, P4 and NET-A for 24 hrs. Figure 6.4 A confirms that in the 
absence of Vpr, the ligands repress LTR transcription. It is also shown that Vpr enhances 
basal LTR transcription and the ligands are still capable of repressing the Vpr enhanced LTR 
transcription (Figure 6.4 A). Figure 6.4 B shows that in the presence of Vpr, the % of ligand-
mediated LTR repression is similar to that in the absence of Vpr. This suggests that Vpr does 





Figure 6.4: Vpr does not affect % ligand-mediated repression of the LTR. HeLa cells 
were seeded into 24-well plates at a density of 7.5 x 104  cells/well and incubated for 24 hrs. 
Thereafter, the cells were transiently transfected with 47 ng/well HIV-1 LTR-luc and 125 
ng/well Tat and HA-Vpr or empty vector and incubated for 24 hrs. Then the cells were either 
treated with 100 nM DEX, 1 µM MPA, 10 µM PROG, 10 µM NET-A or EtOH (0.1% v/v; 
vehicle) for 24 hrs. Thereafter, the cells were washed twice with PBS and lysed with 1X 
reporter lysis buffer and the luciferase activity was measured. Luciferase activity was 
normalized to protein content per well as determined by Bradford assay. In addition, the 
ligand stimulated responses were normalized with the (A) +Tat –Vpr basal activity (EtOH) 
set to 100 or (B) both +Tat –Vpr and +Tat +Vpr vehicle set to 100% to obtain % LTR 
activity. Pooled results are shown of at least five independent experiments, performed in 
triplicate, and plotted as means +/- SEM. Statistical analysis was carried out using GraphPad 
Prism™ software (version 5) using a one-way ANOVA, with Dunnett post-test or paired t-
test. Statistical significance is denoted by * or *** to indicate P< 0.05 or P< 0.0001, 
respectively. 
 
Having shown by transient transfection experiments that Vpr does not affect the % ligand-
mediated repression of the LTR but it does enhance basal LTR transcription in the presence 
of Tat, it was next determined whether Vpr is involved in the DEX-mediated LTR regulation 
using HIV-1 pseudovirus to deliver Vpr protein. This was done by infecting the cells with an 
increasing MOI of HIV-1 wt and HIV-1 ΔVpr (Vpr deletion mutant) for 72 hrs. The cells 
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were then treated with 100 nM DEX for 24 hrs. Thereafter, luciferase activity was measured. 
Figure 6.5 A shows a dose-effect in which increasing amounts of HIV-1 wt results in a 
corresponding increase in fold HIV-1 LTR activation. Although the trend of HIV-1 LTR 
activation remained consistent between each biological repeat, there were large fold 
differences between each repeat which produced the large error (Figure 6.5 A). Nevertheless, 
the results show that in the absence of Vpr (indicated by HIV-1 ΔVpr) there appears to be a 
smaller increase in LTR activity compared to the presence of Vpr (indicated by HIV-1 wt). In 
addition, it appears that DEX may repress activated LTR transcription (Figure 6.5 A). In 
order to normalise the data for the differences in fold between each biological repeat, the 
data-set was plotted to obtain % LTR activity relative to the MOI (0.001) which produced the 
highest LTR activity set to 100% (Figure 6.5 B). Figure 6.5 B shows that HIV-1 wt at a MOI 
0.0005 and 0.001 significantly activated LTR transcription. As expected, DEX repressed the 
HIV-1 wt activated LTR transcription (Figure 6.5 B). In addition, HIV-1 ΔVpR did not 
significantly activate the LTR. Although it appears that HIV-1 ΔVpr activates the LTR, this 
small increase in LTR activity is not significant. These results are consistent with the HeLa 
cells results that show Vpr enhances basal LTR transcription. Taken together with the 
transient transfection experiments these results suggest that Vpr and Tat are required for a 
maximal LTR response. In addition, results suggest that in the TZM-bl cells (under these 
conditions) that Vpr is required for significant LTR activation. Since the LTR is lowly 
activated in the absence of Vpr, the role of Vpr in the DEX-mediated repression of the LTR 




Figure 6.5: Vpr is required for optimal LTR activity. TZM-bl cells were seeded into 96-
well plates at a density of 1 x104 cells/well and incubated for 24 hrs. Thereafter, the cells 
were infected with either HIV-1 wt (pNL43.E- and pLET-LAI) or HIV-1 ΔVpr (pNL43.E-R- 
and pLET-LAI) at an increasing MOI of 0.0001, 0.0005 and 0.001 or virus control (V ctrl) 
for 72 hrs. The cells were then washed twice with PBS and then treated with 100 nM DEX or 
EtOH (0.1% v/v; vehicle) in serum free DMEM for 24 hrs. Thereafter, the cells are lysed 
with 1X Bright-Glo™ and the luciferase activity was measured. In addition, a parallel 
experiment was done and MTT activity was measured. Luciferase activity was normalized to 
MTT activity. Furthermore, (A) relative LTR Activity/MTT was normalized to V ctrl basal 
activity (EtOH) set to 1 to obtain relative fold induction. In addition, (B) relative LTR 
Activity/MTT was normalized to HIV-1 wt MOI 0.001 treated with vehicle to obtain % LTR 
Activity/MTT. Pooled results are shown of at least three independent experiments, performed 
107 
 
in duplicate, and plotted as means +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software (version 5) using a one-way ANOVA, with Dunnett post-test 
and a paired t-test. Statistical significance is denoted by *, ** or *** to indicate P< 0.05, P< 





Chapter 7: Discussion & Conclusion 
 
7.1  MPA, unlike NET-A and P4, acts like a full to partial GR agonist for 
regulation of inflammatory genes in cervical epithelial cells 
The cervical mucosa of the lower FGT is the primary site of infection for HIV-1 during male 
to female transmission (Rametse et al. 2014). The epithelial cells of the endocervix express a 
variety of cytokines and chemokines including IL-6, IL-8 and RANTES (Fichorova & 
Anderson 1999). An excessive release of pro-inflammatory cytokines within the FGT may 
facilitate HIV transmission by either disrupting the epithelial barrier and/or providing the 
virus with a steady supply of target cells. However, a decrease in immune activation markers 
may lower the host’s ability to mount a defence against pathogens. Thus, it is crucial to 
understand how factors such as hormonal contraception may influence the local immune 
response by the epithelial cells. 
This novel study investigated the differential regulation of inflammatory genes by the 
synthetic progestins (MPA and NET-A) used in hormonal contraception and the mechanism 
of action of this regulation in cervical epithelial cells. In the present study, End1/E6E7 and 
HeLa cells were used as model cell systems for the cervical epithelium. Experiments were 
performed in the absence of an immune activator since the cervical epithelial cells 
constitutively express the selected pro-inflammatory cytokines (Fichorova & Anderson 
1999). In addition, experiments in the End1/E6E7 cells in the presence of TNF-α, to mimic 
infection, showed a similar % repression of the pro-inflammatory genes with DEX and MPA, 
unlike P4 and NET-A (Govender et al. 2014).    
Dose response analysis was done to determine whether the synthetic progestins and P4 
differentially regulate the inflammatory genes at hormonal contraceptive serum 
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concentrations (1 nM – 65 nM) (Kirton & Cornette 1974; Hiroi et al. 1975). In addition, two 
time points (4 hrs and 24 hrs) were chosen to perform the dose response analysis in order to 
determine whether the differential regulation by the progestogens is time-dependent. This is 
the first study to perform dose-response analysis on these selected endogenous genes in 
endocervical cells. MPA, unlike NET-A or P4, induced the anti-inflammatory gene (GILZ) 
and repressed the pro-inflammatory cytokines/chemokine genes (IL-6, IL-8 and RANTES) in 
the End1/E6E7 cell line. These results are similar to previous studies showing that MPA and 
NET-A differentially regulate gene expression in cell lines and primary cells (Koubovec et al. 
2005; Ronacher et al. 2009; Tomasicchio et al. 2013; Hapgood et al. 2014). The differential 
regulation of inflammatory genes by the progestogens could be partly explained by their 
different relative binding affinities (RBA) for the GR and is consistent with the reported RBA 
percentages for MPA (~79.1 %, reference agonist DEX), P4 (~5.6%) and NET-A (0.88 – 
1.6%) (Koubovec et al. 2005; Hapgood et al. 2013). Although RBAs of ligands do not 
necessarily correlate quantitatively with  relative agonist activity (Ronacher et al. 2009), for 
these particular ligands they do in terms of rank order. The GC agonist potency for 
transactivation and transrepression of MPA has previously been shown to be greater than 
NET-A and P4 (Koubovec et al. 2005). 
Similar to the findings in the End1/E6E7 cells it was found in this thesis that MPA, unlike 
NET-A and P4, upregulates anti-inflammatory genes (GILZ and IκBα) and downregulates 
pro-inflammatory genes (IL-6 and IL-8) in the HeLa cell line. The findings in both cell lines 
are consistent with the effects of MPA being mediated by the GR. Also, they are consistent 
with the GR being the predominant SR expressed in both cell lines. However, there appears 
to be some cell-specific differences in the ligand-mediated regulation of IL-8 and RANTES 
gene expression. In the End1/E6E7 cell line, 1 μM MPA repressed IL-8 gene expression at 24 
hrs but this did not occur in the HeLa cell line at 24 hrs. However, in the HeLa cell line, 100 
110 
 
nM MPA repressed IL-8 at 4 hrs (Addendum Figure 1).  These findings are consistent with 
the effects of MPA being dose- and time-dependent and are further supported by results from 
the dose-response experiments in the End1/E6E7 cell line (Figure 4.1). Also, it appears that 
RANTES is regulated by hormones at 24 hrs in the End1/E6E7 cell line (Figure 4.1 H) but 
not in the HeLa cell line (Figure 5.6 C); however this could be due to low basal levels of 
RANTES in HeLa cells. 
The differential regulation of the inflammatory genes by the progestogens suggests that 
MPA, unlike NET-A and P4, has anti-inflammatory actions in both the End1/E6E7 and HeLa 
cell lines. Previous reports have suggested that MPA has anti-inflammatory effects in the 
FGT (Elovitz & Wang 2004; Huijbregts et al. 2013). Consistent with this, results from this 
present study suggest that MPA may have immunosuppressive effects in the endocervix of 
the FGT. Importantly, dose response analysis from this thesis shows that MPA at 10 nM 
significantly represses IL-6 and RANTES mRNA levels and MPA has a potency of ~24 nM 
for transactivation of the anti-inflammatory GILZ gene and ~4 – 20 nM for repression of the 
pro-inflammatory genes (Figure 4.2). The serum concentrations for 150 mg intra-muscularly 
(IM) administered DMPA have been reported to be in the range of 2.5 to 65 nM MPA a few 
days after injection and to plateau at about 2.6 nM for about three months thereafter (Kirton 
& Cornette 1974; Hiroi et al. 1975; Hapgood et al. 2013; Stanczyk et al. 2013; Shelton & 
Halpern 2014). Although the levels of MPA in tissue are to the present author’s knowledge 
unknown, it is possible that they may be higher than serum levels. Results from this current 
study suggest that immunosuppressive effects are likely to be relevant at physiological doses 
of MPA used in injectable contraception, particularly shortly after injection, and possibly 
during the plateau phase as well. Recently, it has been reported that Pfizer pharmaceutical 
company has developed a sub-cutaneously (SQ) administered and lowered dose MPA with a 
much better pharmacokinetic profile (Shelton & Halpern 2014). Although the lowered dose 
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SQ MPA has lower peak serum levels (4.1 nM – 6.2 nM) (Shelton & Halpern 2014), it is still 
likely that SQ MPA may have some immunosuppressive effects shortly after administration. 
However, due to proprietary information, this SQ MPA is considerably more expensive and 
therefore unlikely to be used by women in Sub-Saharan Africa who are at high risk for HIV-1 
infection. Although the reported serum concentrations of 200 mg IM administered NET-EN 
are in a similar range (1.5 to 59 nM) (Fotherby 1983) to injectable DMPA, results from this 
thesis suggest that NET-EN is unlikely to exert effects on inflammation via the GR, even 
shortly after injection.  
The concentration of endogenous P4 in serum of premenopausal women is low during the 
follicular phase (0.65 nM) but rises to about 80 nM during the luteal phase, and to about 600 
nM during pregnancy as reviewed in (Africander, Verhoog, et al. 2011). Whether the effects 
of P4 on inflammatory gene regulation in the menstrual cycle and during pregnancy are via 
the GR is unknown, but is possible. Present dose response analysis shows that P4 at 10 – 100 
nM may exert some anti-inflammatory effects by regulation of IL-6 most likely via the GR, 
the only SR expressed in the End1/E6E7 cells, while P4 at concentrations up to 100 nM 
shows very little effect on expression of the other genes investigated. Results from this 
present study also suggest that pregnancy concentrations of P4 (100 nM – 1 μM) may exert 
pro-inflammatory effects on some genes, similar to previous findings in ectocervical and 
vaginal cell lines (Africander, Louw, et al. 2011). Consistent with the pro-inflammatory 
effects of P4 at pregnancy concentrations, a recent study has shown in Ect1/E6E7 cells that 1 
μM P4 upregulates pro-inflammatory cytokine IL-12 and downregulates anti-inflammatory 
cytokine IL-10 (Louw-du Toit et al. 2014). In addition, the Louw-du Toit et al. study has 
shown by GR siRNA that the P4-induced pro-inflammatory response is via the GR (Louw-du 
Toit et al. 2014). Although pregnancy levels of P4 generally promote an anti-inflammatory 
Th2 response which may aid maternal tolerance to fetus in the uterus (Miyaura & Iwata 2002; 
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Arck et al. 2007; Schumacher et al. 2014), present data with previous reports (Africander, 
Louw, et al. 2011; Louw-du Toit et al. 2014) suggest that in the lower FGT high P4 levels 
may be pro-inflammatory most likely via the GR. A previous study has shown that high P4 
concentrations increases RANTES expression in endometrial T-cells (Ramhorst et al. 2006), 
which together with the current results, suggests that regulation of RANTES gene expression 
in the endometrium by P4 may be PR- and not GR-mediated. Since the effect of RANTES 
upregulation, necessary for implantation (Ramhorst et al. 2006), occurs in endometrial cells 
which express PR, upregulation with P4 is likely to be via the PR, for which P4 has a high 
affinity (RBA = 100%, Hapgood et al. 2013). Taken together, these findings suggest that the 
effects with P4 on immune function are unlikely to be mediated via the GR at conditions 
other than at pregnancy, given the low potency of P4 via the GR. However, some gene- and 
cell-specific GR-mediated effects on immune function by P4 may occur in the luteal phase of 
the menstrual cycle, such as promoting a Th2 response. In addition, the effects of P4, during 
pregnancy, on immune function in the lower FGT may be different to that of the upper FGT.  
The MPA-mediated repression of the pro-inflammatory mediators; IL-6, IL-8 and RANTES 
in the endocervical cells via the GR may have physiological significance for cervical mucosal 
immunity, disease susceptibility and predisposition. However, the physiological implications 
are difficult to predict. These immune regulators have been reported to play a role in HIV 
pathogenesis (Fichorova et al. 2004). IL-6 has been shown to induce HIV-1 replication via 
nuclear factor κB (NF-κB) mediated HIV-1 long terminal repeat (LTR) activation, while IL-8 
triggers the recruitment of HIV-1 target cells to the inflammation site and may also stimulate 
HIV-1 replication in T cells and macrophages (Poli et al. 1994; Lane et al. 2001; Alfano & 
Poli 2002; Mamik & Ghorpade 2014). RANTES is a ligand for the chemokine receptor 5 
(CCR5) and has been shown to inhibit HIV-1 replication by competing with HIV for CCR5 
and by causing internalization of the receptor (Colin et al. 2013). However, RANTES has 
113 
 
also been linked to enhancing HIV-1 replication by activating intracellular signalling 
pathways and regulating viral gene expression from the HIV-1 LTR via a mechanism that is 
independent of CCR5 (Gordon et al. 1999). Consequently, MPA-mediated anti-inflammatory 
effects in the lower FGT may decrease HIV-1 acquisition by decreasing the number of target 
cells or decrease HIV-1 replication. However, decreased pro-inflammatory mediators could 
also inhibit immune function, such as B-cell maturation, T-cell activation and differentiation 
and consequently reduce the host’s ability to mount a defence against a pathogen and 
therefore aid initial infection (Janeway Jr et al. 2012). Consistent with the latter, most high 
quality studies show that MPA increases the risk of HIV-1 acquisition in women (Baeten et 
al. 2007; Heffron et al. 2012; Wand & Ramjee 2012; Crook et al. 2014; Noguchi et al. 2014; 
Polis et al. 2014). Although some studies show no significant correlation between MPA and 
HIV-1 risk (Polis et al. 2014), latest meta-analysis reports that DMPA-usage but not NET-EN 
increases risk of HIV-1 infection (Morrison, Chen, et al. 2014). However, the literature on 
whether MPA increases acquisition of HIV-1 or other STI’s by increasing or decreasing pro-
inflammatory markers in the FGT in vivo is inconsistent. Consistent with this present study’s 
findings of MPA repressing pro-inflammatory mediators, a previous report found that women 
on DMPA displayed lower levels of the pro-inflammatory cytokine IFN-α in plasma and 
genital secretions compared to controls with no hormonal contraception (Huijbregts et al. 
2013). Furthermore, more recent findings from the same group showed that MPA, unlike P4, 
NET or LNG, inhibits pro-inflammatory cytokine production by HIV-1 activated T-cells and 
pDCs (Huijbregts et al. 2014). Similarly in non-human primate models, it has been shown 
that MPA suppresses pro-inflammatory cytokines such as IFN-γ in SHIV-infected rhesus 
macaques (Trunova et al. 2006). Studies in mouse models show that MPA increases 
susceptibility to HSV-2 and decreases immune responses to infection (Gillgrass et al. 2003; 
Kaushic et al. 2003). Also consistent with this thesis, results presented at the HIV R4P 
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conference 2014 showed that MPA, unlike NET-A and P4, represses some pro-inflammatory 
cytokines like IL-6 in primary cervical tissue explants (Ray et al. 2014). In addition, it was 
shown in cervical tissue explants that MPA, unlike NET-A, increases HIV-1 replication (Ray 
et al. 2014). In contrast, a clinical study showed that DMPA-usage is associated with 
increased levels of pro-inflammatory cytokines and chemokines such as RANTES and 
increased HIV-1 acquisition (Morrison, Fichorova, et al. 2014). However, in this study it was 
not possible to discriminate between elevated RANTES levels being a cause of infection or a 
consequence of exposure to HIV-1 prior to seroconversion (Morrison, Fichorova, et al. 
2014). Additionally, since ~76 % of the MPA users in this study were positive for an STI, it 
may be that elevated RANTES was a consequence of STI infection, despite attempts to 
correct for that confounding variable. 
7.2 MPA-mediated anti-inflammatory gene regulation in endocervical cells is via 
the GR     
Although evidence in the literature suggests that the MPA-mediated anti-inflammatory action 
is mediated via the GR (Koubovec et al. 2004; Koubovec et al. 2005; Ronacher et al. 2009; 
Huijbregts et al. 2013; Hapgood et al. 2014), this present study aimed to provide direct proof 
of a GR mechanism of action on endogenous genes, via a GR knock down strategy. In order 
to provide this evidence, the End1/E6E7 cell line was first assessed for its SR content. The 
presence of only GR mRNA and protein in the End1/E6E7 cell line suggested that the MPA-
mediated inflammatory gene regulation is via the GR. However, for the first time it was 
shown with the GR knockdown strategy that the GR is required for the MPA-mediated 
regulation of IL-6 and IL-8 mRNA and protein (Figure 4.7), consistent with the hypothesis 
that the MPA-mediated anti-inflammatory action in the endocervical cells is via the GR. It is 
worth noting that NET was included in this experiment as a control to exclude the possibility 
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that the acetate form (NET-A) would regulate the genes differently. However, it is shown that 
NET-A acts similarly to NET. The findings from the GR knockdown experiment highlight 
the importance of choice of progestin used in hormonal contraception and suggest that 
progestins such as MPA, unlike NET-A and P4, will have anti-inflammatory actions in cells 
where the GR is the predominant SR expressed. Consequently, a GR-mediated 
immunosuppressive response in the FGT could result in a lowered immune response and 
thereby aid in STI susceptibility and disease progression. These results together with other in 
vitro, ex vivo, clinical and animal in vivo studies (Gillgrass et al. 2003; Kaushic et al. 2003; 
Koubovec et al. 2004; Koubovec et al. 2005; Trunova et al. 2006; Ronacher et al. 2009; 
Huijbregts et al. 2013; Tomasicchio et al. 2013; Huijbregts et al. 2014; Ray et al. 2014) 
suggest that high dose progestin-only contraceptives like MPA with GR properties should be 
avoided by women at high risk for STI infection. 
In contrast to findings in this thesis, a previous study found that MPA in the presence of 
TNF-α upregulated IL-8 mRNA in the Ect1/E6E7 ectocervical cells (i.e. pro-inflammatory) 
(Africander, Louw, et al. 2011). However, similar to the anti-inflammatory effects of MPA in 
the endocervical cells, Africander et al. found that MPA in the presence of TNF-α repressed 
RANTES mRNA expression in the ectocervical cells while in the Vk2/E6E7 vaginal cells, 
MPA did not regulate the cytokines (Africander, Louw, et al. 2011). Based on results from 
this thesis and previous reports, MPA appears to have differential effects on 
cytokine/chemokine regulation in the ectocervical, vaginal and endocervical cells and this 
requires further investigation. Furthermore, Africander et al. found that the ectocervical and 
vaginal cell lines express a variety of SRs such as PR, GR, AR and ER (Africander, Louw, et 
al. 2011). The differences in SR expression between the endocervical, ectocervical and 
vaginal cell lines could account for the differential MPA-mediated effects in these cell lines. 
In addition, whether other GR isoforms are expressed by these cells and the effects of MPA 
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via the other GR isoforms is unknown but unlikely since the other isoforms are GC-resistant. 
The results collectively suggest that progestins will have differential effects on genital 
mucosal immune function and susceptibility to infections depending on which SRs are 
expressed. Since the AR- and PR-mediated effects of MPA are similar to P4 and NET-A as 
reviewed in (Hapgood et al. 2013), the effects of MPA are likely to be very different to those 
of NET-A and P4, when mediated by the GR, but not the AR or PR. It is also possible that 
there would be differential effects by the progestogens when mediated by the ER or MR since 
NET-A has estrogenic activity while P4 has anti-mineralocorticoid activity (Schindler et al. 
2003; Hapgood et al. 2013).  
In addition to differential inflammatory gene regulation, the ligands have previously been 
shown to affect GR protein levels. Specifically, the GR is degraded in a ligand-selective 
manner (Avenant et al. 2010); that is, full agonist DEX causes the fastest GR degradation 
followed by MPA, P4, and then NET (Avenant et al. 2010). In both cell lines DEX-mediated 
regulation is more potent than MPA, NET-A and P4 which is consistent with the observed 
effects of the ligands on GR protein levels at 24hr. The effects of the DEX and MPA on GR 
protein turnover are consistent with the hypothesis that DEX and MPA-mediated gene 
regulation is via the GR. In addition, in the End1/E6E7 cells the GR protein turnover with 
DEX is more apparent at 24 hr than at 4 hr which is consistent with the effects of DEX on 
gene regulation being more potent at 24 hrs. Although the effects of MPA on gene regulation 
in the End1/E6E7 cell line are mediated by the GR, the effect of MPA on GR protein 
turnover is not as apparent in the single representative Western blot. In retrospect, for the 
End1/E6E7 cell line multiple Western blots should have been analyzed and the effects of the 
ligands on GR protein levels quantitated as done for the HeLa cell line.  
In order to confirm the differential regulation of the inflammatory genes by the progestogens 
in a primary endocervical model, dose-response and antagonist experiments were done in the 
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VEN-100 model which is a bio-engineered multilayer of primary endocervical epithelial 
cells. Unfortunately, the cells did not respond as expected since the viability of the cells 
decreased significantly by the time they were harvested for analysis. This was due to 
logistical delays in the delivery of the tissue from Ashland, MA, USA to Cape Town, RSA. 
Therefore, not much can be concluded from the dose-response or antagonist experiments with 
the primary cells. It is worth noting that it was prohibitively expensive to repeat these 
experiments or attempt to solve the cell viability problems of the VEN-100 cells. Fortunately, 
the SR content of the primary cells was assessed while the cells were still viable and it was 
found that the primary endocervical cells contain GR mRNA and protein, MR mRNA and 
ERα mRNA, but not PR or AR mRNA. This study was not able to investigate MR and ERα 
protein levels due to the insufficient amount of primary cell lysate. Similar to the primary 
endocervical cells, the End1/E6E7, HeLa and TZM-bl cervical cell lines express GR. Also 
similar to the primary endocervical cells, the HeLa and TZM-bl cells express MR. Like this 
current study ERα has previously been shown to be expressed in primary endocervical cells 
(Al-hendy et al. 2006). However, it has been previously shown by immunohistochemical 
analysis, Western blotting and RT-PCR that primary human endocervical cells express both 
PR isoforms, PR-A and PR-B, (Al-hendy et al. 2006) in contrast to the findings of this 
present study. Since the expression of sex SRs are affected by a variety of factors such as 
hormonal status and age of a patient (Brodowska et al. 2010) this could explain the 
differences between the current study’s observations and previous reports. In particular, PR 
protein expression in uterine tissue is dependent on the stages of menstrual cycle. There is an 
increase in PR expression from early proliferative to late proliferative stage and then a 
decrease in PR expression from late proliferative to early secretory and late secretory stages 
(Ingamells et al. 1996). PR protein expression in cervical tissue has also been shown to be 
dependent on hormonal status whereby pregnant women have been found to express much 
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lower amounts of PR than non-pregnant women (Stjernholm et al. 1996). Thus it is possible 
that the VEN-100 endocervical cells may have been collected at a stage when the PR was not 
expressed. This raises interesting questions as to whether changes in SR content for e.g. PR to 
GR ratio during the menstrual cycle may differentially regulate inflammatory gene 
expression in response to progestins and future investigation is warranted.  
To further investigate the mechanism of gene regulation via the GR, de novo protein 
synthesis was inhibited and mRNA expression was measured. The use of cycloheximide 
(CHX) is an established method to prevent de novo protein synthesis and thereby identify the 
type of gene regulation (Baliga et al. 1969; Ravni et al. 2006). This method is a useful tool to 
show whether the GR is directly involved in the gene regulation or indirectly (i.e. by 
upregulation of another protein which in turn regulates the gene of interest). The GR was 
found to be partially involved in the regulation of GILZ and directly involved in the 
regulation of IκBα, IL-6 and IL-8 genes (Figure 4.8). The GILZ and IκBα gene promoters 
have multiple glucocorticoid response elements (GREs) and are examples of GR 
transactivation model genes (Hermoso & Cidlowski 2003; Muzikar et al. 2009). In addition, 
in A549 cells it has been shown that the GR is recruited to the GRE region of the GILZ 
promoter by both DEX and MPA (Hadley et al. 2011). In contrast, the ChIP assay results 
from this thesis did not show GR recruitment to the GILZ promoter with MPA. This is not 
unexpected since it is shown by CHX experiments that MPA-induction of GILZ may in part 
require new protein synthesis and may not only involve direct GR transactivation. However, 
as mentioned above it has been previously shown in A549 cells that the GR is recruited to the 
GRE region of the GILZ promoter by MPA (Hadley et al. 2011) therefore it is likely that a 
small amount of GR is recruited by MPA, but this is below the limits of detection of the ChIP 
assay in HeLa cells. A possible reason for this is that in comparison to the A549 cells, the 
HeLa cells may express lower amounts of GR protein. The IL-6 and IL-8 gene promoters 
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have binding sites for transcription factors that include activator protein-1 (AP-1) and NF-κB 
(McKay & Cidlowski 1999; Koubovec et al. 2004). It is proposed that GR represses IL-6 and 
IL-8 gene expression by interference of these transcription factors (De Bosscher et al. 2003). 
The findings that activation with DEX recruits GR to the IL-6 and IL-8 promoter regions are 
consistent with previous reports (Cvoro et al. 2011; Verhoog et al. 2011). Koubovec et al. 
also showed that MPA represses both IL-6 and IL-8 promoter activity (Koubovec et al. 
2004). However, it is shown for the first time, that stimulation with MPA recruits GR to the 
regions encompassing the AP-1 site of the IL-6 promoter and NF-κB site of the IL-8 
promoter, thereby repressing expression of these genes, as schematically represented (Figure 
7.1). Although stimulation with MPA and DEX recruits the same amount of GR to the IL-6 
promoter, this does not correlate with the ligands potency and efficacy of IL-6 mRNA 
regulation. This suggests that stimulation with MPA and DEX may recruit different amounts 
of co-factors and/or different co-factors and is consistent with a study which shows 
differential binding of co-factors in ligand-selective GR-mediated gene regulation (Ronacher 





Figure 7.1: Schematic model for the role of GR in MPA- and DEX-mediated anti-
inflammatory actions via regulation of GILZ, IL-6 and IL-8. Upon DEX or MPA binding 
to the GR, the GR undergoes a conformational change and translocates to the nucleus where 
it occupies GRE sites of the GILZ promoter to activate transcription of the GILZ gene or 
interacts with pro-inflammatory transcription factors bound to AP-1 sites of the IL-6 
promoter to suppress IL-6 gene transcription or to NF-κB sites of the IL-8 promoter to 
suppress IL-8 gene transcription. Abbreviations: DEX = dexamethasone, MPA = 
medroxyprogesterone acetate GR = glucocorticoid receptor, GRE = glucocorticoid response 
element, AP-1 = activator protein-1, NF-κB = nuclear factor kappa B. Note: Stimulation with 
MPA may not necessarily recruit GR to GILZ in the HeLa cell line. 
 
7.3 Vpr potentiates ligand-mediated reporter gene regulation but not ligand-
mediated endogenous gene regulation 
It has been hypothesized that the GR plays a role in HIV-1 pathogenesis whereby a decrease 
in pro-inflammatory cytokines results in lowered host immune response and thus aids in 
disease progression. The HIV-1 accessory protein Vpr has previously been shown to be 
immunosuppressive since it represses pro-inflammatory cytokines similar to the actions of 
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glucocorticoids (GCs) (Ayyavoo, Mahboubi, et al. 1997; Muthumani et al. 2000; Mirani et al. 
2002). Crosstalk between Vpr and the GR has been proposed to be the mechanism whereby 
the GR modulates both host and viral gene regulation (Hapgood & Tomasicchio 2010). HIV-
1 Vpr has been previously shown to potentiate GR-mediated reporter gene and endogenous 
gene transcription in the presence of DEX (Kino et al. 1999; Mirani et al. 2002; Fakruddin & 
Laurence 2005). However, there is limited data on whether Vpr modulates GR-mediated 
inflammatory gene regulation in the presence of DEX and no data for the synthetic progestins, 
MPA and NET-A. Since the actions of MPA have been shown in this current study to be 
mediated by the GR, it is possible that Vpr may co-activate GR-mediated inflammatory gene 
regulation in the presence of MPA similar to the action of DEX.  
This present study investigated the effects of Vpr on the regulation of inflammatory genes in the 
presence of DEX, P4 and the synthetic progestins. In this study the HeLa and TZM-bl cell lines 
were used as the model systems. The TZM-bl cell line is a HeLa cell line modified to express 
CCR5 and CXCR4. This allows the cells to be infected by HIV-1 and thereby to deliver 
physiological levels of viral proteins such as Vpr. 
The HeLa and TZM-bl cells were assessed for their SR content to determine whether they 
express GR. It was found that they both express GR mRNA and protein similar to the 
End1/E6E7 cell line and primary endocervical cells (as discussed earlier). In addition, both 
the cell lines expressed AR and MR, mRNA whereas only the TZM-bl cells expressed 
detectable AR protein. The HeLa cell line required further investigation to determine whether 
the endogenous GR, AR and MR were functional. It was found by reporter assays, using a 
transactivation model, that endogenous GR was transcriptionally active. The AR and MR 
specific agonists (MIB and ALD, respectively) only produced a transcriptional response in 
the presence of overexpressed AR and MR. Furthermore, it was confirmed on the 
endogenous inflammatory genes that GR is active whereby the GR agonist, DEX, induced 
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anti-inflammatory gene expression (GILZ) and repressed pro-inflammatory gene expression 
(IL-6). This is a typical GR-mediated response (De Bosscher et al. 2000) and suggests that 
the GR plays a role in ligand-mediated anti-inflammatory responses in the cervical cells. 
Interestingly, ALD induced expression of the pro-inflammatory gene, IL-8. This would 
indicate that MR is active in the HeLa cells and suggests that the MR could be responsible for 
the mediation of a pro-inflammatory response. This is consistent with previous studies which 
showed that ALD induced pro-inflammatory cytokines in renal cells and caused vascular 
inflammation by upregulation of pro-inflammatory genes in heart tissue (Rocha et al. 2002; 
Blasi et al. 2003). Results suggest that the MR-mediated response may be promoter-specific 
since ALD only promoted a MR-mediated response on endogenous IL-8 but not on the 
simple reporter gene. The assays to determine whether the SRs are functional were not done 
in the TZM-bl cell line. It was assumed that they would have similar SR functionality since 
they are derived from the HeLa cell line and have the same SR content as them. 
In order to determine whether Vpr co-activates the GR-mediated response in the presence of 
MPA, it was first established that MPA acts as a partial agonist for the GR in the HeLa cell 
line. It was found by promoter-reporter assays that MPA acts as a partial agonist for the GR, 
while P4 and NET-A have no agonist activity, consistent with a previous study done in COS-
1 cells (Ronacher et al. 2009). The ligands did not produce the expected responses on the 
transrepression model reporter genes (Addendum Figure 2). It could be that the IL-6 reporter 
gene promoter may require an additional co-factor for the GR to mediate repression and this 
co-factor is lacking in the HeLa cells. In hind sight, this should have been confirmed by 
performing reporter gene assays using the AP-1 reporter gene in the presence of the ligands 
in the HeLa cell line. It was decided that the IL-6-luc reporter genes were not a suitable 
transrepression model for the HeLa cell line and consequently the endogenous 
transrepression genes were investigated. 
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The hypothesis that HIV-1 Vpr acts as a co-activator of the GR is supported by the result that 
shows Vpr enhances the DEX-mediated transactivation of a reporter gene. In addition, these 
results are consistent with previous studies which show that Vpr enhances the GC-mediated 
response of TAT-GRE and mouse mammary tumour virus (MMTV) reporter genes, in a 
variety of cell lines such as human embryonic kidney 293T cells and the T lymphoblastoma–
derived CEM and Jurkat cells (Kino et al. 1999; Sherman et al. 2000). It has also been 
previously shown by in vitro binding and co-immunoprecipitation assays that this co-
activation response may be due to Vpr interacting with the GR via the LXXLL motif (Kino et 
al. 1999). However, for the first time it is shown here that Vpr also enhances MPA-mediated 
transactivation of a TAT-GRE reporter gene. Western blots show that Vpr does not affect the 
expression of GR protein and therefore rules out the possibility that Vpr increases GR protein 
expression which could enhance transactivation. Consistent with this it has been shown that 
Vpr does not affect ligand-dependent serine 203, 211 or 226 GR phosphorylation (Grantham 
2012). It has been previously hypothesized that tissue hypersensitivity to GCs in HIV-1 
patients occurs via Vpr enhancing transactivation of the GR (Kino & Chrousos 2001). The 
results from this present study support this hypothesis and suggest a mechanism whereby Vpr 
enhances the efficacies of both DEX and MPA for transactivation. Again, results from this 
present study highlight the importance of choice of progestin used in contraception. Results 
also suggest that injectable MPA, unlike NET-A and P4, could mimic the effects of GC 
hypersensitivity and/or potentially enhance GC hypersensitivity in HIV-1 patients. Consistent 
with this, a previous study has shown that MPA, unlike NET-A and P4 increases apoptosis of 
T-cells via the GR and this is potentiated by Vpr (Tomasicchio et al. 2013). This may 
potentially decrease the ability of T-cells to mount an anti-viral defence and thereby 
contribute to immunodeficiency and therefore MPA may not be the best contraceptive option 
for women infected with HIV-1. 
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Investigation into the endogenous genes revealed that Vpr does not modulate the DEX- or 
MPA-mediated regulation of the selected inflammatory genes. This is in contrast to a 
previous report that shows Vpr potentiates DEX-mediated repression of the pro-inflammatory 
cytokine IL-12 in human monocytes (Mirani et al. 2002). This present study only 
investigated the cytokine genes (IL-6, IL-8 and RANTES) which are known to be 
constitutively expressed in cervical epithelial cells. Thus it is possible that Vpr acts as a GR 
co-activator on other cytokine genes such as IL-12. Previous reports also show that Vpr 
enhances DEX-mediated induction of Receptor of Activated NF-κB Ligand (RANKL) 
protein levels (Fakruddin & Laurence 2005). However, this present study showed that 
although DEX upregulates RANKL mRNA, Vpr does not enhance this DEX-mediated 
upregulation (Addendum Figure 3). This suggests that the Vpr-mediated co-activation of 
RANKL may be post-transcriptional. Alternatively, since the Fakruddin & Laurence study 
transfected higher amounts of Vpr expression vector (2 – 6 μg) than this present study and 
since this present study shows that effects with Vpr are dose-dependent, it is possible that at 
higher concentrations Vpr may act as a co-activator on RANKL (Fakruddin & Laurence 
2005). Another possibility is that the Vpr co-activation response seen by Fakruddin et al. is a 
non-specific response and an artefact due to the very high amounts of DNA transfected 
(Fakruddin & Laurence 2005). On the other hand, the lack of Vpr co-activation in this present 
study may be due to cell type differences. The experiments done in this present study were in 
HeLa cells while the experiments done in the Fakruddin & Laurence study were done in the 
Jurkat cell line and PBMCs (Fakruddin & Laurence 2005). It is possible that the Jurkat cells 
and PBMCs may have the transcription factor/s required for the Vpr co-activation response 
on RANKL and this transcription factor/s may be lacking in the HeLa cell line.  
There are several possible explanations for the different findings with Vpr between the 
reporter gene assays and endogenous genes. Although the reporter gene and endogenous 
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genes investigated have GRE sites, again, it is possible that Vpr regulation could be 
promoter-specific. Since the aim of this study was to investigate the role of Vpr in GR-
mediated inflammatory gene regulation, the GILZ and IκBα inflammatory endogenous GRE 
genes were investigated. However, the promoter-reporter assays were done using a model 
GRE-reporter gene, TAT, which encodes for a metabolic liver enzyme. Although the 
promoters of TAT, GILZ and IκBα all contain 2 or more GRE sites, it is possible that the 
presence of not only GRE sites but other factors such as GRE distance from basal promoter 
may dictate Vpr co-activation. In addition, it has been previously shown that minor changes 
in the TATA-box region of a gene promoter can modulate GR-mediated responses (Meyer et 
al. 1997). It is therefore likely that discrepancy in the responses could be attributed to the 
differences in TATA-box element of the genes. Thus, it is still possible that Vpr may act as a 
GR co-activator on other GRE inflammatory genes. The differences in the promoter 
architectures between a reporter gene and an endogenous gene could also account for the 
contrasting results. Endogenous genes have more complicated promoters than the simple 
reporter gene promoters. In addition, endogenous genes are surrounded by chromatin which 
could affect the accessibility and spatial organization at transcription sites unlike the reporter 
genes which are not packaged into native chromatin (Müller et al. 2007). Thus it is possible 
that Vpr may only regulate gene transcription in the absence of chromatin. Another 
explanation for the differing results is that there could be differences in the amount of Vpr 
protein expressed in the cells for the reporter vs. the endogenous gene experiments. The 
reporter gene assays had a lower ratio of Vpr plasmid DNA to cells and thus it is possible that 
lower Vpr protein was expressed in the cells than in the endogenous gene experiments. If this 
were the reason, this would suggest that Vpr modulation of DEX-mediated gene regulation is 
dose-specific and thus this hypothesis was tested. 
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This hypothesis was investigated by performing Vpr dose response analysis in the HeLa cells. 
The reporter gene assay revealed that Vpr dose-dependently enhances DEX-mediated 
induction of the TAT-GRE reporter gene. This is consistent with previous studies that 
showed Vpr dose-dependently enhances the DEX-mediated induction of TAT-GRE and 
MMTV reporter genes in the 293T, CEM, Jurkat and A204 cell lines (Kino et al. 1999; 
Sherman et al. 2000). However, investigation into the endogenous GRE genes showed that 
the increasing amounts of Vpr did not affect the DEX-mediated induction of GILZ or IκBα 
mRNA. Similarly, the increasing amounts of Vpr did not affect the DEX-mediated repression 
of the pro-inflammatory IL-6 or IL-8 genes. To determine whether Vpr delivered in a more 
physiologically relevant context i.e. in the context of whole virus could act as a co-activator 
on the endogenous inflammatory gene, HIV-1 pseudovirus experiments were performed in 
the TZM-bl cell line. Consistent with the transient transfection experiments, HIV-1 
pseudovirus experiments showed that Vpr does not affect the DEX-mediated regulation of the 
endogenous inflammatory genes in TZM-bl cells. Taken together, results from this present 
study suggest that Vpr can dose-dependently co-activate GR-mediated transactivation (as 
illustrated in Figure 7.2) in the presence of GCs and MPA. However, while this co-activation 
occurs on synthetic reporter genes, the response on endogenous genes may be highly 
promoter- and/or cell-specific and/or dependent on the absence of chromatin. The current 
results suggest that Vpr does not co-activate the GR-mediated regulation of endogenous 
GILZ, IκBα, IL-6 and IL-8 genes in the presence of ligands in HeLa and TZM-bl cells, even 
when exogenously expressed, or delivered in HIV-1 pseudovirus particles. Nevertheless, it is 
possible that Vpr may co-activate other GR-regulated endogenous inflammatory genes in the 






Figure 7.2: Schematic model of Vpr dose-dependent co-activation of GR-mediated 
transactivation in the presence of DEX and MPA. Upon ligand binding, GR undergoes a 
conformational change and translocates to the nucleus. Activated GR-ligand complex binds 
to GRE sites of the promoter region of the TAT gene and (A) activates transcription in the 
absence of Vpr, (B) in the presence of small amounts of Vpr, GR-mediated transactivation is 
enhanced and (C) in the presence of high amounts of Vpr, GR mediated transactivation is 
further enhanced. Abbreviations: DEX = dexamethasone, MPA = medroxyprogesterone 
acetate, GR = glucocorticoid receptor, Vpr = viral protein R, GRE = glucocorticoid response 
element, TAT = tyrosine aminotransferase. Note: evidence for Vpr directly associating with 
GR taken from Kino et al. 1999. 
 
In the absence of DEX, although Vpr does not affect the DEX-mediated regulation of the 
inflammatory genes, it does appear to regulate the pro-inflammatory cytokine genes ligand-
independently. In particular, it was shown in this thesis by transient transfection experiments 
in the absence of GCs that exogenously expressed Vpr upregulates IL-6 and IL-8 mRNA 
levels in the HeLa cells, suggesting that Vpr is pro-inflammatory. This is supported by a 
previous study that showed exogenously expressed Vpr upregulates IL-8 protein levels in 
Jurkat, A549 and U937 cell lines (Roux et al. 2000). However in the present study, delivery 
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of Vpr by pseudovirus did not affect IL-8 mRNA levels, unlike the result with exogenously 
expressed Vpr. Work by others has shown that delivery of Vpr by pseudovirus upregulates 
IL-8 protein levels in A549 and U937 cell lines and primary human T-cells and macrophages 
(Roux et al. 2000). Consistent with the effects of Vpr being dose-dependent, the difference 
between the findings for pseudovirus delivery between the current study and that of Roux et 
al. could be explained by the difference in amount of virus used, or by cell-specific effects. In 
support of the former possibility, it is notable that the current study infected cells with an 
apparently lower dose of pseudovirus compared to the Roux et al. study (Roux et al. 2000). 
In addition, the pseudovirus constructs used in the Roux et al. study is different to the ones 
used in the present study. Consequently, differences in stoichiometry of the Vpr protein 
complexes between the different pseudovirus and the exogenously expressed Vpr could also 
be attributed for the discrepancies. Contrary to previous studies that suggest Vpr is 
immunosuppressive (Ayyavoo, Mahboubi, et al. 1997; Muthumani et al. 2000; Mirani et al. 
2002) in the absence of GCs, findings from this thesis suggest that Vpr may promote a pro-
inflammatory response under certain conditions (Figure 5.9 and 5.11 A). It is proposed based 
on the current findings and literature reports that Vpr may have both anti-inflammatory and 
pro-inflammatory properties, depending on the life cycle of HIV and concentration of Vpr in 
the cells, Vpr may switch between these two effects to aid in viral pathogenesis.  
Although Vpr regulates the selected pro-inflammatory genes in the absence of GR ligand, it 
is still possible that the GR plays a role in this regulation. Previous reports have shown that 
the GR antagonist, RU-486, reverses the GC ligand-independent Vpr-mediated regulation of 
NF-κB reporter gene and endogenous inflammatory genes (Mirani et al. 2002; Muthumani et 
al. 2006). Furthermore, a previous study from the present author’s laboratory has shown that 
the GR can act ligand-independently to regulate inflammatory genes (Verhoog et al. 2011). 
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Therefore, it is also proposed that the unliganded GR may play a role in the Vpr-mediated 
anti-inflammatory response (as illustrated in Figure 7.3 A).  
 
 
Figure 7.3: A model for the mechanism of unliganded GR involvement in Vpr-mediated 
regulation of pro-inflammatory genes.  It is proposed that depending on the concentration 
of Vpr and stage of infection, Vpr associates with unliganded GR to either (A) repress or (B) 
upregulate pro-inflammatory gene expression. Abbreviations: GR = glucocorticoid receptor, 
Vpr = Viral protein R GRE = glucocorticoid response element, TF = transcription factor, 
TFRE = transcription factor response element, X = unknown transcription factor. 
 
Attempts were made to investigate the role of unliganded GR in Vpr-mediated upregulation 
of IL-6 and IL-8 by GR knockdown in the HeLa cells. However, this was unattainable due to 
the difficulty to obtain efficient GR knockdown whilst preserving cell viability of the HeLa 
cell line. Nevertheless, experiments in End1/E6E7 cells showed that Vpr upregulation of IL-8 
is attenuated when GR is knocked down (unpublished, C. Avenant), consistent with a role for 
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the unliganded GR in modulating Vpr-mediated regulation of pro-inflammatory genes. 
Although the mechanism of this regulation is currently under investigation by others in the 
present author’s laboratory, results from this present study rule out the possibility that Vpr 
promotes a pro-inflammatory response by regulation of GR protein levels. Results from this 
thesis have important implications for HIV-1 pathogenesis and suggest that depending on the 
stage of HIV-1 infection that Vpr may be pro-inflammatory in the absence of GCs as 
illustrated in Figure 7.3 B.  
7.4  The GR plays a role in ligand-mediated repression of HIV-1 LTR 
transcription 
In addition to a role for the GR in regulating host inflammatory genes in response to HIV-1 
infection, the GR has been shown to play a role in HIV-1 LTR transcription. However, there 
have been conflicting reports on whether the GR mediates an increase or decrease in HIV-1 
LTR transcription (Laurence et al. 1989; Furth et al. 1990; Kolesnitchenko & Snart 1992; 
Mitra et al. 1995; Kurata & Yamamoto 1999; Russo et al. 1999; Kino et al. 2000). An 
increase in HIV-1 transcription would result in an increase in viral replication and whereas a 
decrease in HIV-1 LTR transcription would most likely decrease viral replication. On the 
other hand, a decrease in HIV-1 replication could increase viral latency. Thus, it is important 
to understand the exact role of the GR in regulating HIV-1 transcription.  
Previous studies have observed DEX-mediated regulation of HIV-1 LTR transcription in 
multiple cell lines (Laurence et al. 1989; Mitra et al. 1995; Kino et al. 2000). However, there 
are no data on whether the synthetic progestins, MPA and NET-A, regulate HIV-1 LTR 
transcription. Given that MPA acts like a partial to full agonist for the GR, it is proposed that 
MPA, like DEX, regulates HIV-1 LTR transcription via the GR. This present study 
investigated the effects of DEX, P4 and the synthetic progestins on HIV-1 LTR transcription in 
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the HeLa and TZM-bl cell lines. Again, the TZM-bl cell line was used for its ability to be 
infected by HIV-1. In addition, it was used since it contains a stably integrated HIV-1 LTR-luc 
reporter gene. 
It was found that DEX repressed Tat-activated LTR transcription in the HeLa cell line similar to 
previous reports (Laurence et al. 1989; Mitra et al. 1995; Kino et al. 2000). It was also found 
that 100 nM P4 represses Tat-activated LTR transcription which is similar to results from a 
previous study in U937 cells (Lee et al. 1997). In addition, in attempts to determine whether 
P4 could re-activate LTR activity in the absence of virus, a previous study has also shown in 
TZM-bl cells that 100 nM P4 represses basal LTR activity (Asin et al. 2008). Results from 
this thesis suggest that mid-secretory phase concentrations of P4 may reduce HIV-1 
replication and are consistent with previous findings that show by p24 levels in PBMCs that 
100 nM P4 alone and the combination of 100 nM P4 + 1 nM E2 reduces HIV-1 replication 
(Asin et al. 2008). Taken together, results presented here and by others suggest that P4 may 
reduce HIV-1 replication by a mechanism of transcriptional repression of the LTR. 
Interestingly, Asin et al. also found that mid-proliferative phase concentrations of E2 and P4 
may enhance HIV-1 replication in PBMCs (Asin et al. 2008) suggesting that HIV-1 viral 
loads may increase or decrease depending on the stage of the menstrual cycle, consistent with 
clinical reports that show cyclic changes in HIV-1 levels (Greenblatt et al. 2000; 
Reichelderfer et al. 2000).  
For the first time it was shown here that both the synthetic progestins, MPA and NET-A, 
repress LTR transcription. Consistent with these findings the HIV-1 pseudovirus experiment 
results showed that all the ligands repressed the stably integrated LTR transcription in the 
TZM-bl cell line. These findings show that the delivery of Tat by transient transfection is 
comparable to the HIV-1 pseudovirus delivery of Tat protein. In addition, it shows that the 
transiently transfected LTR-luc expression vector which is not surrounded by chromatin 
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yielded similar results to the stably integrated LTR-luc in the presence of chromatin. These 
results have implications for HIV-1 pathogenesis in vivo and suggest that progestins, like DEX, 
may decrease transcription of the HIV-1 LTR in HIV-1 infected cells.  
The GR antagonist, RU-486, has been suggested to have anti-viral effects on HIV-1 (Schafer 
et al. 2006; Benton et al. 2013). In particular, it has been previously shown that RU-486 
decreases HIV-1 replication in monocyte-derived macrophages and PBMCs (Schafer et al. 
2006; Benton et al. 2013). This is consistent with this present study’s findings which show 
RU-486 represses Tat-activated LTR transcription in the HeLa cells. This present study also 
shows that the combination of DEX and RU-486 represses LTR transcription. The 
mechanism of RU-486-mediated repression of the LTR has been suggested to be via the 
antagonism of GR (Kino et al. 2000; Schafer et al. 2006; Benton et al. 2013). The current 
findings are not consistent with a mechanism of GR antagonism. The results suggest that the 
unliganded GR is required for Tat-activated LTR transcription, and that this effect of the 
unliganded GR can be inhibited by RU486, acting in agonist mode. In the presence of DEX, 
RU486 also does not act as a DEX antagonist, but rather appears to act in agonist mode, 
resulting in no lifting of the DEX effect, or possibly even more repression. RU-486 has been 
shown to manifest both GR antagonist and agonist properties depending on the GR density in 
the cells (Zhao et al. 2003). At high GR density, RU-486 can behave as a full agonist for GR-
mediated transrepression while at low GR density, RU-486 can act a full GR antagonist 
(Zhao et al. 2003). The current results suggest that the HeLa cell line has a GR density that 
promotes agonist properties of RU-486 in GR-mediated transrepression of the LTR, in the 
absence and presence of DEX. RU-486 has also been shown to bind GRβ and have GRβ-
mediated transcriptional effects (Lewis-Tuffin et al. 2007). Alternatively, results suggest that 
the HeLa cells may express GRβ and transrepression of the LTR by RU-486 may be via GRβ. 
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The role of the GR in the ligand-mediated repression of HIV-1 LTR transcription was 
investigated by GR knockdown experiments. The GR knockdown revealed that all the 
ligands still repressed LTR transcription. This suggests that the GR may not be involved in 
the ligand-mediated repression or it could suggest that the ligands require very little GR to 
mediate transcriptional repression of the LTR gene in the TZM-bl cells. The latter 
explanation seems likely since ~60% of the GR was still present. Also consistent with the 
latter explanation, depending on the percentage GR knockdown, some transrepression model 
genes have shown to be hypersensitive to GR whereby ligand-mediated repression still occurs 
in the presence of GR siRNA transfection e.g. IL-6 in A549 cells (unpublished, C. Kemp). 
Attempts to increase the % GR knockdown were unsuccessful due to cell death. The addition 
of NET and LNG to the panel of ligands revealed a linear trend in the rank order in which the 
ligands repress LTR transcription i.e. DEX>MPA>P4>NET-A>NET>LNG. The rank order 
of DEX>MPA>P4>NET-A>LNG is similar to that of the ligands relative binding affinity for 
the GR (Koubovec et al. 2005; Hapgood et al. 2013). In addition, it is similar to the ligands 
potency for GR-mediated transactivation of GRE-regulated genes and transrepression of NF-
κB-regulated genes (Koubovec et al. 2005; Ronacher et al. 2009). Furthermore, a previous 
study showed by GR overexpression experiments that the GR is involved in the DEX-
mediated repression of the LTR (Mitra et al. 1995). Taken together, it is most likely that the 
GR mediates the responses the ligands in LTR repression. In addition, insensitivity to ~40% 
GR knockdown suggests that very little GR is required for the regulation of the LTR. In 
comparison to the effects of the ligands on inflammatory gene regulation, it appears as if the 
presence of virus has blunted the differences between ligand activities via the GR on LTR 
regulation. That is, in the presence of virus the LTR gene is hypersensitive to GR bound to 
any of the ligands. For example, GR-mediated repression of the pro-inflammatory cytokines 
IL-6 and IL-8 in the HeLa and End1/E6E7 cells occurs with DEX and MPA and not with P4 
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and NET-A. In addition, GR-mediated repression of HIV-1 LTR transcription in the HeLa 
and TZM-bl cells occurs with both DEX and the progestogens. Furthermore, although the 
low dose intra-vaginal progestin contraceptive LNG has a reported RBA for the GR (> 1%); 
it has no reported GR activity (Hapgood et al. 2013). However, for the first time, results from 
this thesis suggest that LNG may regulate LTR transcription via the GR. Results from this 
present study suggest that both high dose progestins like MPA and NET-A and low dose 
progestins like LNG used in contraception and GCs used in therapeutics may regulate HIV-1 
replication via the GR. This has important implications for both women on progestin-only 
contraception and patients with chronic inflammation on GCs. As mentioned earlier, a 
decrease in HIV-1 replication could have positive effects for the host. On the other hand, a 
decrease in HIV-1 replication by the progestins could possibly promote viral latency in 
women on hormonal contraception and this would allow the virus to persist at low levels for 
years prior to the onset of AIDS (Levy et al. 1994).  A leading theory for how HIV-1 latency 
is initially established involves infection of activated CD4+ T cells as they are returning to a 
resting state to form long-lived memory T cells (Siliciano & Greene 2011; Hakre et al. 2012). 
During this transition, HIV-1 gene expression is largely suppressed (Abbas & Herbein 2012). 
Consequently, a stably integrated but transcriptionally silent provirus in a memory T cell is 
formed. Results presented in this thesis provide a possible molecular mechanism for the role 
of progestins in viral latency.  As suggested earlier, the progestins repress LTR transcription 
via the GR. The classical GR mechanism of action for transrepression is via recruitment of 
co-repressors and chromatin remodelling complexes such as HDACs which facilitate 
chromatin condensation and consequently gene repression (Chinenov et al. 2013). HDACs 
have previously been shown to be responsible for suppression of HIV-1 gene expression 
(Kumar et al. 2014). In addition, HDAC-1 recruitment has been shown to promote latency of 
HIV-1 LTR (Williams et al. 2006). Furthermore, HDAC inhibitors such as vorinostat have 
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been used therapeutically to reactivate HIV-1 from latency in patients undergoing HAART 
(Archin et al. 2012). Therefore, it is suggested that the progestins acting via the GR may 
promote recruitment of HDACs to the LTR and consequently promote viral latency. To the 
present author’s knowledge there have been no reports on the effects of progestins on viral 
latency. 
Although results from this thesis are contrary to previous reports from non-human primate 
models and clinical studies involving humans that suggest MPA-usage is associated with 
higher mean peak and acute viral loads as reviewed in (Stringer & Antonsen 2008), it is 
possible that the effects of hormones may differ during different stages of infection. Clinical 
reports also show that use of hormonal contraception is associated with increased HIV-1 
disease progression in women not yet on anti-retroviral therapy (Stringer et al. 2009) while 
others show that MPA-usage is not associated with deleterious consequences for HIV-1 
disease progression (Heffron et al. 2013; WHO 2014). Future research should assess how 
these hormones affect acute vs. chronic infection in the context of disease progression. 
Results from this thesis also suggest that further investigation into the biological activity of 
low dose progestins such as LNG and etonogestrel (ETG) in the context of HIV-1 infection is 
warranted. In particular, emphasis should be placed on LNG since this low dose progestin 
used in implants (Norplant) has recently been chosen to be investigated in a new randomised 
clinical trial (announced at the HIV R4P meeting, October 2014) (Rees 2014). In addition, 
LNG (vaginal ring) in combination with microbicides for multi-purpose prevention 
technologies is under current investigation by CONRAD (Thurman et al. 2013). Furthermore, 
ETG used in the implant Implanon has been recently rolled out at public health facilities 
across South Africa (SA to offer women free implant contraceptives, 2014). It would be 
crucial to determine whether progestins, like LNG and ETG, have differential off-target 
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biological effects in the context of HIV-1 before being considered for clinical trials and 
public use. 
Interestingly, in this current study when GR was knocked down, basal LTR transcriptional 
activity also decreased. This suggests that the unliganded GR protein is required for efficient 
HIV-1 LTR transcription. Alternatively, the decrease in basal LTR transcription could be due 
to fewer virus particles entering the cells in the knockdown condition. This is consistent with 
a previous study which showed by GR knockdown that GR protein is required for optimal 
provirus integration (Wiegers et al. 2008). Taken together, this may have implications for 
HIV-1 pathogenesis whereby unliganded GR protein levels may be regulated by the virus to 
ensure optimal infectivity and is consistent with a clinical study which suggests there is a link 
between changes in GR levels and HIV-1 infection (Guo et al. 1996). Although, this present 
study showed that Vpr does not regulate GR protein levels, this does not rule out the 
possibility that other non-Vpr related mechanisms by HIV-1 may regulate GR protein levels. 
Consequently, it would be important to determine whether HIV-1 infected individuals have 
significantly different GR levels than uninfected individuals. These results also imply that 
factors such as GCs and some progestin contraceptives that are shown here and by others to 
regulate GR protein levels may influence HIV-1 replication. 
7.5   Vpr does not play a role in GR-mediated regulation of HIV-1 LTR 
transcription 
Evidence in the literature suggests that Vpr plays an important role in HIV-1 LTR 
transcription. In particular, Vpr has been shown to both activate viral transcription in the 
absence of Tat and enhance Tat-activated viral transcription (Forget et al. 1998; Zhu et al. 
2001; Kino et al. 2002; Varin et al. 2005; Cui et al. 2006). However, there is limited data on 
role of Vpr in the regulation of HIV-1 LTR transcription in the presence of DEX and no data 
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for the synthetic progestins, which was thus explored in this thesis. In this study, the HeLa 
and TZM-bl cell lines were again used as the model systems. 
Similar to previous results obtained in this thesis; DEX, P4, MPA and NET-A all repressed 
LTR transcription in the absence of Vpr but in the presence of Tat. It was found that Vpr 
enhances Tat-activated LTR transcription in the HeLa cell line, consistent with previous 
reports in human primary micoglial cells, Jurkat cells and A204 cells (Kino et al. 2000; 
Sawaya et al. 2000; Kino et al. 2002). This is also consistent with the idea that Tat and Vpr 
are required for optimal HIV-1 replication (Sawaya et al. 2000). Similar to a previous report, 
this current study shows that Vpr does not modulate the suppressive effects of DEX on Tat-
activated HIV-1 LTR promoter (Kino et al. 2000). For the first time it is shown that Vpr also 
does not affect the progestin-mediated suppression of Tat-activated HIV-1 LTR transcription. 
This suggests that unlike host gene regulation Vpr does not modulate GR-mediated LTR 
repression in the presence of the ligands. 
HIV-1 pseudovirus experiments were performed in the TZM-bl cell line to confirm the result 
that Vpr does not affect the GR-mediated HIV-1 LTR repression. Consistent with previous 
findings in this thesis, DEX repressed HIV-1 wt activated LTR transcription. It was found 
that wt virus (Tat + Vpr protein) dose-dependently activated the LTR while the LTR 
activation with ΔVpr virus (Tat protein alone) was not statistically significant. This is 
consistent with the suggestion that Vpr and Tat are required for optimal HIV-1 replication. 
Since the LTR activation with ΔVpr virus was too low to detect using luciferase assays in the 
TZM-bl cells, the DEX-mediated suppression of the LTR in the absence of Vpr could also 
not be detected. Therefore, transient transfection experiment results could not be confirmed 




7.6  Conclusions 
In summary the present study demonstrates directly for the first time that the anti-
inflammatory effects of MPA, unlike NET-A and P4, in endocervical epithelial cells are via 
the GR. In addition, this study shows that the GR mechanism of action is via transcriptional 
regulation of the inflammatory genes. Furthermore, it is shown that at physiological doses 
particularly shortly after injection, MPA is anti-inflammatory for the genes investigated. 
Although the endocervical cells do not get productively infected by pathogens such as HIV-1, 
these cells play an important role in mucosal barrier protection. Therefore results from this 
thesis have implications for genital mucosal immune function and disease susceptibility and 
progression. In particular, effects of MPA are likely to be very different to those of NET-A 
and P4, when mediated via the GR, whereby a decrease in immune activation markers by 
MPA may inhibit T-cell activation and result in a lowered T-cell immune response. This is 
consistent with literature that shows MPA like the GC, DEX, has other consequences for T-
cell function such as increased apoptosis of T-cells. Accordingly, this may lower the host’s 
ability to mount a defence against pathogens such as HIV-1. Consequently, results from this 
thesis provide a mechanism for most observational reports that suggest injectable MPA 
increases the risk of HIV-1 acquisition in women whereby the GR is likely to play a major 
role in HIV-1 susceptibility in the FGT in the presence of MPA.  
In addition, it was established that the GR may play a role with Vpr in HIV-1 pathogenesis. 
In HIV-1 infection, extracellular Vpr may enter host cells and thereby modulate host gene 
regulation via the GR in the absence or presence of GR ligands. In the presence of GR 
ligands, Vpr may promote an anti-inflammatory response via the GR which could lead to an 
immunocompromised individual and this could allow opportunistic pathogens to infect the 
host. Vpr may enhance GR-mediated gene regulation in the presence of DEX and MPA, but 
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not NET-A or P4 in some contexts. The physiological implications could be that MPA, unlike 
NET-A and P4, may mimic the effects of GC hypersensitivity and/or potentially enhance the 
GC hypersensitivity observed in AIDS patients. In addition, it is possible that Vpr could 
discriminate between MPA vs. NET-A in HIV-1 disease progression. While in the absence of 
hormones, Vpr may hijack the unliganded GR to promote a pro-inflammatory response which 
would then most likely recruit more target cells to be infected. Results from this thesis 
suggest that depending on its concentration in host plasma and/or cells, Vpr may switch 
between anti-inflammatory or pro-inflammatory properties and this will also most likely be 
dependent on stage of HIV-1 infection. In addition, Vpr modulation of host genes may be 
highly promoter-specific and/or dependent on the absence of chromatin.  
The GR may also play a role in HIV-1 pathogenesis by viral LTR regulation in the absence 
and presence of GR ligands. In the absence of GR ligands the unliganded GR may be 
required for efficient viral replication. While in the presence of GR ligands; the activated GR 
may be involved in the ligand-mediated regulation of HIV-1 LTR transcription. It was shown 
for the first time that MPA, NET-A and LNG like DEX and P4 suppress LTR transcription, 
possibly via the GR, and Vpr does not modulate this regulation. These results have 
implications for HIV-1 replication and disease progression. Results suggest that, depending 
on the stage of HIV-1 disease, a decrease in HIV-1 replication by the progestogens and GCs 
may either have positive effects for the host or aid viral latency and consequently support 
HIV-1 pathogenesis. 
Of most significance, results from this thesis highlight the importance of choice and 
concentration of progestin used in contraception. Collectively present in vitro results with 
previous ex vivo, animal in vivo and clinical studies suggest that relatively high dose 
progestins such as injectable MPA, that have off-target biological effects via the GR may not 
be the best contraceptive option for women at high risk for HIV-1 infection. Since injectable 
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contraception is the method of choice in high risk areas, an alternative contraceptive for 
women in these areas must not only have good contraception efficacy but also be practical, 
acceptable and discrete. The other available injectable progestin-only contraceptive, NET-
EN, may represent a safer alternative to MPA, based on the results reported here. Since the 
observational clinical data on whether injectable contraceptives, in particular DMPA, 
increases risk of HIV-1 acquisition and disease progression is controversial it was not 
considered to be persuasive enough by the WHO to recommend discontinuation of any 
particular form of contraception (WHO 2014). Therefore a randomized clinical trial designed 
to compare the effects of MPA to other contraceptives may be the only way to get a clearer 
answer on whether there is an increased HIV-1 risk associated with DMPA-usage.  
7.7  Future perspectives 
Based on literature reports and results from this thesis, there appears to be major differences 
in SR content between the three compartments of the FGT and this may explain the 
differences in the MPA-mediated regulation of inflammation in these compartments. It would 
be interesting to directly compare the role of MPA in inflammation in the three different 
compartments of the FGT (vaginal vs. ectocervix vs. endocervix) and possibly determine the 
mechanism of action of the MPA-mediated regulation in each compartment. This could be 
done by performing experiments in the vaginal (Vk2/E6E7), ectocervical (Ect1/E6E7) and 
endocervical (End1/E6E7) cell lines. This should also be confirmed in primary cells by 
isolating cells from each compartment. Dose-response analysis could be done to determine 
whether the synthetic progestins regulate inflammatory genes at hormonal contraception 
concentrations. To gain insight into the mechanism of action, the SR content of primary cells 
should be assessed, if not previously known. 
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The question as to whether changes in SR content for e.g. PR to GR ratio during the 
menstrual cycle differentially regulate inflammatory gene expression in response to 
progestins was raised in thesis. The relative PR/GR ratio in different compartments of the 
FGT should be investigated and then could be mimicked in the End1/E6E7 cell lines to 
determine whether SR ratios affect gene regulation. Varying amounts of PR could be 
overexpressed to mimic different stages of the menstrual cycle and inflammatory gene 
regulation could be assessed in the presence of progestins. It would also be interesting to 
investigate whether changes in PR to GR ratio during the menstrual cycle influence HIV-1 
infection and/or replication. 
Results from this thesis suggest that MPA-mediated anti-inflammatory effects in endocervical 
cells may have important implications for HIV-1 susceptibility and progression in the lower 
FGT. In order to investigate this hypothesis, the effects of MPA-regulated cytokine secretions 
on T-cell susceptibility to HIV-1 infection need to be determined. This could be done by 
incubating the endocervical cell line and/or primary endocervical cells with different doses of 
MPA, NET-A, P4 and DEX for 24 hrs and/or 48 hrs. After incubation, the medium which 
would contain the ligand-regulated cytokine protein secretions could be collected. Thereafter, 
T-cells could be pre-incubated with the cytokine secretions and then infected with HIV-1 
pseudovirus or infectious molecular clones (IMCs). Then p24 levels could be measured to 
determine whether the ligand-regulated cytokine secretions affect HIV-1 infection. 
Another strategy to determine whether progestins such as MPA increase HIV-1 susceptibility 
would be to perform experiments on cervical tissue explants. Cervical tissue could be 
collected from pre-menopausal women undergoing hysterectomies for benign reasons. 
Primary cervical explants could be used to measure the productive infection of HIV-1 target 
cells such as CD4+ T-cells. Cervical explants could be treated with different doses of MPA, 
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NET-A, P4 and DEX and then infected with HIV-1 IMCs. Then, as above, p24 levels could 
be measured. 
In this present study it is suggested that the effects of the progestins when mediated via the 
GR may have negative consequences for genital mucosal immune function and possibly HIV-
1 pathogenesis. In addition, although LNG has no reported GR activity results from this 
thesis shows that it may act via the GR in regulation of HIV-1 LTR transcription. All these 
findings highlight the importance of choice of progestin used in contraception. LNG is a 2nd 
generation contraceptive and is used in vaginal rings and implants. Therefore it would be 
crucial to determine whether this progestin and other newer generation progestins such as 
ETG used in implants and vaginal rings would affect genital mucosal immune function. This 
could be done by treating the endocervical cell line and/or primary endocervical cells and/or 
cervical explants with a panel of newer generation progestins and then measure inflammatory 
gene and cytokine protein regulation. If the newer generation progestins affect inflammatory 
gene regulation, it would be important to determine whether this affects HIV-1 susceptibility 
and could be done as explained above.  
Given the controversy around MPA-usage, it would also be important to determine the effects 
of new and existing contraceptives on a broad panel of genes such as genes involved in innate 
and adaptive immunity, cell proliferation, cell integrity and structure. For existing 
contraceptives this could be done by performing RNA sequencing analysis on blood, 
cytobrush and/or cervical tissue samples from women. 
It would also be important to determine whether the synthetic progestins, MPA and NET-A, 
differentially regulate cytokine expression in in vivo models. This could be done using 
‘humanized’ mouse models. This is a mouse model in which various types of human cells 
and tissues are engrafted and function as they would in humans (Ito et al. 2012). Experiments 
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could be done by having 4 groups of mice which represent the panel of ligands (control, 
DEX, MPA and NET-A). These mice could be treated with injectable hormonal contraceptive 
concentrations of MPA (every 3 months) and NET-A (every 2 months). Thereafter blood and 
cervical tissue sample could be collected to determine the effect of the hormones of 
inflammatory gene expression. The serum levels of natural hormone P4, MPA and NET-A in 
the blood and cervical tissue could also be tested. Furthermore, the SR content and the effects 
of the ligands on SR levels could be determined. It would also be important to determine 
whether MPA increases HIV-1 susceptibility and investigate the effect of MPA on cytokine 
regulation in the presence of HIV-1 infection in vivo. This could also be done using the 
‘humanized’ mouse model for HIV-1 infection (Denton & Garcia 2011). 
Results from this thesis show that Vpr dose-dependently co-activates GR-mediated 
transactivation but this co-activation may be highly promoter-specific. In order to investigate 
this hypothesis, first the expression of a large number of genes in the absence of presence of 
DEX and/or Vpr needs to be analyzed. This could be done by performing RNA sequencing 
which has the capacity to analyze the expression of thousands of genes at one time. Once the 
genes that are co-activated by Vpr are identified, GR siRNA knockdown can be done to 
determine whether the GR is required for the gene regulation. Thereafter, the promoters of 
the GR-regulated genes that are co-activated by Vpr can be analyzed further to identify if the 
promoter of these genes have a common site/region that allows this co-activation response. 
Evidence in the literature suggests that Vpr is anti-inflammatory similar to GCs by the 
regulation of inflammatory mediators (Ayyavoo, Mahboubi, et al. 1997; Muthumani et al. 
2000; Mirani et al. 2002). This current study showed that Vpr-mediates an induction of pro-
inflammatory cytokines in the absence of ligands. This result taken together with previous 
reports in the literature suggest that Vpr may be anti-inflammatory and pro-inflammatory 
depending on the HIV-1 life cycle and concentration of Vpr. Results also suggest that the 
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unliganded GR may be involved in the Vpr-mediated pro-inflammatory response. This could 
be further investigated in the peripheral blood mononuclear cells (PBMCs). Varying amounts 
of HIV-1 pseudovirus/IMC could be used to deliver different doses of Vpr protein and GR 
knockdown could be done to assess whether the GR is involved in the Vpr-mediated 
regulation of the inflammatory genes. To gain further insight into mechanism of action, ChIP 
assays could be done to determine whether the GR and/or Vpr are recruited to the promoters 
of the inflammatory genes. 
In addition to the role of the GR in inflammatory gene regulation, this present study suggests 
that the GR is involved in the regulation of HIV-1 LTR transcription in the presence of DEX 
and the progestins. Although antagonist experiments using RU-486 and GR knock down 
using siRNA were performed to establish the role of the GR in LTR regulation, these 
experiments were inconclusive. Since 41% knockdown of GR protein did not reverse the 
ligand-mediated repression of the LTR, it was suggested that the LTR gene is hypersensitive 
to GR. To test this hypothesis dose response analysis with the ligands could be done. It is 
predicted that at lower concentrations of ligands, there would be less repression of the LTR. 
Since a higher protein knockdown using GR siRNA transfection could not be achieved while 
preserving cell viability, lentiviral knockdown using GR shRNA could be performed to 





Addendum: Supplementary Data 
 
 
Addendum Figure 1: MPA acts like a GR agonist in the regulation of inflammatory 
genes. HeLa cells were seeded at a density of 15 x 104 cells/well and incubated for 24 hrs. 
The cells were then treated with 100 nM DEX, MPA, P4, NET-A or EtOH (0.1% v/v, 
vehicle) for 4 hrs. Thereafter, the cells were washed twice with PBS and harvested for total 
RNA with TRIzol® and 500 ng RNA was reverse-transcribed. (A) Relative GILZ, (B) IL-6 
and (C) IL-8 gene expression was measured by qRT-PCR and normalised to GAPDH mRNA 
expression. In addition, relative gene expressions were normalized to basal activity (EtOH) in 
order to obtain relative fold expression. Graphs represent pooled results of at least three 
independent experiments and are plotted as mean +/- SEM. Statistical analysis was carried 
out using GraphPad Prism™ software (version 5) using a one-way ANOVA, with Dunnett 
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post-test. Statistical significance is denoted by *, ** or *** to indicate P< 0.05, P< 0.001 or 




Addendum Figure 2: DEX does not appear to repress IL-6 reporter gene. HeLa cells 
were seeded into a 24-well plate at a density of 7.5 x 104 cells/well and incubated for 24 hrs. 
Thereafter, the cells were transiently transfected with either 250 ng/well (A) IL-6 minimal 
promoter (p(IL-6κB)3-50hu.IL-6P-luc) or (B) IL-6 full length promoter (p1168hu-IL-6P-luc). 
After 24 hrs, the cells were treated with/without TNF-α in combination with 100 nM DEX, 1 
µM MPA, 10 µM P4, 10 µM NET-A or EtOH (0.1% v/v; vehicle) for 24 hrs.  Then, the cells 
were washed twice with PBS and lysed with 1X reporter lysis buffer and the luciferase 
activity was measured. Luciferase activity was normalized to protein content per well as 
determined by Bradford assay. In addition, the ligand stimulated responses were normalized 
with the basal activity (EtOH) in order to obtain a fold induction. Graph represents pooled 
results of at least two independent experiments, performed in triplicate, and are plotted as 

















Addendum Figure 3: Vpr does not affect DEX- and MPA-mediated transactivation of 
RANKL. HeLa cells were seeded into a 12-well plate at a density of 15 x 104 cells/well and 
incubated for 24 hrs. Thereafter, the cells were transiently transfected with 1 µg/well HA-Vpr 
or empty vector. After 24 hrs, the cells were treated with 100 nM DEX, 1 µM MPA, 10 µM 
P4, 10 µM NET-A or EtOH (0.1 % v/v; vehicle) for 24 hrs. Thereafter, the cells were washed 
twice with PBS and harvested for total RNA with TRIzol® and 500 ng RNA was reverse-
transcribed. Relative RANKL gene expression was measured by qRT-PCR and normalised to 
GAPDH mRNA expression. In addition, relative gene expression was normalized to basal 
activity (EtOH) in order to obtain relative fold expression. Graphs represent pooled results of 
at least three independent experiments and are plotted as mean +/- SEM. Statistical analysis 
was carried out using GraphPad Prism™ software (version 5) using a one-way ANOVA 
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Abstract
Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to
infections such as HIV-1, unlike the injectable contraceptive norethisterone enanthate (NET-EN). We investigated the
differential effects, molecular mechanism of action and steroid receptor involvement in gene expression by MPA as
compared to NET and progesterone (P4) in the End1/E6E7 cell line model for the endocervical epithelium, a key point of
entry for pathogens in the female genital mucosa. MPA, unlike NET-acetate (NET-A) and P4, increases mRNA expression of
the anti-inflammatory GILZ and IkBa genes. Similarly, MPA unlike NET-A, decreases mRNA expression of the pro-
inflammatory IL-6, IL-8 and RANTES genes, and IL-6 and IL-8 protein levels. The predominant steroid receptor expressed in
the End1/E6E7 and primary endocervical epithelial cells is the glucocorticoid receptor (GR), and GR knockdown experiments
show that the anti-inflammatory effects of MPA are mediated by the GR. Chromatin-immunoprecipitation results suggest
that MPA, unlike NET-A and P4, represses pro-inflammatory cytokine gene expression in cervical epithelial cells via a
mechanism involving recruitment of the GR to cytokine gene promoters, like the GR agonist dexamethasone. This is at least
in part consistent with direct effects on transcription, without a requirement for new protein synthesis. Dose response
analysis shows that MPA has a potency of ,24 nM for transactivation of the anti-inflammatory GILZ gene and ,4–20 nM
for repression of the pro-inflammatory genes, suggesting that these effects are likely to be relevant at injectable
contraceptive doses of MPA. These findings suggest that in the context of the genital mucosa, these GR-mediated
glucocorticoid-like effects of MPA in cervical epithelial cells are likely to play a critical role in discriminating between the
effects on inflammation caused by different progestins and P4 and hence susceptibility to genital infections, given the
predominant expression of the GR in primary endocervical epithelial cells.
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Introduction
A central issue in women’s health in developing countries is
choice of contraceptive with minimal effects on susceptibility to
infectious diseases, in particular to human immunodeficiency virus
(HIV)-1 acquisition via the female reproductive tract (FRT).
Epithelial cells lining the FRT are the first line of defence against
pathogens and serve not only as a physical barrier but also express
a wide variety of immune mediators aiding in both innate and
adaptive immunity [1–3]. Interleukin (IL)-6, IL-8 and regulated-
upon-activation-normal-T-cell-expressed-and-secreted (RANTES)
are expressed in both primary and immortalised vaginal and
cervical epithelial cells [4–6]. In particular, the simple columnar
epithelial cells of the endocervix constitutively express IL-6, IL-8,
and RANTES genes [5], with the endocervical cells being more
active in cytokine secretion than the ectocervical cells [7,8].
Pathogens such as herpes simplex virus (HSV), human papillo-
mavirus (HPV), and HIV have been shown to infect epithelial cells
of the FRT and the process is affected by treatment with hormones
such as progesterone (P4) [9,10].
Several reports suggest that endogenous steroid hormone levels
and synthetic progestins used in contraception, influence suscep-
tibility and disease predisposition to many genital tract infections
(reviewed in [2,11]). Treatment of animals and humans with P4 or
synthetic progestins has been reported to increase susceptibility to
viral and bacterial infections [12–16]. Consistent with these
findings, the progestin medroxyprogesterone acetate (MPA) is used
as an immuno-compromising agent to induce viral infectivity in
mice [17]. Furthermore, a prospective cohort study reported that
injectable contraceptive users are more susceptible to both
chlamydia and gonococcal infections than oral contraceptive users
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e96497
[15]. MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg three-monthly intramus-
cular injection used by millions of women worldwide, particularly
in Sub-Saharan Africa with high HIV-1 incidence and prevalence
[18,19]. Norethisterone enanthate (NET-EN) is a 200 mg two-
monthly injectable with less widespread use than MPA, although
its usage is high in some regions of South Africa [20]. In most
studies the adjusted hazard ratio for HIV-1 acquisition by DMPA,
or injectable contraceptives users where the majority of women are
on MPA, is higher than that associated with no contraception or
oral contraception [18,21–30]. While only a few studies have
investigated the risks associated with the use of injectable NET-EN
on HIV-1 acquisition, none have shown a significant association
with HIV-1 acquisition [18,27,30]. In addition, increases in both
HIV-1 and HSV shedding have been reported with MPA [31,32],
as well as the presence of more viral variants and higher viral loads
in DMPA users infected with HIV than non-users [33]. The
mechanisms whereby endogenous P4 and synthetic progestins
affect pathogen entry and transmission in the FRT are not well
understood, but may involve modulation of the immune response
both at the systemic level and at the genital mucosa. Understand-
ing the relative effects of MPA vs NET on genital mucosal immune
function is extremely important for choice of contraception,
especially for developing countries where injectable contraception
usage is high. For example, at the Kwazulu-Natal site in South
Africa for the CAPRISA microbicide trial, about 80% of the
women investigated were on injectable progestin-only (DMPA or
NET-EN), as compared to 15% on oral contraceptives [34]. HIV
prevalence among young women in the general population in
southern Africa is highest (about 25%) in the 20–24 age group and
the ratio of the prevalence of HIV infection among women relative
to men shows that these women are approximately 3.3 times more
likely to be infected with HIV than young men in this region [35].
Clinical research on the effects of contraceptives on HIV-1
acquisition, transmission and disease progression has been
hampered by a lack of understanding of the molecular mecha-
nisms of action of the progestin components of contraceptives and
a lack of appreciation of the differences between progestins, which
cannot be considered to act as a single class of compounds
regarding their side-effect profiles [36–38]. Although MPA and
NET elicit similar progestational effects to P4 [39,40], differences
in biological effects mediated via steroid receptors other than the
progesterone receptor (PR) could be expected [36–38], and have
been demonstrated for the GR [41]. Synthetic progestins were
designed to mimic the actions of the natural ligand P4 but with
better bioavailability [38]. Both NET-EN and NET-A are
metabolised to the active molecule NET, as well as other
metabolites, unlike MPA, which is itself the active compound
[42]. Progestins were also designed to be potent, high affinity PR
agonists. However, many progestins bind to other members of the
steroid receptor family, including the GR, the androgen receptor
(AR) and mineralocorticoid receptor (MR) [43], thereby exhibiting
off-target effects via these receptors [37,38]. It has been shown that
MPA has a higher relative binding affinity compared to NET-A
and P4 for the human GR (relative binding affinity % of 79.1, 0.88
and 5.57 for MPA, NET-A and P4, respectively) [41] and unlike
NET-A and P4, acts as a potent partial to full GR agonist for both
transactivation and transrepression [41,44]. The GR, a ligand
activated steroid receptor, has potent anti-inflammatory and
immunosuppressive activity [45]. Consistent with this idea, we
have previously shown that MPA, at doses in the range found in
serum of contraceptive users, represses expression of mRNA and
protein levels of the pro-inflammatory cytokine IL-6 and the
chemokine IL-8, in mouse fibroblast cells, most likely via the GR
[46]. Similarly, Bamberger et al. showed that MPA represses IL-2,
IL-1, and IL-6 protein expression in normal human lymphocytes,
most likely via the GR [47]. Thus it is possible that MPA used as
contraceptive modulates immune function and inflammation, and
hence responses to pathogens, by changes in cytokine gene
expression, particularly in the genital mucosa. A key question that
remains to be investigated is what the effect is of different synthetic
progestins as compared to P4 on cytokine gene expression and
immune function in the FRT. These are likely to vary since we
have previously shown that MPA, compared to NET-A and P4,
elicit very different effects on IL-8 promoter expression in
HEK293 cells, mediated via the GR [41], as well as exhibit
differential effects in several steps of the GR pathway [44]. In
support of an immunosuppressive role of MPA in increasing HIV-
1 pathogenesis, MPA was recently shown to have immunosup-
pressive effects on key regulators of cellular and humoral immunity
and increased HIV-1 replication in activated peripheral blood
mononuclear cells (PBMCs) ex vivo [48,49]. The Hel laboratory
also showed that women using DMPA displayed lower levels of
IFNa in plasma and genital secretions compared to controls with
no hormonal contraception, consistent with an immunosuppres-
sive effect of DMPA in vivo [48,49]. A possible mechanism for
differential effects of progestins and P4 on HIV-1 acquisition may
include differential effects on inflammation in the FRT. However
the direct effects of MPA, as compared to NET and P4, on
expression of inflammatory markers in endocervical cells, the
prime site for HIV-1 acquisition, have not been previously
investigated. Using a human immortalised endocervical (End1/
E6E7) epithelial cell line [50] as a model for the mucosal surface of
the endocervix, as well as the HeLa cervical cell line, the present
study aimed to determine the relative effects, molecular mecha-
nisms and steroid receptor involvement of MPA, P4 and NET-A
in expression of key inflammatory response genes.
Materials and Methods
Antibodies and Compounds
The following primary antibodies were obtained from Santa
Cruz Biotechnology Inc., USA; GR(H-300): sc-8992, PR(C-20)
(which detects PRA and B isoforms): sc-539, AR(441): sc-7305,
GAPDH(0411): sc-47724, MR(MCR, H300): sc-11412, ERa(MC-
20): sc-542. The flotillin-1 (610820) antibody was purchased from
BD Transduction Laboratories (USA). The following secondary
antibodies were obtained from Santa Cruz Biotechnology Inc.,
USA; anti-mouse: sc-2005, anti-goat: sc-2350 (used as IgG for the
ChIP assay) and anti-rabbit: sc-2313. The ligands dexamethasone
(DEX), MPA, P4, NET-A, NET, aldosterone (ALD) and
mibolerone (MIB) were obtained from Sigma-Aldrich (South
Africa). Human tumour necrosis factor a (TNFa) was obtained
from Celtic Diagnostics (South Africa). Protease inhibitor cocktail
tablets (EDTA-free) (cat #04693159001) were obtained from
Roche (South Africa). Cycloheximide (CHX) was purchased from
Sigma-Aldrich (South Africa).
Cell Culture
Human epithelial cervical cancer cells (HeLa) purchased from
America Type Culture Collection (ATCC, USA) were cultured in
75 cm2 flasks (Greiner Bio-one International, Austria) in Dulbec-
co’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, South
Africa) supplemented with 10% (v/v) foetal bovine serum (High-
veld Biological, South Africa) 100 IU/mL penicillin and 100 mg/
mL streptomycin (Gibco, Invitrogen, UK). End1/E6E7 (human
endocervical cells immortalized with human papillomavirus E6/
E7 [54] were obtained from Dr Fichorova, OB/GYN Depart-
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ment, Brigham & Women’s Hospital, Boston, USA. The End1/
E6E7 cells were cultured in 75 cm2 flasks (Greiner Bio-one
International, Austria) in keratinocyte serum-free medium (ker-
sfm; Sigma-Aldrich, South Africa) supplemented with keratinocyte
growth supplement, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Gibco, Invitrogen, UK). All cells were maintained at 37uC
in a 5% CO2 incubator. Cells were passaged with 0.25% trypsin/
0.1% EDTA in PBS (Highveld Biological, South Africa).
Trypsinization was terminated with neutralization medium
[DMEM (Sigma-Aldrich, South Africa), 10% (v/v) calf serum
(Highveld Biological, South Africa), 100 U/ml penicillin and
100 mg/ml streptomycin (Gibco, Invitrogen, UK)]. The cell lines
were regularly tested for mycoplasma infection by means of
Hoechst staining [55], and only mycoplasma-negative cells were
used in experiments.
Plasmids
pcDNA3 (empty vector) plasmid was obtained from Invitrogen,
while the pcDNA3-hGR (GR) plasmid was a gift from Prof. D.W.
Ray (Centre for Molecular Medicine, School of Clinical and
Laboratory Sciences, University of Manchester, UK [56]. pMT-
PR-B (PR) was obtained from Prof. S. Okret (Karolinska Institute,
Sweden) [51]. pRS-hMR (MR) expression plasmid was obtained
from Prof. R.M. Evans (University of California, USA) [52]. pSV-
hAR (AR) was a kind gift from Prof.F. Classens (Catholic
University of Leuven, Belgium) [53]. pSG5-hER (ER) was
obtained from Prof.F. Gannon (EMBL, Germany) [54].
RNA Isolation and Quantitative Real Time PCR (qRT-PCR)
Total RNA was isolated from cells using Tri-reagent (Sigma-
Aldrich, South Africa) according to the manufacturer’s instruc-
tions, and RNA (500 ng) was reverse transcribed using the
Transcriptor First Strand cDNA synthesis kit (Roche Applied
Science, South Africa) according to the manufacturer’s instruc-
tions. RT-PCR was performed using the Rotor-gene, RG-3000A
(Corbett Research, South Africa) according to the manufacturer’s
instructions using the Sensi-Mix SYBR Green I system (Celtic
Diagnostics, South Africa). The specific primer sets used were as
follows; for GILZ (cat #QT00091035, Qiagen, South Africa), for
IkBa, 59-ACTCGTTCCTGCACTTGGCC-39 (forward primer)
and 59-TGCTCACAGGCAAGGTGTAG-39 (reverse primer), for
IL-6, 59-TCTCCACAAGCGCCTTCG-39 (forward primer) and
59-CTCAGGGCTGAGATGCCG-39 (reverse primer), for IL-8,
59-TGCCAAGGAGTGCTAAAG-39 (forward primer) and 59-
CTCCACAACCCTCTGCAC-39 (reverse primer), for RANTES
59-TACCATGAAGGTCTCCGC-39 (forward primer) and 59-
GACAAAGACGACTGCTGG-39 (reverse primer), for GAPDH
59-TGAACGGGAAGCTCACTGG-39 (forward primer) and 59-
CCACCACCCTGTTGCTGTA-39 (reverse primer). Relative
transcript levels were calculated with the method described by
Pfafflet al 2001 and were normalized to relative GAPDH transcript
levels [55].
Western Blotting
For the steroid receptor controls, COS-1 cells were seeded into
12-well plates (Greiner bio-one, Cellstar, Austria) at a density of
256104 cells/well. The next day the cells were transfected with
1 mg/well of empty vector, GR, AR or PR and 2 mg/well of MR
or ER using FuGENE 6 (Roche Diagnostics, South Africa). After
24 hrs, the cells were washed once with PBS and lysed with 50 ml
2X SDS sample buffer (5 X SDS sample buffer: 100 mM TRIS-
HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% b-
mercaptoethanol and 0.1% (w/v) bromophenol-blue) and boiled
for 10 min at 100uC. In addition, lysates were prepared from
End1/E6E7 and HeLa cells seeded into 12-well plates at a density
of 356104 cells/well and 156104 cells/well, respectively. Equiv-
alent amounts of protein were loaded on either a 6% or 8% SDS-
PAGE before being transferred onto a Hybond-ECL nitrocellulose
membrane (Amersham, South Africa) using the Mini Protean III
blotting system (Bio-Rad, South Africa). Blots were probed for
anti-GR (1:4000), anti-PR (1:1000), anti-AR (1:1000), anti-ER
(1:500), anti-MR (1:1000), anti-GAPDH (1:20 000) at 4uC
overnight. Blots were washed 3 times with TBS containing 0.1%
Tween for 5 mins each and subsequently incubated with
horseradish peroxidise (HRP)-conjugated goat anti-rabbit
(1:10000) or goat anti-mouse (1:5000) secondary at room
temperature for 1 hr. Protein detection was performed using
ECL substrate (Thermo Scientific, South Africa) with visualization
on X-ray hyperfilm (Amersham, South Africa). Bands on the X-
ray film were quantified using AlphaEaseFC software version 3.1.2
(Alpha Innotech Corporation).
GR Knockdown by Small Interference RNA (siRNA)
GR knockdown was performed as previously described [56], but
briefly End1/E6E7 cells were seeded in 12-well plates at a density
of 356104 cells/well and incubated for 24 hrs. Thereafter, the
cells were transfected with 10 nM validated GR HS_NR3C1_5
(cat #SI02654757) (Qiagen, South Africa) siRNA directed against
the human GR or validated non-silencing scrambled sequence
control (NSC) siRNA (cat#1027310) (Qiagen, South Africa) using
HiPerfect transfection reagent (Qiagen, South Africa) as per the
manufacturer’s instructions. Cells were incubated for 48 hrs before
being treated for 24 hrs with 100 nM test compounds. RNA was
then harvested and mRNA levels were analysed by qRT-PCR, as
described above. To verify the protein knockdown, cells were
transfected in parallel and analysed by Western blotting as
described above.
Luminex
Supernatants were collected from the siRNA experiments prior
to cell harvest. Thereafter, cytokine protein levels were measured
using a luminex assay kit according to the manufacturer’s protocol
(Bio-rad, South Africa).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP was performed as described in Verhoog et al 2011 with
modifications [56]. HeLa cells were plated at 36106 cells per dish
in 15 cm dishes and grown for 24 hrs in full DMEM, before
changing to phenol red-free DMEM (Sigma-Aldrich, South
Africa) for an additional 24 hrs. Thereafter, the cells were
incubated with serum-free, phenol-free DMEM for 2 hrs, before
treatment with 100 nM DEX, MPA, P4 and NET-A for 1 hr.
Cells were crosslinked for 10 min at 37uC with1% formaldehyde
and the reaction was stopped with 0.1 mM glycine for 5 min,
shaking at room temperature. Cells were scraped in PBS, pelleted
by centrifugation and resuspended in 500 ml nuclear lysis buffer
(1% SDS, 50 mMTRIS-HCL, pH 8.0, 10 mM EDTA, 1x
protease inhibitor cocktail), before sonication. For immunopre-
cipitation, 100 mg DNA was pre-cleared with protein A/G agarose
beads (sc-2003, Santa Cruz Biotechnology, USA) for 1 hr, rotating
at 4uC, before incubating with 2 mg anti-GR (H300) (Santa Cruz
Biotechnology, USA) or 2 mg anti-goat (Santa Cruz Biotechnol-
ogy, USA), as IgG control, overnight on a rotator at 4uC. The
following day, the complex was precipitated with protein A/G
agarose beads for 6 hrs at 4uC, before being washed sequentially
with 1 ml each of wash buffer I, II and III [57], followed by three
washes with 1 ml TE buffer [10 mMTris pH 8, 0.1 mM EDTA].
Proteins were eluted from the beads by addition of 300 ml elution
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buffer (1% SDS, 100 nM NaHCO3), before the addition of
300 nM NaCl and incubation at 65uC overnight to reverse
crosslinks. The following day 15 nM EDTA, 125 nM TRIS-HCL
pH 6.5 and 20 mg proteinase K (Roche, South Africa) were added
and samples were then incubated at 45uC for 1 hr. DNA was
purified using PCR cleanup columns (Qiagen, South Africa). Real
time qRT-PCR was performed on a Corbett Rotorgene, using the
Sensimix (Quantace, South Africa), which measures SYBR Green
fluorescence. ChIP primers used: for IL-6 59-TCTACAA-
CAGCCGCTCACAG-39 (forward primer) and 59- AGCGTTC-
CAGTTAATTTGTATTTGT-39 (reverse primer), for IL-8 59-
GGGCCATCAGTTGCAAAT-39 (forward primer) and 59-
TTCCTTCCGGTG GTTTCTTC-39 (reverse primer).
Primary Cervical Epithelial Cells
Primary cervical epithelial cells (VEN-100) were bought from
Mat Tek Corporation (USA). Delivery time was 5 days. Upon
arrival, the cells were incubated overnight in VEN-100-MM
medium (Mat Tek Corporation, USA) at 37uC in a 5% CO2
incubator. The following day cell viability was determined using
the Thiazolyl Blue Tetrazolium Bromide (MTT) cell determina-
tion kit (cat #CGD1, Sigma-Aldrich, South Africa) according to
the manufacturer’s instructions [58]. At this time, some cells were
washed with PBS and either lysed with a N-[Tris(hydroxymethyl)-
methyl]-3-aminopropanesulfonic acid (TAPS) buffer (0.1 M
TAPS, pH 9.5) on ice (to perform Western blotting as above) or
with TRIzolH (for RNA isolation, cDNA synthesis and qRT-PCR
as described above). Having established the viability of the cells,
the majority of the VEN-100s were incubated in VEN-100-ASY-
HCF hydrocortisone free assay medium (Mat Tek Corporation,
USA) and 100 nM test compound for 48 hours, before performing
an additional MTT assay.
Results
MPA, but not NET-A, Acts like a Full to Partial GR Agonist
for Upregulation of anti-Inflammatory and
Downregulation of Pro-inflammatory mRNAs
We investigated the effects of the synthetic progestins on the
expression of GR regulated inflammatory genes in the End1/
E6E7 endocervical epithelial cell line as well as the HeLa cervical
epithelial cell line. These cell lines were chosen as the model
systems for this study due to the ability to perform mechanistic
studies using current methodology. Furthermore, the End1/E6E7
cell line displays similar morphological and immunocytochemical
properties to those of primary endocervical epithelial cells [50].
The genes investigated were chosen based on their established
mechanism of regulation via the GR, and their constitutive
expression in endocervical epithelial cells [7]. GILZ and IkBa are
anti-inflammatory genes that are upregulated by glucocorticoids
(GCs) such as DEX, while IL-6, IL-8 and RANTES are pro-
inflammatory genes that are downregulated by DEX [59,60]. The
GILZ and IkBa genes contain multiple glucocorticoid response
elements (GREs) and are commonly referred to as GR
transactivation genes [61,62]. The IL-6 and IL-8 gene promoters
have binding sites for transcription factors that include activator
protein-1 (AP-1) and nuclear factor kB (NFkB) [63], and these
genes are transrepressed by the liganded GR via tethering
mechanisms [64]. Cells were treated with P4, MPA and NET-A,
as well as the GR agonist DEX for 24 hrs. Thereafter, cytokine
gene mRNA was measured by real time qRT-PCR. As expected
the GR synthetic agonist DEX upregulated both GILZ and IkBa
mRNA in both the cell lines (Figure 1). In addition, MPA
upregulated GILZ and IkBa mRNA in both End1/E6E7 and
HeLa cell lines (Figure 1). P4 and NET-A have no effect on the
expression of GILZ or IkBa mRNA in either of the cell lines
(Figure 1). Figure 2 A and B show that DEX and MPA, unlike
NET-A and P4, repress both IL-6 and IL-8 mRNA levels,
respectively, in the End1/E6E7 cell line. Interestingly, RANTES
mRNA levels are repressed by DEX, MPA and P4 (Figure 2 C).
The regulation of IL-6 mRNA levels by the ligands in the HeLa
cells (Figure 2 D) is similar to the End1/E6E7 cells (Figure 2 A),
where both DEX and MPA repress IL-6 mRNA levels.
Furthermore, it appears that NET-A upregulates IL-6 mRNA
levels in the HeLa cells (Figure 2 D). Similar to the End1/E6E7
cell line, DEX appears to repress IL-8 mRNA levels in the HeLa
cells (Figure 2 E). However, unlike the End1/E6E7 cell line, at the
24 hr time point MPA does not appear to effect IL-8 mRNA
expression in the HeLa cells (Figure 2 E). Interestingly though, at a
4 hr time point both DEX and MPA repress IL-8 gene expression
in the HeLa cell line (Figure 2 H). It appears that NET-A and P4
upregulate IL8 mRNA levels in the HeLa cells (Figure 2 E). In
contrast to the End1/E6E7 cells, the DEX, MPA and P4
repression of RANTES mRNA levels does not occur in the HeLa
cells (Figure 2 F), although this could be due to low basal levels of
RANTES in HeLa cells (as indicated by real time qRT-PCR Ct
values, data not shown). Interestingly, it appears that NET-A
upregulates RANTES mRNA levels (Figure 2 F). Taken together,
these results show that MPA acts like the GR agonist DEX in
upregulating GILZ and IkBa anti-inflammatory gene and
generally downregulating IL-6, IL-8 and RANTES pro-inflam-
matory gene mRNA levels, unlike P4 and NET-A, with some
exceptions. The results also suggest cell-specific, gene-specific and
temporal differences in the regulation of some of the genes in
response to the ligands, such as undetectable repression of IL-8
and RANTES mRNA by MPA in HeLa cells at 24 hrs, but similar
repression of IL-8 in HeLa cells at 4 hrs compared to IL-8 in
End1/E6E7 cells at 24 hrs. In addition, some experiments show
repression by P4 of RANTES in the End1/E6E7 cells at 24 hrs,
unlike in HeLa cells. Furthermore, it appears that regulation of
mRNA levels by the ligands may be time dependent (Figure2).
The experiments in Figure 1 and 2 were performed in the absence
of induction of the cytokine/chemokine genes with a pro-
inflammatory ligand, since these genes are constitutively expressed
in cervical epithelial cells. Experiments performed in the presence
of TNFa, to mimic infection, showed a similar % repression of the
pro-inflammatory genes with DEX and MPA, unlike P4 and NET
(Figure S1). All further experiments were performed in the absence
of TNFa.
MPA Regulation of Inflammatory Gene mRNA Levels is
dose- and Time-dependent
Having shown that MPA acts like a GR agonist in regulating
mRNA levels of inflammatory genes, it was next determined if this
regulation is dose- and/or time-dependent. End1/E6E7 cells were
treated with increasing concentrations of the ligands for 4 hr and
24 hrs, respectively, followed by qRT-PCR analysis. Figure 3 A
and B show that both DEX and MPA increase GILZ mRNA
levels in a dose-dependent manner, whileP4 and NET-A appear to
have no effect on GILZ gene expression at any of the
concentrations or time points. It also appears that the maximal
response for MPA and DEX regulation of GILZ mRNA levels
does not change between 4 and 24 hours. DEX and MPA, unlike
P4 and NET-A, repress IL-6 mRNA levels in a dose-dependent
mannerat both 4 hrs and 24 hrs (Figure 3 C and D). However,
MPA appears to show a greater maximal repression of IL-6
mRNA levels at 24 hrs than at 4 hrs, acting like a partial agonist at
4 hrs, but a full agonist at 24 hrs. Interestingly, it appears that
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1 mM NET-A may upregulate IL-6 mRNA at 24 hrs. Figure 3 E
and F show that IL-8 mRNA levels are also dose-dependently
repressed by DEX and MPA at both 4 hrs and 24 hrs, with the
MPA dose-dependent repression of IL-8 being more robust at
24 hrs. In addition, P4 and NET-A appear to be upregulating IL-8
at 4 hrs only. No repression of RANTES mRNA is apparent at
4 hrs (Figure 3 G). However, at 24 hrs RANTES mRNA levels are
repressed by DEX and MPA in a dose-dependent manner, while
NET-A and P4 appear to show some partial agonist activity (10–
20%) for repression at high concentrations (Figure 3 H). MPA
appears to have a potency (EC50) of,24 nM for transactivation of
GILZ and a potency of ,21, 4 and 5 nM for repression of IL-6,
IL-8 and RANTES mRNA, respectively at 24 hrs.
The GR is the Predominant Steroid Receptor Protein
Detected in Cervical Cell Lines and Primary Cervical
Epithelial Cells
Given the differential steroid receptor selectivity of MPA, NET
and P4, we next investigated whether the GR, AR, PR, MR or
ERa are expressed in these cell lines, with a view to determination
of steroid receptor involvement in the differential gene expression
responses. Cell lysates were prepared and the steroid receptor
mRNA and protein levels were detected by qRT- PCR and
Western blotting, respectively. The Western blot and PCR screen
show that the End1/E6E7 cells express only endogenous GR
mRNA and protein, respectively (Figure 4 A and B). According to
the PCR screen (Figure 4 A), HeLa cells express endogenous GR,
AR and MR mRNA. However the Western blot (Figure 4 B)
Figure 1. MPA, but not NET-A or P4, acts like a partial GR agonist for upregulation of anti-inflammatory mRNAs. (A and B) End1/E6E7
cells were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (C and D) HeLa cells were treated for 24 hrs with 100 nM
DEX, 1 mM MPA, 10 mM P4, 10 mM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested; total RNA was isolated and reverse-
transcribed. Relative GILZ and IkBa gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition,
relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled results of at least
three independent experiments and are plotted as mean6SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a
one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g001
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reveals that in HeLa cells only endogenous GR protein is
detectable. Although it appears that the HeLa and End1/E6E7
cells express MR protein (Figure 4 B), this is a non-specific band
that also appears in the negative control. Since the End1/E6E7
cells do not express detectable MR mRNA it is highly unlikely that
the cells express MR protein. However, it is possible that the HeLa
cells do express low levels of the AR and MR that are beyond the
detection level of the Western blots. It was therefore determined if
the repression of cytokine genes in this cell line could be mediated
via the AR and MR. HeLa cells were treated with the GR, AR
and MR specific agonists (DEX, mibolerone and aldosterone,
respectively) and cytokine gene expression was measured by qRT-
PCR. IL-6 and IL-8 gene expression was measured since it was
established above that RANTES is not regulated by the ligands of
interest in the HeLa cells. Figure 4 C shows that only DEX
represses IL-6 gene expression, while it appears that aldosterone,
and possibly and mibolerone, upregulate IL-6 mRNA expression.
In addition, it appears that DEX represses IL-8, while aldosterone,
and possibly mibolerone, upregulate IL-8 gene expression (Figure 4
D). These results indicate that DEX- and MPA-mediated
repression of the cytokine genes in HeLa cells is likely to occur
via the GR. Additionally, since only GR mRNA and protein were
Figure 2. MPA, but not NET-A, acts like a full/partial GR agonist for repression of pro-inflammatory mRNAs. (A–C) End1/E6E7 cells
were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (D–H) HeLa cells were treated for 24 hrs (D–F) or 4 hrs (G–H)
with 100 nM DEX, 1 mM MPA, 10 mM P4, 10 mM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested, total RNA was isolated and
reverse-transcribed. Relative IL-6, IL-8 and RANTES gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression.
In addition, relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled
results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software
(version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001,
respectively.
doi:10.1371/journal.pone.0096497.g002
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detected in the End1/E6E7 cells, these results indicate that in both
the cell lines, the DEX and MPA regulation of expression of the
inflammatory genes is most likely mediated via the GR.
Whether the steroid receptor expression profile in the cervical
epithelial cell lines mimics that of primary cervical epithelial cells is
unknown. We investigated the steroid receptor content in
commercially available primary endocervical cells (VEN-100;
bio-engineered multilayer of primary cells) by PCR and Western
blot. While we could detect GR, MR, AR and ERa mRNA
(Figure5 A), the only steroid receptor protein we detected in the
primary cells was the GR (Figure 5 B). No PR mRNA or protein
was detected in the cell lines or primary cells, despite positive
controls showing that PR expression can be detected by these
methods. Thus despite the finding that some MR, AR or ERa
mRNA was detected in some of the cells lines or primary cells, the
only steroid receptor protein detected in any of the models was the
GR, suggesting that the GR is the predominant steroid receptor
mediating responses to MPA in both the cervical epithelial cell
lines and primary endocervical cells.
Regulation of Inflammatory Gene mRNA Levels by DEX
and MPA is Mediated by the GR and is Mimicked at the
Protein Level for IL-6 and IL-8
In order to provide direct proof that the GR is involved in the
regulation of the inflammatory genes in response to the synthetic
progestin MPA, GR knockdown experiments were performed in
the End1/E6E7 cell line. Reduction of GR protein in these cells
was verified by Western blotting (Figure 6 A and 6B). As expected
DEX and MPA upregulated GILZ mRNA, while P4, NET-A and
NET did not (Figure 6 C). Notably, NET was included in this
experiment as a control to exclude the possibility that the acetate
form (NET-A) would regulate the genes differently. However, it is
shown that NET-A acts similarly to NET. Both the DEX- and
MPA-induced upregulation of GILZ mRNA is diminished when
GR is knocked down. Figure 6 D shows that DEX upregulates
IkBa mRNA levels and this induction is repressed when GR is
knocked down. Here the MPA induction of IkBa is not significant,
possibly due to the blunting of the response in the NSC
knockdown conditions, and therefore a loss of induction is not
apparent with the knockdown. Western blotting revealed that,
unlike for the mRNA levels, DEX, MPA and NET-A all
significantly increased total IkBa protein levels (Figure S2).
Protein levels could not be determined for GILZ due to the
unavailability of a suitable antibody. As expected DEX and MPA
repress IL-6 mRNA levels (Figure 7 A), which is lifted when the
GR is knocked down. In addition, DEX-mediated repression is
also evident on IL-6 protein levels (Figure 7 B). Consistent with the
mRNA data, MPA appears to repressIL-6 protein levels and the
repression is lifted in the knockdown. Interestingly P4 also appears
to repress IL-6 protein levels, although significance could not be
established. Similarly, a significant difference is observed for both
DEX and MPA responses upon GR knockdown for IL-8 mRNA
levels (Figure 7 C). Figure 7 D shows that DEX and MPA also
appear to repress IL-8 protein levels, while GR knockdown
appears to lift this repression. RANTES mRNA levels are shown
in Figure 7 E to be repressed by both DEX and MPA, but not by
P4 or NET-A, in a GR-dependent manner. We were unable to
detect secreted RANTES protein, possibly due to its instability in
the medium (data not shown). Gene expression studies could not
be performed with the primary cells since they did not maintain
cell viability for the long periods of time required for the
assessment (Figure S3). Taken together, these results show that
DEX- and MPA-mediated regulation of the inflammatory gene
mRNA levels is mediated via the GR in the endocervical cell line.
This GR dependence is mimicked at the protein level for DEX
and appears to also be mimicked at the protein level for MPA, for
IL-6 and IL-8.
We have previously shown in COS-1 cells that the most potent
GR ligands result in the most rapid GR degradation, with a good
correlation shown between ligand-selective GR half-life and
transactivation and transrepression efficacy [65]. Consistent with
these results, we show that in the End1/E6E7 cells, MPA results in
GR turnover typical for a relatively potent GR partial agonist,
unlike NET-A and P4 (Figure S4).
Inhibition of Protein Synthesis Supports a Mechanism of
Direct Regulation by the GR of the Inflammatory Genes
In order to investigate whether the GR is directly or indirectly
involved in the regulation of these genes, cycloheximide (CHX;
de novo protein synthesis inhibitor) experiments were performed in
the End1/E6E7 cells to determine whether the GR-mediated
regulation of the mRNA levels requires new protein synthesis [66].
Figure 8 A shows that the addition of CHX only partially dampens
the DEX while ablating the MPA induction of GILZ mRNA.
However, the effects of all the ligands on IkBa mRNA levels were
unchanged by CHX (Figure 8 B). These results suggest that
upregulation of GILZ mRNA levels is only partially dependent on
transactivation by the GR and it is also in part dependent on
synthesis of another protein. IkBa mRNA upregulation, however,
appears independent of new protein synthesis, suggesting that the
mechanism predominantly involves direct transactivation by the
GR of the IkBa gene. Figure 8 C shows that DEX, but not MPA-
mediated repression of RANTES is partially lifted by treatment
with CHX, suggesting a mechanism at least partially involving
transrepression of these promoters by the GR. In contrast, both
DEX- and MPA-mediated repression of IL-6 are independent of
new protein synthesis, as they are not affected by CHX treatment
(Figure 8 D). A similar trend is observed for DEX on the IL8
promoter (Figure 8 E), although for this gene the results for MPA
were inconclusive. To confirm that the CHX inhibited de novo
protein synthesis, End1/E6E7 cells were pre-treated with CHX
and then treated with DEX (in the presence of CHX) for 24 hrs,
thereafter cell lysates were prepared and Western blotting was
performed. lkBa protein levels were used as a positive control to
show that the concentration of CHX used was sufficient to prevent
new protein synthesis (Figure 8 F and G). In summary, we
demonstrate that under conditions where CHX is shown to inhibit
new protein synthesis, all the anti-inflammatory and pro-inflam-
Figure 3. MPA-mediated regulation of inflammatory gene mRNA levels is dose- and time-dependent. End1/E6E7 cells were treated with
increasing amounts (1 nM, 10 nM, 100 nM and 1 mM) of DEX, MPA, P4 or NET-A, or vehicle (ethanol) (CTRL) for 4 and 24 hrs, respectively. Thereafter,
the cells were harvested, total RNA was isolated and reverse-transcribed. Relative (A, B) GILZ, (C, D) IL-6, (E, F) IL-8 and (G, H) RANTES gene
expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative GILZ gene expression was
normalized to 1 mM DEX set to 100% in order to obtain % partial agonist activity. Relative IL-6, IL-8 and RANTES expression was normalized to basal
activity (CTRL) set to 100 in order to obtain % repression. For IL-6 and RANTES mRNA, statistically significant repression with MPA relative to control
was found at 10 nM, 100 nM and 1 mM. The 1 mM data point for P4 on IL-8 4 hrs (E) is 231% and is not displayed due to the y-axis scale. Graphs
represent pooled results of at least three independent experiments and are plotted as mean 6 SEM.
doi:10.1371/journal.pone.0096497.g003
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Figure 4. End1/E6E7 and HeLa cells only express detectable GR protein. (A and B) (A) HeLa and End1/E6E7 cells were harvested, total RNA
was isolated and reverse-transcribed. Steroid receptor (SR) gene expression was measured by real time qRT-PCR. SR expression vectors (pcDNA3-hGR,
pMT-PR-B, pSV-hAR, pRS-hMR and pSG5-hER) served as positive controls (+CTRL) for the GR, PR-B, MR and ER, respectively. COS-1 cells transiently
transfected with pcDNA3 (empty vector) served as negative control (2CTRL). (B) Whole cell lysates were prepared from the HeLa and End1/E6E7 cell
lines. Equal volumes of lysate were analysed by Western blotting with antibodies against specific SRs and GAPDH as loading control. (C and D) SR
agonist screen indicates that in the cervical cells the GR, but not the MR or AR repress IL-6 and IL-8 in the presence of receptor-
specific agonist. HeLa cells were treated with 100 nM DEX, 100 nM mibolerone (MIB), 10 nM aldosterone (ALD) or vehicle (ethanol) (CTRL) for 4 hrs.
Total RNA was isolated and reverse-transcribed. Relative (C) IL-6 and (D) IL-8 gene expression was measured by real-time qRT-PCR and normalised to
GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The
primers and antibody used to investigate PR levels are capable of detecting both PR-A and PR-B isoforms, however the positive protein control
shown is specific for PR-B isoform only. Graphs represent pooled results of at least three independent experiments and are plotted as mean 6 SEM.
Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance
is denoted by * to indicate P,0.001.
doi:10.1371/journal.pone.0096497.g004
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matory genes investigated are at least in part regulated by direct
effects of DEX without a requirement for new protein synthesis,
and where this could be established, similar trends are observed for
MPA.
DEX and MPA Result in Recruitment of the GR to the
Promoters of the IL-6 and IL-8 Genes
In order to further investigate the mechanism of transcriptional
regulation of these cytokine genes via the GR, ChIP assays were
performed in HeLa cells. Attempts to perform ChIP assays in the
End1/E6E7 cells were unsuccessful. This may be due to high
background and low sensitivity for ChIP signals in these cells.
Figure 9 A shows that stimulation with DEX, but not MPA results
in the recruitment of the GR to the GILZ promoter. Furthermore,
both DEX and MPA stimulation resulted in significant recruit-
ment of the GR to the IL-6 and IL-8 promoters (Figure 9 B and
C). The inability to observe GR recruitment to the GILZ
promoter with MPA may be because some of the effects of
MPA on GILZ are not direct, as suggested by the CHX
experiments. However, since we have previously shown in A549
cells that the GR is recruited to the GRE region of the GILZ
promoter by both DEX and MPA [67], it is more likely that a
small amount of GR is recruited by MPA, but this is below the
limits of detection of the ChIP assay in these cells. In summary
these results strongly support a model whereby both DEX and
MPA suppress inflammation in the cervical epithelial cells by
activating and thereby recruiting the GR to promoters of these
genes and consequently inducing transcription of the anti-
inflammatory gene GILZ, while repressing transcription of the
pro-inflammatory genes IL-6 and IL-8.
Discussion
We show for the first time that the synthetic progestins MPA
and NET-A, used in contraception and hormone replacement
therapy, exert differential effects on expression of mRNA levels of
key pro-inflammatory and anti-inflammatory genes constitutively
expressed in an endocervical epithelial cell line, as compared to
P4. MPA, unlike NET-A and P4, increases mRNA expression of
the anti-inflammatory genes GILZ and IkBa, in both the cervical
epithelial cells lines. Interestingly, this differential regulation of
IkBa mRNA is not mimicked by IkBa protein levels, suggesting
that GR-mediated increase in IkBa protein levels does not play a
major role in regulation of IL-6, IL-8 and RANTES genes in these
cells, consistent with reports for some cells but not others [68–72].
Figure 5. Only GR protein is detected in primary cervical epithelial cells (VEN-100). (A) Upon arrival the VEN-100 cells were rested
overnight before being washed once with PBS and harvested with TRIzolH. Total RNA was isolated and 500 ng RNA was reverse-transcribed. Steroid
receptor gene expression was measured by qRT-PCR with receptor-specific primers, followed by gel electrophoresis to confirm the PCR products. (B)
VEN-100 cells were rested overnight before harvesting in 2X SDS sample buffer. COS-1 cells were transiently transfected with 1 mg/well pcDNA3
(empty vector) which served as negative control (2CTRL) or with 1 mg/well steroid receptor expression vectors (GR, PR-B, AR, MR and ERa) which
served as positive controls (+CTRL). Twenty fourhrs later, the COS-1 cells were washed once and lysed with 2X SDS sample buffer. Equal volumes of
cell lysate (VEN-100 and COS-1 ctrls) were analysed by Western blotting with antibodies specific for the GR and Flotillin-1 (loading control),
respectively.
doi:10.1371/journal.pone.0096497.g005
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MPA unlike NET-A, decreases expression of the pro-inflamma-
tory IL-6, IL-8 and RANTES genes in the endocervical epithelial
cell line, as well as IL-6 and IL-8 in the HeLa cell line. These
effects are mimicked at the protein levels for IL-6 and IL-8 in the
epithelial cell line. Thus MPA, unlike NET-A and P4, shows an
anti-inflammatory profile in both cell lines, for most genes
investigated. Furthermore, we show for the first time that the
predominant steroid receptor protein detected in the endocervical
epithelial cell line and in primary endocervical epithelial cells is the
GR, with no detectable PR mRNA or protein. Consistent with this
finding, we also demonstrate by a combination of GR knockdown
and ChIPs, that MPA, unlike NET-A, represses pro-inflammatory
cytokine gene expression in cervical epithelial cells via a
mechanism involving recruitment of the GR to cytokine gene
promoters. These results are consistent with a direct effect of the
GR without a requirement for new protein synthesis, as shown by
cycloheximide experiments. Our findings that DEX recruits GR to
the IL-6 and IL-8 promoter regions are consistent with previous
reports [56,73], while we show here for the first time, that
stimulation with MPA recruits GR to the IL-6 and IL-8 promoter
regions, thereby repressing expression of these genes. These results
are consistent with our hypothesis and our previously published
data that MPA, unlike NET-A or P4, acts like a partial to full GR
agonist with a relatively high affinity for the GR on endogenous
genes in other cells and via synthetic reporter genes [36,41,44,74].
The findings of the present study suggest that in the context of the
genital mucosa, these GR-mediated effects of MPA in cervical
epithelial cells are likely to play a critical role in discriminating
Figure 6. MPA- and DEX-mediated upregulation of anti-inflammatory mRNAs is mediated via the GR. End1/E6E7 cells were transfected
with 10 nM GR or NSC siRNA (A–D) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A, NET or vehicle (ethanol) (CTRL). For verification of
GR knockdown a representative blot is shown in (A). (B) Western blots of at least three independent experiments were quantified to determine the
relative GR protein expression and is plotted as mean 6 SEM. Total RNA was isolated and reverse-transcribed. Relative (C) GILZ and (D) IkBa gene
expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized
to basal activity (CTRL) in order to obtain relative fold expression. Graphs in (C) and (D) represent pooled results of at least three independent
experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA
with either a Dunnett post-test, followed by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by * or
*** to indicate P,0.05 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g006
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between the effects on inflammation caused by different progestins
and progesterone and hence susceptibility to genital infections,
given the predominant expression of the GR and lack or PR
protein expression in these cells. The GR knockdown results
furthermore suggest that changes in GR expression levels are likely
to significantly modulate the inflammatory response in the
endocervix, with reduced GR levels even possibly resulting in
some pro-inflammatory effects by both MPA, NET-A and P4.
Our findings that MPA has anti-inflammatory gene expression
effects in the endocervical cells are consistent with previous reports
that show MPA suppresses pro-inflammatory immune markers in
primary mouse uterine and cervical tissue and in primary human
vaginal mucosal mononuclear cells [49,75]. Given the different
steroid receptor selectivities of MPA, NET and P4 [36–38], it is
likely, however, that the steroid receptor profile of different
compartments of the female genital tract will determine the
outcome of inflammatory gene expression effects of these ligands.
In the current paper we show that both primary endocervical cells
and the endocervical cell line express predominantly the GR. In
contrast, we have previously shown that the Ect1/E6E7
Figure 7. MPA- and DEX-mediated repression of pro-inflammatory cytokine gene mRNA is mediated via the GR. End1/E6E7 cells were
transfected with 10 nM GR or NSC siRNA (A–F) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). Total RNA
was isolated and reverse-transcribed. Relative (A) IL-6 (C) IL-8 and (E) RANTES gene expression was measured by real-time qRT-PCR and normalised to
GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The
corresponding cytokine protein levels for (B) IL-6 and (D) IL-8 were determined by Luminex of supernatants collected prior to cell harvest. Graphs
represent pooled results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed by a student’s t-test to compare specific conditions
to each other. Statistical significance is denoted by * or ** to indicate P,0.05 or P,0.001, respectively.
doi:10.1371/journal.pone.0096497.g007
Differential Repression of Inflammation by Progestins







































































Relative Protein Expression 

































Gl ;;<= Gl 






































Relative mRNA Expression 
(RANTES/GAPDH) ... ... 















Relative mRNA Expression 
(GILZ/GAPDH) 




























ectocervical epithelial and Vk2/E6E7 vaginal epithelial cell lines
appear to express a greater variety of steroid receptors, including
the PR, GR, AR and ERa [76]. This is consistent with the report
that the ectocervix is covered by a mucosal layer that is
histologically similar to the vagina but different to the endocervix
[77]. Our previous results show that IL-6, IL-8 and RANTES
mRNA levels are regulated differently in the ectocervical and
vaginal cell lines compared to the endocervical cell line, consistent
with their different steroid receptor profiles. MPA and NET have
no effect on IL-6 mRNA levels in both the ectocervical and vaginal
cell lines, while MPA is pro-inflammatory for IL-8 in the
ectocervical cell line, in contrast to the anti-inflammatory results
we observed for MPA in the endocervical cell line. P4 appears to
be pro-inflammatory at 1 mM concentrations for most of the pro-
inflammatory genes in the ectocervical and vaginal cell lines, an
effect which we also observe for some genes at 1 mM P4 for IL-6,
but not IL-8 or RANTES. Interestingly MPA represses RANTES
in both the ectocervical and endocervical cell lines, with no
significant effect in vaginal cells. However, in the ectocervical cells,
this effect is mediated predominantly via the AR, while in the
endocervical cells, we show that it is mediated via the GR.
Interestingly, we have recently found that MPA, unlike P4 and
NET, shows a very similar pattern and potency of repression of
pro-inflammatory genes in human PBMCs to that observed in the
current study in the endocervical cell line, with a similar
predominantly GR steroid receptor profile [78]. Collectively, our
results support the hypothesis that MPA, when acting predomi-
nantly via the GR, is likely to exert anti-inflammatory effects on
gene expression via classical transrepression mechanisms, unlike
NET and P4, but when the steroid receptor profile is changed, the
responses are likely to vary. Furthermore the results collectively
suggest that different compartments of the genital tract are likely to
exhibit different inflammatory responses to MPA vs NET vs P4,
with their associated different effects on susceptibility to genital
infections. Our lack of detection of PR expression in the
endocervical primary cells or cell lines raises the question as to
what is the role of the PR in mediating responses to progestins and
progesterone in the endocervix. It is possible that other cells
besides epithelial cells in the cervix express functional PR, as is
suggested from one report [79], while others report the expression
of both the GR and ERa [80].
Whether the observed effects of MPA, NET and P4 are relevant
to the physiological doses of these ligands in vivo is a critical
question, which we investigated here by dose response analysis
[81] to determine potencies (EC50s) and efficacies (maximal
response). The MPA serum concentrations of DMPA-users are
reported to be in the range 2.5 to 65 nM a few days after injection
and to plateau at about 2.6 nM for about three months thereafter
[38,48,82], while serum concentrations for injectable NET-EN, in
the range of 1.5–59 nM have been reported [83]. The concen-
tration of endogenous P4 in serum of premenopausal women is
low during the follicular phase (0.65 nM) but rises to about 80 nM
during the luteal phase, and to about 600 nM during pregnancy
[37]. We show that MPA at 10 nM significantly represses both IL-
6 and RANTES at 24 hrs (Figure 3 C and H). Furthermore our
dose response analysis show that MPA has a potency of ,24 nM
for transactivation of the anti-inflammatory GILZ gene and a
potency of ,4–20 nM for repression of the pro-inflammatory IL-
6, IL-8 and RANTES genes. This suggests that these immuno-
suppressive effects are likely to be relevant at physiological doses of
MPA used in injectable contraception, particularly shortly after
injection, while any possible effects of NET-EN injectable
Figure 8. The GR at least in part directly regulates mRNA levels of the inflammatory genes. End1/E6E7 cells were pretreated with 1 mg/ml
cycloheximide (CHX) then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL), in the absence or presence of CHX. Total
RNA was isolated and reverse-transcribed. Relative (A) GILZ (B) IkBa, (C) RANTES, (D) IL-6 and (E) IL-8 gene expressions was measured by real-time
qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to
obtain relative fold expression. Graphs represent pooled results of at least three independent experiments and are plotted as mean 6 SEM. To verify
that the CHX inhibited de novo protein synthesis, End1/E6E7 cells were pretreated with CHX then treated with 100 nM DEX or vehicle (ethanol) (CTRL)
for 24 hrs. (F) Cells were harvested and equal volumes of lysate were analysed by Western blotting with an antibody specific for IkBa and a GAPDH
specific antibody as loading control. (G) Western blots of four independent experiments were quantified to determine the relative GR protein
expression. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed
by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,
0.0001, respectively.
doi:10.1371/journal.pone.0096497.g008
Figure 9. DEX and MPA recruit GR to the IL-6 and IL-8 cytokine gene promoters. HeLa cells were serum starved for 2 hrs and then treated
for 1 hr with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). ChIP was carried out using an anti-GR antibody to immunoprecipitate
endogenous GR and an anti-IgG antibody as a negative control. Real-time qRT-PCR was performed on input and immunoprecipitated DNA with
primers specific for endogenous (A) GILZ, (B) IL-6 and (C) IL-8 promoters. GR recruitment was measured relative to input. Graphs represent pooled
results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software
(version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by * or *** to indicate P,0.05 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g009
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contraceptive on inflammation via the GR are likely to be
negligible, even shortly after injection. Since P4 at concentrations
up to 100 nM shows very little effect on expression of the genes
investigated, P4 at doses other than during pregnancy, are unlikely
to exert major effects on inflammation or immune function in
endocervical epithelial cells. However, about 20% repression of
IL-6 is observed by P4 at 4 hrs at 10–100 nM, suggesting that in
the presence of a predominant GR, P4 could exert some anti-
inflammatory effects. At pregnancy concentrations, P4 may exert
some pro-inflammatory effects on some genes, as suggested by our
dose response analysis showing this trend for some genes at 1 mM.
It should, however, be noted that the concentrations of MPA,
NET and P4 in cervical tissue may not be the same as that found
in the serum of contraceptive users.
The physiological significance of changes in expression of pro-
inflammatory mediators like IL-6, IL-8 and RANTES in genital
epithelial cells is difficult to predict. Increased pro-inflammatory
mediators could increase recruitment of dendritic cells (DCs) or
Langerhans cells (LCs) as well as CD4+ T cells and monocytes/
macrophages, thus potentially increasing HIV-1 acquisition by
increasing the number of target cells. Thus progestins like MPA,
unlike NET-A, that exert anti-inflammatory gene expression
effects in the female genital tract may decrease HIV-1 acquisition
by decreasing the number of target cells. However, decreased pro-
inflammatory mediators could also inhibit immune function, such
as B-cell maturation, T-cell activation and differentiation, IgA
production, neutrophil/monocyte/macrophage/dendritic cell ac-
tivity, reducing the host’s ability to mount a defence against a
pathogen [84]. Additionally, RANTES is a ligand for the CCR5
receptor, which has the ability to block HIV-1 entry [85]. Thus a
decrease in RANTES expression by endocervical epithelial cells,
as we show for MPA but not NET, with a potency of 5 nM, could
increase HIV-1 infection of CD4+ T cellsin vivo. Interestingly,
MPA shows the greatest efficacy for RANTES mRNA repression,
acting like a full GR agonist. Whether or not DMPA usage
increases or decreases the expression of inflammatory mediators in
the female genital tract in vivo is unclear and requires further
investigation. Several studies suggest that a pro-inflammatory
environment is associated with an increase in HIV-1 acquisition
[86–88]. Furthermore, DMPA-usage was recently reported to be
associated with increased HIV-1 acquisition and increased levels of
RANTES [88]. However, in this study it was not possible to
discriminate between elevated RANTES levels being a cause of
infection or a consequence of exposure to HIV-1 prior to
seroconversion. Additionally, since 76% of the DMPA users in
this study were positive for an STI, it may be that elevated
RANTES was a consequence of STI infection, despite attempts to
correct for that confounding variable. In contrast to the latter
study, the study by Huijbregts et al. found that DMPA-usage is
associated with immunosuppressive effects in the cervical mucosa
[49]. Furthermore, we have recently shown that MPA, unlike
NET or P4, increases apoptosis of T-cells, which is potentiated
after HIV-1 infection [74], potentially decreasing the ability of T-
cells to mount an anti-viral defence. Currently available clinical
data from women on DMPA, taken together with animal data plus
our and other biochemical ex vivo data, certainly suggest that
immunosuppressive properties of long term MPA contraceptive
usage may be a significant factor contributing towards increasing
HIV-1 acquisition, transmission and possibly disease progression.
Importantly, our results show that MPA effects on genital mucosal
immune function and susceptibility to infections are likely to be
very different to those of NET and P4, when mediated via the GR,
and that choice and concentration of progestin in contraception
are likely to be critical factors.
Supporting Information
Figure S1 Only DEX andMPA represses basal as well as
TNF-induced cytokine mRNA expression. End1/E6E7 cells
were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or
vehicle (ethanol) (CTRL), in the absence or presence of 20 ng/ml
TNFa. Thereafter the cells were harvested, total RNA was isolated
and reverse-transcribed. Relative (A) IL-6, (B) IL-8 and (C)
RANTES mRNA expression was measured by real-time qRT-
PCR and normalised to GAPDH mRNA expression. In addition,
relative gene expression was normalized to basal activity (CTRL)
in order to obtain relative fold expression. Graph represents
pooled results of at least three independent experiments and are
plotted as mean 6 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA
with Dunnett post-test, followed by a student’s t-test to compare
specific conditions to each other. Statistical significance is denoted
by * or ** to indicate P,0.05 or P,0.001, respectively.
(TIF)
Figure S2 DEX, MPA and NET-A induce total IkBa
protein. End1/E6E7 cells were treated for 24 hrs with 100 nM
DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). Thereafter,
cells were harvested and equal volumes of lysate were analysed by
(A)Western blotting with an antibody specific for total IkBa and a
GAPDH specific antibody as loading control. (B) Western blots of
five independent experiments were quantified to determine the
relative GR protein expression. Statistical analysis was carried out
using GraphPad Prism software (version 5) using a one-way
ANOVA with a Dunnett post-test followed by a student’s t-test to
compare specific conditions to each other. Statistical significance is
denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001,
respectively.
(TIF)
Figure S3 Cell Viability of VEN-100. VEN-100 cells were
either incubated for 24 hrs (day 1, treatment day) or 72 hrs (day 3,
end of treatment day), followed by, analysis for cell viability (MTT
assay). Absorbance readings were measured at 570 nm. Cell
culture media served as the control (CTRL). CTRL for each day
was set to 1 to obtain relative fold cell viability. The graph
represents results of at least three independent experiments,
plotted mean +/2 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA
with a Dunnett post-test followed by a student’s t-test to compare
specific conditions to each other. Statistical significance is denoted
by ** or *** to indicate P,0.001 or P,0.0001, respectively.
(TIF)
Figure S4 Ligand-selective GR protein turnover. End1/
E6E7 cells were treated with increasing amounts (1 nM, 10 nM,
100 nM and 1 mM) of DEX, MPA, P4 or NET-A, or vehicle
(ethanol) (CTRL) for 24 hrs. Thereafter, the cells were harvested
and equal volumes of lysate were analysed by Western blotting
with antibodies specific for GR and GAPDH as loading control.
(TIF)
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Whether hormonal contraceptives increase HIV-1 acquisition, transmis-
sion and disease progression are critical questions. Clinical research has
been hampered by a lack of understanding that different progestins used
in contraception exhibit differential off-target effects via steroid recep-
tors other than the progesterone receptor. Of particular, relevance is the
relative effects of medroxyprogesterone acetate (MPA) and norethister-
one enanthate (NET-EN), widely used as injectable contraceptives in
sub-Saharan Africa. While most high-quality clinical studies find no
increased risk for HIV-1 acquisition with oral contraception or injectable
NET-EN, most do find an increase with MPA, particularly in young
women. Furthermore, mounting evidence from animal, ex vivo and bio-
chemical studies are consistent with MPA acting to increase HIV-1
acquisition and pathogenesis, via mechanisms involving glucocorticoid-
like effects on gene expression, in particular genes involved in immune
function. We report that MPA, unlike NET and progesterone, represses
inflammatory genes in human PBMCs in a dose-dependent manner, via
the glucocorticoid receptor (GR), at concentrations within the physiolog-
ically relevant range. These and published results collectively suggest
that the differential GR activity of MPA versus NET may be a mecha-
nism whereby MPA, unlike NET or progesterone, differentially modu-
lates HIV-1 acquisition and pathogenesis in target cells where the GR is
the predominant steroid receptor expressed.
Introduction
Whether hormonal contraceptives increase HIV-1
acquisition is a critical and unresolved issue, in par-
ticular for young women in high risk areas, and is
the subject of intense worldwide research and
debate.1,2 Furthermore, whether hormonal contra-
ceptives increase HIV-1 transmission and disease
progression, as well as increase susceptibility to other
infectious diseases and STIs, are also critical health
issues. These issues are also mostly unresolved and
are topics of ongoing research. Clinical research in
these areas has been hampered by a lack of under-
standing of the molecular mechanisms of action of
the progestin components of contraceptives and by a
lack of appreciation of the differences between prog-
estins, which cannot be considered to act as a single
class of compounds regarding their side effect pro-
files.3–5 Although progestins are designed to act like
the natural ligand progesterone (P4) via the proges-
terone receptor (PR), they are likely to exert very
different side-effects due to their differential affinities
and activities via other members of the steroid
receptor family.3–5 Currently a wide range of proges-
tins is used in contraceptives, with several different
delivery methods and varying progestin doses. Until
recently, clinical studies investigating effects of con-
traceptives on HIV-1 have grouped together data
based on methods of delivery (injectable versus
oral), while ignoring both the type of progestin and
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dose used within those groups. More recently,
attempts have been made to investigate effects of
one progestin versus another, but usually the sample
size has been too small to establish significant differ-
ences, above other confounding variables. Neverthe-
less, a picture is emerging from clinical, animal,
ex vivo and biochemical studies that the injectable
contraceptive, medroxyprogesterone acetate (MPA),
is likely to increase HIV-1 acquisition in women and
transmission from women to men.
The injectable contraceptive
medroxyprogesterone acetate (MPA), unlike
norethisterone enanthate (NET-EN), appears to
increase HIV-1 acquisition
MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg 3-monthly
intramuscular injection that is used by millions of
women worldwide, particularly in sub-Saharan
Africa with high HIV-1 prevalence.1,6 Norethisterone
enanthate (NET-EN) is a 200 mg 2-monthly inject-
able that is used less than MPA globally, although
its usage is high in some regions of South Africa.7
Injectable contraceptive usage and HIV-1 prevalence
are particularly high in young women in some areas
of South Africa, such as at the KwaZulu-Natal site
for the CAPRISA microbicide trial. In this trial,
about 82% of the women investigated were on
injectable progestin-only contraceptives, as com-
pared to 15% on oral contraceptives.8 The majority
of high-quality studies, in which the most common
progestin used was levonorgestrel (LNG), showed no
significant increase in HIV-1 acquisition for oral con-
traceptive pills.9 Although only a few studies have
investigated the risks associated with the use of
injectable NET-EN on HIV-1 acquisition, none have
shown a significant association with HIV-1 acquisi-
tion.9 However, the majority of high-quality studies
do show an increased risk associated with only or
predominantly injectable DMPA usage.9–11 Many
clinical observational studies do not investigate risks
associated with subgroups of women, such as those
grouped by age or HSV-2 status, usually due to a
lack of sufficient study size for a particular subgroup.
However, of particular concern is the finding of an
adjusted hazard ratio (HR) for DMPA of 9.29 in
women aged 18–20.12 Although others have not
reported such age-related findings, they may not
have had sufficient young women with high HIV-1
exposure in their studies.13–16 Also of concern is the
finding of an HR of 4.5 for DMPA for HSV-2 nega-
tive women.12 However, establishing indisputable
evidence from such studies is extremely difficult
due to methodological challenges and multiple
confounding factors, such as the degree of exposure
to HIV-1, condom usage, HSV-2 exposure as well as
varying ages of women that have been enrolled in
these studies.9 Furthermore increases in both HIV-1
and HSV shedding have been reported in women
using contraception,17–19 as well as the presence of
more viral variants and higher viral loads in HIV-
1-infected DMPA users than non-users.20 These
findings are consistent with an increase in HIV-1
transmission found for injectable DMPA users.16
DMPA usage has also been associated with increased
acquisition of cervical chlamydial and gonococcal
infections.21 These STIs have also been linked to
increased HIV-1 acquisition. Consistent with the
clinical data, MPA increases susceptibility to vaginal
simian–human immunodeficiency virus (SHIV)
transmission and suppresses the antiviral cellular
immune response in SHIV-infected rhesus maca-
ques.22 No information is available regarding other
progestins and HIV-1 acquisition. Contraceptives
may also affect diseases progression. Most of the
clinical studies to date indicate no effect of hor-
monal contraception on disease progression. How-
ever, this may be due to several study limitations
such as insufficient power to discriminate between
progestin groups or methods of contraception deliv-
ery, analysis of only chronically infected patients,
and confounding variables such as antiretroviral
(ARV) usage and pregnancy. This suggests that
effects of specific progestins like MPA on disease
progression from the time of HIV-1 acquisition, can-
not as yet be excluded.23,24 Collectively, these find-
ings raise questions as to the choice of progestin,
dose and method of administration in determination
of susceptibility to and transmission of pathogens,
such as HIV-1, particularly in young women. Since
the current data from observational studies are not
considered persuasive enough to recommend using
methods of contraception other than DMPA,1,2 more
research is urgently required. The key question is
what information is needed and how feasible it is to
obtain. Some have argued that more large-scale ran-
domized trials are needed,25 but these may not be
ethical or conclusive. Another approach is to investi-
gate direct biological effects and mechanisms ex vivo
of different progestins at specific doses for different
target cells relevant to HIV-1 pathogenesis.
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The mechanism of action is likely to involve
differential effects on gene expression on immune
function genes by MPA versus NET, mediated via
the glucocorticoid receptor
Effects of progestins on HIV-1 acquisition and trans-
mission are proposed to occur via multiple mecha-
nisms, including changes in vaginal structure,
endometrial thinning, effects on genital flora, effects
of other sexually transmitted infections, as well as
changes in immune function.26 At the cellular level,
progestins and sex steroid hormones mediate their
effects via alterations in transcription of specific
genes via binding to and regulating the activity of
steroid receptors.4 Progestins differ widely in their
steroid receptor selectivity profiles.3–5 MPA, NET and
LNG all exhibit some binding to the androgen recep-
tor with undetectable anti-androgenic activity and
some androgenic activity. MPA and NET exhibit very
little antimineralocorticoid activity at contraceptive
doses,27 unlike some reports for LNG.4,27 However,
MPA binds to the GR with an affinity (Kd of
4–11 nM) similar to that of the endogenous gluco-
corticoid cortisol and acts as a full to partial agonist
for the GR, whereas P4 and NET bind to the GR
with about a 50- to 100-fold lower affinity and are
very weak partial GR agonists with much lower
potency and efficacy.4,5 In contrast, the fourth-
generation progestins are much more selective for
the PR. The GR is a well-established regulator of
immune function via regulation of transcription of a
wide variety of immune function genes. Glucocortic-
oids are potent immunosuppressive agents which
exert multiple complex actions on dendritic cells,
myeloid cells and B- and T-lymphocytes, including
effects on apoptosis and differentiation fate and inhi-
bition of cytokine release and cell migration.28–30
Consequently, glucocorticoids are widely used as
anti-inflammatory and immunosuppressive drugs.
The immunosuppressive actions of glucocorticoids
are largely due to their repression of transcription of
target genes such as cytokine and chemokine genes,
via inhibition of the transcription factors nuclear fac-
tor kappa B (NFjB) and activator protein 1 (AP-1).30
Glucocorticoids, like cortisol, bind to inactive GR in
the cytoplasm. Ligand-bound GR is subsequently
hyperphosphorylated and translocates into the
nucleus where it is able to modulate transcription.
Once in the nucleus, ligand-bound GR binds as a
dimer to glucocorticoid response elements (GREs)
resulting in positive transcriptional regulation, called
transactivation.28–30 Additionally, ligand-bound
monomeric GR is also known to negatively regulate
transcription by interfering either directly or indi-
rectly with other DNA-bound transcription factors,
like NFjB or AP-1.30 This mechanism, known as
transrepression, prevents NFjB- and AP-1-mediated
transcription.28–30 Given that MPA, unlike other
progestins, acts as a relatively potent full to partial
agonist for the GR, MPA is likely to exert much
more potent and efficacious effects on gene promot-
ers involved in immune function than P4 or NET via
the GR, as we have demonstrated in cell lines.31–33
We proposed in 2004 that due to the differential
activity of MPA versus NET via the GR, MPA is
likely to exert different effects on immune function
and hence modulate susceptibility to infections like
HIV-1.3 MPA has been reported to modulate tran-
scription of a number of genes via the GR, including
IL2 in normal human lymphocytes,34 and IL6 and
IL8 in a mouse fibroblast cell line.31 We have also
recently shown that MPA, unlike NET and P4,
exhibits differential regulation of apoptotic genes
and dose-dependently enhances HIV-1-mediated
apoptosis in primary human CD4+ T cells via a
GR-dependent mechanism,35 consistent with the ste-
roid receptor selectivity of these ligands. Further-
more, MPA, to a greater extent than P4, suppresses
ex vivo the production of key regulators of cellular
and humoral immunity involved in orchestrating
the immune response to invading pathogens such as
HIV-1, most likely via the GR.36 It remains to be
determined how different progestins affect expres-
sion of key genes involved in immune function in
primary cells relevant to HIV-1 pathogenesis.
We have addressed this question in peripheral
blood mononuclear cells (PBMCs), representing key
targets for HIV-1 infection and replication. We deter-
mined the effects of varying doses of MPA, NET and
P4, in comparison with dexamethasone (DEX), a
synthetic GR agonist, on expression of four-key
immunomodulatory genes namely, glucocorticoid-
interacting leucine zipper (GILZ), interleukin (IL) 6,
IL8 and regulation on activation normal T cell
expressed and secreted (RANTES). The GILZ gene is
GRE-regulated and encodes an anti-inflammatory
protein that inhibits the activation of pro-inflamma-
tory transcription factors.37 IL6 and IL8 genes, which
are upregulated by NFjB and AP-1, are pro-inflam-
matory cytokines expressed by a number of innate
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and adaptive immune function cells.38 RANTES
(CCL5), also upregulated by NFjB, is a chemokine
that is involved in the recruitment of mononuclear
cells to sites of chronic inflammation39 and interferes
with HIV-1 entry into target cells by competitive
binding to the CCR5 co-receptor.40 A decline in
RANTES protein expression is also associated with
an increase in HIV-1 disease progression.39 Freshly
isolated PBMCs were stimulated with varying con-
centrations of the different ligands for 48 hrs, fol-
lowed by RNA isolation, reverse transcription and
real-time quantitative PCR. The results show that
DEX and MPA, unlike NET and P4, repress IL6 and
IL8 pro-inflammatory gene mRNA levels while
increasing GILZ anti-inflammatory mRNA levels
(Fig. 1), while RANTES mRNA repression was only
detectable with DEX under these conditions (Fig. 1).
Concurrent with mRNA expression analysis, protein
expression analysis by flow cytometry indicated that
the progestins mediated differential regulation on
IL6 and GILZ protein levels (Fig. 1 E and F). MPA
and DEX significantly repressed IL6 protein expres-
sion after 48 hrs, while P4, NET-A, NET and LNG
did not affect basal expression in CD14+ monocytes
(Fig. 1e). DEX significantly increased GILZ protein
expression levels in CD4+ T cells, while MPA indi-
cated a moderate, but not significant, increase in
basal expression of GILZ after 48 hrs. P4, NET, NET-
A and LNG did not affect GILZ protein expression
levels (Fig. 1 e and f). Both NET and NET-A were
included in these experiments to show that the lack
of an effect with NET-A is not due to an inability to
be metabolized to NET in PBMCs. We did not detect
substantial GILZ expression in monocytes or IL6
expression in CD4+ T cells. These results showing
immunosuppressive effects of MPA on gene expres-
sion are consistent with our previous data,31–33 as
well as with results reported by others in Bacillus
Calmette–Guerin-stimulated PBMCs and murine
M. tuberculosis models,41,42 and those from the Hel
laboratory in activated T cells and in primary vaginal
mucosal mononuclear cells (VMMCs)36 and cyto-
brushes from patients on DMPA.36
To investigate the role of the GR in mediating the
responses, PBMCs were treated with DEX and MPA in
the absence and presence of RU486, a known GR
antagonist. In Fig. 2, IL6, IL8 and RANTES mRNA
repression by DEX and MPA was lifted in the presence
of RU486, while DEX and MPA induction of GILZ
mRNA was attenuated by RU486 (Fig. 2 a-d). Simi-
larly Huijbregts et al. found that RU486 treatment
together with MPA lifted the MPA-mediated repres-
sion of IFN-c protein expression in VMMCs and acti-
vated PBMCs, CD3+ and CD14+ cells.36 Although
RU486 can also antagonize the PR, we have recently
shown that PBMCs under our conditions express no
detectable PR mRNA or protein.35 Thus, our RU486
results support a role for the GR in mediating these
anti-inflammatory effects in PBMCs. Importantly we
show for the first time that the GR is likely to play a
key role in discriminating between immunosuppres-
sive responses by MPA versus NET and P4 in primary
human cells representing key targets for HIV-1 infec-
tion and replication. We have recently shown that
this discriminatory role of the GR is also observed in
the End1/E6E7 endocervical epithelial cell line, a
model for the endocervical mucosa and site of hetero-
sexual HIV-1 transmission (data not shown). Interest-
ingly in these cells, as well as in primary endocervical
epithelial cells, the GR is the predominant steroid
receptor expressed (data not shown).
The concentrations of progestins used are critical
and determine dose–response
Previous research on the biological effects of
progestins and P4 has been hampered by a lack of
understanding of the significance that doses have
in determination of physiologically relevant
responses.43 Unfortunately there is also a paucity of
information about serum concentrations of progestins
in contraception users, which show high interindivid-
ual variability, as well as concentrations in tissues at
target sites, which may not mimic serum concentra-
tions. We investigated whether the observed effects
of MPA, NET and P4 are relevant to the physiological
doses of these ligands4,5 by dose–response analysis to
determine potencies and efficacies.43 Endogenous P4
serum concentrations vary substantially during the
menstrual cycle in pre-menopausal women and are
low during the follicular phase (0.65 nM), rising to
about 80 nM during the luteal phase, with higher
concentrations of about 600 nM during pregnancy.4
MPA serum concentrations are reported to be in the
range 2.5 to 65 nM a few days after injection in
injectable users and to plateau at about 2.6 nM for
about 3 months, while serum concentrations of NET-
EN are reported to be in the range 1.5–59 nM.4,5 Our
dose–response analysis in these experiments suggests
that MPA is likely to exert anti-inflammatory immu-
nosuppressive effects via GILZ gene expression within
the range of concentrations found in the serum of
American Journal of Reproductive Immunology 71 (2014) 505–512
508 ª 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
HAPGOOD ET AL.
injectable contraceptive users (1–100 nM), as well as
possibly on IL6 and IL8, particularly shortly after
injection. However, the immunosuppressive effects of
NET-EN on PBMCs via the GR are likely to be negligi-
ble, even shortly after injection, while P4 is unlikely
to exert immunosuppressive effects in PBMCs even
during pregnancy via these genes. Interestingly, we
have recently shown that the GR may also play a key
role in PBMCs in discriminating between apoptotic
effects by MPA, unlike NET and P4, at doses within
the contraceptive range, in the absence and presence
of HIV-1 infection.35 The physiological consequences
of immunosuppressive and apoptotic effects of MPA
on PBMCs could include a wide range of effects bene-
ficial to the virus. These could include compromising
the ability of the host to mount effective innate and
adaptive immune responses, as well as increasing
binding of HIV-1 to CCR5 co-receptors. Effects seen
with MPA in PBMCs may also occur in T cells and
monocytes in the genital mucosa.
Conclusions
While controversy continues, a trend is emerging
from multiple clinical studies that the injectable




Fig. 1 DEX and MPA, dose-dependently regulate IL6, IL8, RANTES and GILZ mRNA levels in primary human PBMCs and decrease IL6 protein
expression in CD14+ monocytes and increase GILZ expression in CD4+ T cells. (a-d) PBMCs were stimulated with increasing amounts of DEX, MPA,
P4, NET-A or vehicle (EtOH) for 48 hrs. Relative levels of IL6 (a), IL8 (b), RANTES (c) and GILZ (d) mRNA were normalized to GAPDH mRNA levels.
(e-f) PBMCs were treated with 100 nM DEX and MPA, 1 lM P4, 10 lM NET-A, NET, and LNG (GR saturation concentrations) or vehicle (ETOH) for
48 hrs. Thereafter, cells were stained with surface antibody markers (CD4+ and CD14+) followed by IL6 (e) or GILZ (f) intracellular antibody staining
for protein expression. Protein expression was measured using a Becton–Dickinson FACS Calibur flow cytometer and analysed using FlowJo
software (Version X, Treestar Inc., Ashland, Ore). Fold changes in protein expression are indicated, with vehicle (EtOH) set to 1. Histograms show
pooled results from three to five independent experiments with samples from female donors. Statistical significance was determined by one-way
ANOVA with Student’s t-test to control where, *P < 0.05, **P < 0.01 and ***P < 0.001.
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acquisition and transmission, in particular in young
women with high exposure to HIV-1, unlike other
progestin contraceptives, such as the injectable con-
traceptive NET-EN. Several modelling studies have
attempted to weigh up the competing risks between
contraception and HIV-1 acquisition versus with-
drawal of contraception and associated maternal
mortality and other factors associated with unwanted
pregnancies.44–46 Their results suggest that with HRs
<2, the risks of withdrawal from DMPA outweigh
potential benefits. However, it should be noted that
risk assessments have not, to our knowledge, been
published for HRs associated with only younger
women in high risk areas for HIV-1 infection, or for
changing to another method of contraception such as
NET-EN, which has similar pregnancy risks and
compliance factors to DMPA. This would seem highly
relevant, given that risks for young women in sub-
Saharan Africa carry a disproportionate percentage of
the worldwide HIV-1 burden and are the highest
users of DMPA. Although the findings showing
increased HIV-1 acquisition and transmission with
DMPA could be due to confounding behavioural fac-
tors, the finding that NET-EN does not increase HIV-
1 acquisition argues against this, since DMPA and
NET-EN users would be expected to display similar
behavioural factors such as condom usage. Further-
more, both animal and ex vivo biochemical studies,
using contraceptive concentrations of MPA, support
the possibility that MPA increases HIV-1 infection
and transmission.47 We show directly for the first
time that the GR is likely to play a key role in dis-
criminating between immunosuppressive responses
by MPA versus NET and P4 in primary human cells
representing key targets for HIV-1 infection and repli-
cation. Biochemical studies such as we report here
provide strong support for a mechanism whereby
MPA, unlike other progestins like NET-EN, is likely
to modulate gene expression and immune function,
at concentrations within the range of peak serum
MPA concentration in injectable users, acting via the
GR. The GR is ubiquitously expressed, unlike the PR.
More research is needed to investigate the concentra-
tions of different progestins in target tissues and to
assess their likely dose–response effects. Given its
central role in transcription regulation in all mamma-
lian cells, effects of MPA on gene expression via the
GR are likely to be the molecular basis for several dif-
ferential effects of MPA versus other progestins that
do not act via the GR. These could include effects on
HIV-1 replication, host cell apoptosis, expression lev-
els of several host cell receptors, cell cycle and prolif-
eration effects and epithelial cell barrier function.
Future research on the effects of different progestins
on modulation of HIV-1 pathogenesis, at doses within
the contraceptive range, in primary cell and tissue
models will undoubtedly provide necessary insight
into the question of choice of progestin and dose
effects. However, it remains to be seen whether con-
firmatory information from such studies will be
(a) (b)
(c) (d)
Fig. 2 DEX- and MPA-mediated regulation of
GILZ, IL6, IL8 and RANTES mRNA requires the
presence of the GR. (a-d) PBMCs were
stimulated with 100 nM DEX and MPA in the
presence and absence of 1 lM RU486 for
48 hrs. Relative levels of IL6 (a), IL8 (b),
RANTES (c) and (d) GILZ transcripts were
determined by qPCR and normalized to
GAPDH. Histograms show results from three
independent experiments. Statistical
significance was determined by one-way
ANOVA with Dunnet’s post-test or paired
student t-tests. P < 0.05 denoted as *,
P < 0.01 denoted as ** and P < 0.001
denoted as ***.
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enough to change health policy, in the absence of
clinical data, which may not be possible or feasible to
obtain.
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